m

mm
m

--

EEEEEEEEEmZJ

IT

r'ltq"tfijl~["iill~.J'j~. ~~/

du
r

H
HHHE

?HHHHHH

-M
M[

ny

AVHHHHHH
t
HH
fHHHHHHH?f

17

]|

E-mail:shang-yuh@shang-yuh.com
http://www.shang-yuh.com

ASME.BPE.PIC/S-cGMP

KOBOLD Messring GmbH

measurmg

monitoring

.....

_;

l~

analysing

-.

()

EE
E

()

()

()

Dsseldorf, Germany, 2-4 December 2014

pH

()

jj (/)

HEN

M E 2

Web-Site : www.kobold.com

~~

114 123 247 1

TEL: 02-8792 6335 FAX: 02-8792 6115

E-mail : info.tw@kobold.com

Biennial Valve World Conference & Exhblflon

CONFERENCE

Suppor ed by

www.vIveworldexpo.com

ene''irl

Sponsored

Hl( NEWAYPENTAIR - /
KITZ VEIAN
L~
MRC Globar
VlRIiO

rotorl+

Kaigo (0. , Ltd.

8F.3 , No.9 , Oehuei Street_ Taipei 10461. Taiwan
Te l. +886 (2) 2595421 2- fax +886 (2) 25955726
messeduesseLdorf@kaigo.com.tw

www.kaigo.com.tw

Messe
Dsseldorf

,. CONTENTS

.. CONTENs

2014 8 257

2014 8 257

II' II
Tissue Engineering and Chemlcal Engineering

'

39

40
56

36

21

55

56

FFJ-JP

122

58

('_

'

-, ,

J
<

~~

163 2014JIS

164

~.-r

165

~'

...

154 BP

81

,.F

04

-
6

82

160

f..'

" 1

22

103

162

2014 9-10

,. CONTENTS

.. CONTENs

2014 8 257

2014 8 257

II' II
Tissue Engineering and Chemlcal Engineering

'

39

40
56

36

21

55

56

FFJ-JP

122

58

('_

'

-, ,

J
<

~~

163 2014JIS

164

~.-r

165

~'

...

154 BP

81

,.F

04

-
6

82

160

f..'

" 1

22

103

162

2014 9-10

I"'f' 11"

SAIN GOBAIN

2014
8 267

/
/
/

/
/
/;
/

100
cGMP CIP SIP

ASME

- BPE - PICI S

1t

I;

1t

~t |
'.lf: f

jRlj

t;

m~n'l i~Se'al@
Spring-Energized Seals

E( 521)

E /

: ( 855 )

/
/

/105 51 3()

TE(02)87125539()

FAX!(02)87126567

A A a

http://www.mmmpc.com.tw

E.mail :

. CIP/SIP/ASME

- BPE-PIC/S 10

00

(WFI

SYSTEM)

(PFW SYSTEM)

mmm 11 @mmmpc.com.tw()

/4256 g

TE(04)22511670

FAX!(04)22521315

: 50261920
1385
/

/m

Head Office : 3F., No.51 , 5ec. 4 , Nanjing E. Rd., 50ngshan Dis t.,

SHANG YUH MACHINE CO. , L TD.

: 389 46

Taipei City 105 , Tai wan

Welcome to contact with us by the above address.

/()

: 14

TEL:(886-2)8601-4966 < REP)

FAX : (886-2)8601-2866
http://www.shang-yuh.com
E-mail: shang-yuh@shang-yuh.com

Omni Seal@

.; 250 5 0 0

TEL:

G810X0003

(010)68433147

/
/

TEL:(07)8214538

FAX:(07)8232238

16 .

29.

17 .

30.

1 .

18 .

31

4.

19 .

32.

7.

20.

33.

8.

20.

34.

9.

23.

35. 1

10 .

24.

36.

i2f

25.

37.

12 .

26.

38.

13 .

27.

14 .

28.

15 .

28.

. seepex

(stripper)
IPA()

GMMP

GMB

;J;~:-800C-+2800C

;J)Ei :-20 C-+130 C

316
:90W. 200W. 400W. 550W

:316
:60W
:8M
:20 Ll min

:31M
:95 Ll min

GMSW
:-80 C-+280 C
:316
:1-7.5HP
:60M
:600 Ll min

:-30 C-+230 C
:316
:1-5HP
:91M
:56 Ll min

I ~~~o~~
;~:-800C-+2800C

:316
:7.5HP-25HP
:133M
:1400 Ll min

TEL: 07-3720913

FAX: 07-3720923

: 814 395 -17

http://www.ricopump.com.tw
!

E f

2726567

DIN

:
/!

2. ?

3. ?

( )

5. /? ()

I | I

4. ? ()

?
:

90-100

80-90

70-80

60-70

60

90-100

80-90

70-80

60-70

60

90-100

80-90

70-80

60-70

60

90-100

80-90

70-80

60-70

60

90-100

80-90

70-80

-70

60

TEL:(0223656107 .

z~;~EE

?:
?:

NEDERMAN FIL TERBOX

NEDERMAN

99%

D.O.P.TEST 99.97%

EL~...Il

:
:
:

: :]
:

:
()

E-mail:

E
E _ 1
E

1 1

[I.'"I. ..m.DIJ imllllIJ

23

| r
-

s...."

95%

'

Em
E

()

Water

JE|

//

: (200.C-400.C)

: 1.

2. -99%

3.Thermal Nox

auH HMRunu

%%

J 12

J
.

'

@ETZITFE!
38

99 2

TEL:886-2-29384848()

:
:
:

FAX:886-2-29384864

http://www.geto.tw
E-mail:geto@ms17.hine t. net
20148

20 14
|

(tendon)

40

(1) (inflammatory stage) (2)

(collagen) 30%

(proliferative stage) (3 )

86%

(remodeling

2% 1-5%

(proteoglycan) 0.2%

97-98%

22 8

20148

stage)

41

20 14
|

(tendon)

40

(1) (inflammatory stage) (2)

(collagen) 30%

(proliferative stage) (3 )

86%

(remodeling

2% 1-5%

(proteoglycan) 0.2%

97-98%

22 8

20148

stage)

41

2014
|

11.

2005 Miskulin

(peroneus

brevis tendon)

: (1)

(2) (3)
1

(4)

III

(fibroblasts) ,

(patellar

(extracellular matrix)

tendon) ! (achilles tendon)

(flexion tendon)

[1]

III

(:

(1) (tendon prosthesis) (2)

: (1) (scaffold) (2)

(allograft) (3) (autograft or

(cell) (3) l (signal)

6~8

42

mosaicplasty)

22 8

20148

43

2014
|

11.

2005 Miskulin

(peroneus

brevis tendon)

: (1)

(2) (3)
1

(4)

III

(fibroblasts) ,

(patellar

(extracellular matrix)

tendon) ! (achilles tendon)

(flexion tendon)

[1]

III

(:

(1) (tendon prosthesis) (2)

: (1) (scaffold) (2)

(allograft) (3) (autograft or

(cell) (3) l (signal)

6~8

42

mosaicplasty)

22 8

20148

43

2014
|

16

[21]

PLGA

Bosworth

(PGA)l9 10 1

. (PLGA)[ll 12]

[3]

(PCL)[13] (PVA)[

()

PGA6

1.

PGA

[1

PGA PGA

[16]

PLGA

[45] ( chitosan)[6]

[17]

PVA

(fibroin) [7]

PVA

44

[7] PVA

[14]

PVA

[19 20]

[ 16

228

20148

45

2014
|

16

[21]

PLGA

Bosworth

(PGA)l9 10 1

. (PLGA)[ll 12]

[3]

(PCL)[13] (PVA)[

()

PGA6

1.

PGA

[1

PGA PGA

[16]

PLGA

[45] ( chitosan)[6]

[17]

PVA

(fibroin) [7]

PVA

44

[7] PVA

[14]

PVA

[19 20]

[ 16

228

20148

45

zzti;l

Juncosa-Melvin

[8]

(stiffness)

[31]

-l(TGF-l)

[ Zhao

[36]

[]Dressler

[]

(tendon

stem/progenitor cells)

()

Stavros

[37]

[27]

mesenchymal stem cells)

(IGF) (EGF)

(FGF)

Dang

(PDGF)

(bone

46

marrow

22 8

()

20148

47

zzti;l

Juncosa-Melvin

[8]

(stiffness)

[31]

-l(TGF-l)

[ Zhao

[36]

[]Dressler

[]

(tendon

stem/progenitor cells)

()

Stavros

[37]

[27]

mesenchymal stem cells)

(IGF) (EGF)

(FGF)

Dang

(PDGF)

(bone

46

marrow

22 8

()

20148

47

2014
| !

4)[]

48

()

Dan

/ 583

364

5.0 MPa 70.5 MPa( 2)

[31] 18

( 3)

Jonathan

(4% ' 0.1 Hz ' 1 /2

( 4)

[ Jun

C
os
a

(2 .4% ' 0.003 Hz ' 8/)

3 4

(2.5

nm '

nm '

22 8

(A)(B)

(A B)(C D)7

20148

49

2014
| !

4)[]

48

()

Dan

/ 583

364

5.0 MPa 70.5 MPa( 2)

[31] 18

( 3)

Jonathan

(4% ' 0.1 Hz ' 1 /2

( 4)

[ Jun

C
os
a

(2 .4% ' 0.003 Hz ' 8/)

3 4

(2.5

nm '

nm '

22 8

(A)(B)

(A B)(C D)7

20148

49

EZti
Butler, D. L., "Effects of cell-to-collagen
ratio in stem cell-seeded constructs for

[11] Ouyang , H. W.; Goh , J.C.; Thambyah ,

Achilles tendon repair" , Tissue Eng. 12 ,

A.; Teoh , S.H.; Lee , E.H. , "Knitted

681-689(2006).

poly-lactide-co-glycolide scaffold

[6]Bagnaninchi , P.O.; , Yang , Y.; Zghoul ,

loaded with bone maow stromal cel1 s

H A.J.

in repair and regeneration of rabbit

"Chitosan microchannel scaffolds for

Achilles tendon" , Tissue Eng. 9, 431-

tendon tissue engineering characterized

439(2003).

N.; Maffulli , N.; Wang , R. K.;

using optical coherence tomography" ,

Tissue Eng. 13 , 323-331(2007).

(A C)(B D)

12 (A B)H&E (C D)

T.E.; Toh , S. L., "Characterization of a

novel polymeric scaffold for potential

Karageorgiou , V.; Kap lan , D.;

application in tendon/ligament tissue

Gronowicz , G. , "RGD-tethered silk

engineering" , Tissue Eng. 12 , 91-

substrate stimulates the differentiation

99(2006).

Relat. Res. 448 , 234-239(2006).

[1 Peach

M.S.; James , R.; Toti , U.S.;

Deng, M.; Morozowich , N. L.; Allcock,

[8] Fang , Q.; Chen ,D. , "In vitro and in

H.R.; Laurencin , C.T.; Kumbar, S.G. ,

vivo research on using Antheraea pemyi

"Polyphosphazene functionalized

[3] Ingber, D.E.; Mow, V.C.; Butler, D.;

silk fibroin as tissue engineering tendon

polyester fiber matrices for tendon

Niklason , L.; Huard, J.; Mao , J.; Yannas ,

scaffolds" , Mater. Sc i. Eng. C, 29 , 1527-

tissue engineering: in vitro evaluation

[1]Robertson , A.; Nutton , R. W.; Keating ,

I.; Kaplan , D.; Vunjak-Novakovic , G. ,"

1534(2009).

with human mesenchymal stem cells" ,

J.F. , "Current Trends in the Use of

Tissue engineering and developmental

Tendon Allografts in Orthopaedic

biology: going biomimetic" , Tissue Eng.

L.; Cao , Y., "Repair of tendon defect

[14]Kobayashi , M.; Toguchida , J.; Oka , M. ,

Surgery" , J. Bone Join t. Surg. Br. , 288 ,

12 , 3265-3283(2006).

with dermal fibroblast engineered tendon

"Development of polyvinyl alcohol-

in a porcine mode" , Tissue Eng. 12 , 775-

hydrogel (PVA-H) shields with a high

water content for tendon injury repair" ,

988-99(2006).

[4]Awad , H.A.; Boivin , G.P.; Dressler,

[9]L

w.; Chen, B.; Deng, D.; Xu , F.; Cui,

Biomed Mater. 7, 045016(2012).

[2]Miskulin , M.; Miskulin , A.; Klobucar,

M.R.; Smith, F. N.; Young , R. G.; Butler,

882 , 2006.

H.; Kuvalja , S. , "Neglected Rupture

D. L., "Repair of patellar tendon injuries

[10]Cao , Y.;

of the Achilles Tendon Treated with

using a cell-collagen composite" , J.

Buonocore , S.D.; Cui , L., "Bridging

[15]Wang , B.; Liu, w.; Zhang , Y.; Jiang, Y.;

Peroneus Brevis Transfer: A Functional

Orthop. Res. 21 , 420-431(2003).

tendon defects using autologous

Zhang , W.J.; Zhou , G.; Cui , L.; Cao ,

[5]Juncosa-Melvin , N.; Boivin , G.P.;

tenocyte engineered tendon in a

Y. , "Engineering of extensor tendon

Galloway, M.T.; Gooch , C.; West, J.R.;

hen model" , Plas t. Reconst r. Surg.

complex by an ex vivo approach" ,

Assessment of 5 Cases". J. Foot Ankle.

Surg. , 44 , 49-56(2005).

50

[12]Sahoo S.; Ouyang , H.; Goh , J.C.; Tay,

[7]Kardestuncer, T.; , McCarthy , M.B.;

of human tendon ce l1 s" , Clin. Orthop.

4

110: 1280-1289(2002).

22 8

20148

Y.; Liu , W.; Shan , Q.;

J Hand Surg. Br. 26 , 436-440(2001).

51

EZti
Butler, D. L., "Effects of cell-to-collagen
ratio in stem cell-seeded constructs for

[11] Ouyang , H. W.; Goh , J.C.; Thambyah ,

Achilles tendon repair" , Tissue Eng. 12 ,

A.; Teoh , S.H.; Lee , E.H. , "Knitted

681-689(2006).

poly-lactide-co-glycolide scaffold

[6]Bagnaninchi , P.O.; , Yang , Y.; Zghoul ,

loaded with bone maow stromal cel1 s

H A.J.

in repair and regeneration of rabbit

"Chitosan microchannel scaffolds for

Achilles tendon" , Tissue Eng. 9, 431-

tendon tissue engineering characterized

439(2003).

N.; Maffulli , N.; Wang , R. K.;

using optical coherence tomography" ,

Tissue Eng. 13 , 323-331(2007).

(A C)(B D)

12 (A B)H&E (C D)

T.E.; Toh , S. L., "Characterization of a

novel polymeric scaffold for potential

Karageorgiou , V.; Kap lan , D.;

application in tendon/ligament tissue

Gronowicz , G. , "RGD-tethered silk

engineering" , Tissue Eng. 12 , 91-

substrate stimulates the differentiation

99(2006).

Relat. Res. 448 , 234-239(2006).

[1 Peach

M.S.; James , R.; Toti , U.S.;

Deng, M.; Morozowich , N. L.; Allcock,

[8] Fang , Q.; Chen ,D. , "In vitro and in

H.R.; Laurencin , C.T.; Kumbar, S.G. ,

vivo research on using Antheraea pemyi

"Polyphosphazene functionalized

[3] Ingber, D.E.; Mow, V.C.; Butler, D.;

silk fibroin as tissue engineering tendon

polyester fiber matrices for tendon

Niklason , L.; Huard, J.; Mao , J.; Yannas ,

scaffolds" , Mater. Sc i. Eng. C, 29 , 1527-

tissue engineering: in vitro evaluation

[1]Robertson , A.; Nutton , R. W.; Keating ,

I.; Kaplan , D.; Vunjak-Novakovic , G. ,"

1534(2009).

with human mesenchymal stem cells" ,

J.F. , "Current Trends in the Use of

Tissue engineering and developmental

Tendon Allografts in Orthopaedic

biology: going biomimetic" , Tissue Eng.

L.; Cao , Y., "Repair of tendon defect

[14]Kobayashi , M.; Toguchida , J.; Oka , M. ,

Surgery" , J. Bone Join t. Surg. Br. , 288 ,

12 , 3265-3283(2006).

with dermal fibroblast engineered tendon

"Development of polyvinyl alcohol-

in a porcine mode" , Tissue Eng. 12 , 775-

hydrogel (PVA-H) shields with a high

water content for tendon injury repair" ,

988-99(2006).

[4]Awad , H.A.; Boivin , G.P.; Dressler,

[9]L

w.; Chen, B.; Deng, D.; Xu , F.; Cui,

Biomed Mater. 7, 045016(2012).

[2]Miskulin , M.; Miskulin , A.; Klobucar,

M.R.; Smith, F. N.; Young , R. G.; Butler,

882 , 2006.

H.; Kuvalja , S. , "Neglected Rupture

D. L., "Repair of patellar tendon injuries

[10]Cao , Y.;

of the Achilles Tendon Treated with

using a cell-collagen composite" , J.

Buonocore , S.D.; Cui , L., "Bridging

[15]Wang , B.; Liu, w.; Zhang , Y.; Jiang, Y.;

Peroneus Brevis Transfer: A Functional

Orthop. Res. 21 , 420-431(2003).

tendon defects using autologous

Zhang , W.J.; Zhou , G.; Cui , L.; Cao ,

[5]Juncosa-Melvin , N.; Boivin , G.P.;

tenocyte engineered tendon in a

Y. , "Engineering of extensor tendon

Galloway, M.T.; Gooch , C.; West, J.R.;

hen model" , Plas t. Reconst r. Surg.

complex by an ex vivo approach" ,

Assessment of 5 Cases". J. Foot Ankle.

Surg. , 44 , 49-56(2005).

50

[12]Sahoo S.; Ouyang , H.; Goh , J.C.; Tay,

[7]Kardestuncer, T.; , McCarthy , M.B.;

of human tendon ce l1 s" , Clin. Orthop.

4

110: 1280-1289(2002).

22 8

20148

Y.; Liu , W.; Shan , Q.;

J Hand Surg. Br. 26 , 436-440(2001).

51

2014
|

Biomaterials , 29 , 2954-2961(2008)

the anterior cruciate ligament, medial

[32]Tohyama , H.; Yasuda , K. , "Extrinsic

[16]Qin T. W.; Zhang , S.; Yang , Z.1.; 10

[22]Sahoo , S.; Toh , S.L.; Goh , J.C. , "A

collateral ligament , achilles tendon

Cell 1nfiltration and Revascularization

X.T.; Li , X.Q. , "Mechanical Properties

bFGF -releasing silk/PLGA-based

and patellar tendon as cell sources

Accelerate Mechanical Deterioration

and Related Histological Alterations

biohybrid scaffold for ligament/tendon

for tissue-engineered ligament" ,

of the Patellar Tendon After Fibroblast

of Engineered Tendons 1n Vivo" , Key

tissue engineering using mesenchymal

Biomaterials , 27 , 2747-2754(2006).

Necrosis" , J Biomech. Eng. 122 , 594-

Engineering Materials , 288-289 , 11-

progenitor cells" , Tissue Eng. , 12 ,

14(2005).

91-99 (2006).

[28]Juncosa-Melv

N.; Boivin , G.P.;

599(2000).

Gooch, C.; Galloway, M.T.; West, J.R.;

[33]Bi , Y.; Ehirchiou , D.; Kilts , T.M;

P.W.; Smith, T. L.; Poehling ,

Dunn , M. , Butler, D. L., "The effect of

1nkson , C.A.; Embree , M.C.;

Freeman , J.W.; Attawia , M.A.; Ko ,

G.G.; Shilt, J.S.; Van Dyke , M. , "A

autologous mesenchymal stem cells on

Sonoyama , W.; Li , L.; Leet , A. I.;

F. K.; Laurencin , C.T. , Anterior cruciate

naturally derived, cytocompatible, and

the biomechanics and histology of gel-

Seo , B.M.; Zhang , L.; Shi , S.; Young ,

ligament regeneration using braided

architecturally optimized scaffold for

collagen sponge constructs used for

biodegradable scaffolds: in vitro

tendon and ligament regeneration" ,

rabbit patellar tendon repair", Tissue

progenitor cells and the role of the

optimization studies. Biomaterials , 26 ,

Biomaterials, 28 , 4321-4329(2007).

Eng. 12 , 369-379(2006).

extracellular matrix in their niche" ,

[17] Lu , H.H.; Cooper, J.A.; Manuel , S.;

4805-4816(2005).

[2 Whitlock

"1dentification of tendon stem/

Nat .Med. 13 ,1219-1227(2007).

[24 ]Bosworth , L.; Clegg , P.; Downes ,

[29]Zhao , C.; Chieh, H.F.; Bakri, K.; 1keda,

[18]Wang , X.; Yucel , T.; Lu , Q. , Silk

S. , "Electrospun nanofibres of

J.; Sun , Y. L.; Moran , S. L.; An , K. N.;

[34]Chen , C.H.; Cao , Y.; Wu , Y. F.; Bais ,

nanospheres and microspheres from

polycaprolactone and their use for

Amadio , P.C. , "The effects of bone

A.J.; Gao , J.S.; Tang , J.B. , "Tendon

silkIP VA blend films for drug delivery.

tendon regeneration" , 1nt. J. Nano and

marrow stromal cell transplants on

healing in vivo: gene expression and

Biomaterials , 31 , 1025-1035(2010).

Biomaterials, 1, 263-279(2008).

tendon healing in vitro" , Med. Eng.

production of multiple growth factors

Phys.31 , 1271-1275(2009).

in early tendon healing period" , J.

[1 Lee K.H.; Baek , D.H.; Ki , C.S. ,

[2 Jeon S.H.; Chung , M.S.; Baek , G.H.;

Preparation and characterization

Lee , Y. H.; Kim , S.H.; Gong , H.S. ,

[30]Dressler, M.R.; Butler, D.L.; Boivin ,

Hand Surg. Am. 33 , 1834-1842(2008).

of wet spun silk fibroin/poly(vinyl

"Comparison of loop-tendon versus

G.P. , Effects of age on the repair

[35]Molloy, T.; Wang, Y.; Murrell , G. A. C. ,

alcohol) blend filaments. 1nt. J. Bio l.

end-weave methods for tendon transfer

ability of mesenchymal stem cells in

"The roles of growth factors in tendon

Macromo l., 41 , 168-172(2007).

or grafting in rabbits" , J. Hand Surg.

rabbit tendon. J. Orthop. Res. 23 , 287-

and ligament healing" , Sports Med.

Am..34,1074-1079(2009).

293(2005).

33 , 381-394(2003).

[20]Li MZ , Lu SZ, Wu ZY, et al. "Structure

and properties of silk fibroin

[26]Be am M.; Ralpl

[36]Hou , Y.; Mao , Z.; Yu , C. , "The roles

J. R. , "The cell

[31]Deng , D.; Liu , W.; Xu , F.; Yang , Y.;

poly(vinyl alcohol) gel" , 1nter J Biol

and developmental biology of tendons

Zhou , G.; Zhang , W.J.; Cui , L.; Cao ,

ofTGF-1

Macro , 2002 , 30(2): 89-94.

and ligaments" , 1nt. Rev. Cyto l. 196 ,

Y., "Engineering human neo-tendon

formation during Achilles tendon

85-130(2000).

tissue in vitro with human dermal

healing" , Biochem. Biophys. Res.

Comm. , 383 , 235-239(2009).

[21]Chen , X.; Qi , Y. Y.; Wang , L.L. ,

52

3692(2008).

"Ligament regeneration using a knitted

[27]Cooper, J.A.; Bailey, L. O.; Carter, J. N.;

fibroblasts under static mechanical

silk scaffold combined with collagen

Castiglioni , C.E.; Kofron , M.D.; Ko ,

strain" , Biomaterials. 30 , 6724-

matrix" , Biomaterials , 29 , 3683-

F. K.; Laurencin , C.T. , "Evaluation of

6730(2009).

228

20148

gene transfer on collagen

[37]Thomopoulos , S.; Harwood , F.L.;

Silva , M.J.; Amiel , D.; Gelberman ,

53

2014
|

Biomaterials , 29 , 2954-2961(2008)

the anterior cruciate ligament, medial

[32]Tohyama , H.; Yasuda , K. , "Extrinsic

[16]Qin T. W.; Zhang , S.; Yang , Z.1.; 10

[22]Sahoo , S.; Toh , S.L.; Goh , J.C. , "A

collateral ligament , achilles tendon

Cell 1nfiltration and Revascularization

X.T.; Li , X.Q. , "Mechanical Properties

bFGF -releasing silk/PLGA-based

and patellar tendon as cell sources

Accelerate Mechanical Deterioration

and Related Histological Alterations

biohybrid scaffold for ligament/tendon

for tissue-engineered ligament" ,

of the Patellar Tendon After Fibroblast

of Engineered Tendons 1n Vivo" , Key

tissue engineering using mesenchymal

Biomaterials , 27 , 2747-2754(2006).

Necrosis" , J Biomech. Eng. 122 , 594-

Engineering Materials , 288-289 , 11-

progenitor cells" , Tissue Eng. , 12 ,

14(2005).

91-99 (2006).

[28]Juncosa-Melv

N.; Boivin , G.P.;

599(2000).

Gooch, C.; Galloway, M.T.; West, J.R.;

[33]Bi , Y.; Ehirchiou , D.; Kilts , T.M;

P.W.; Smith, T. L.; Poehling ,

Dunn , M. , Butler, D. L., "The effect of

1nkson , C.A.; Embree , M.C.;

Freeman , J.W.; Attawia , M.A.; Ko ,

G.G.; Shilt, J.S.; Van Dyke , M. , "A

autologous mesenchymal stem cells on

Sonoyama , W.; Li , L.; Leet , A. I.;

F. K.; Laurencin , C.T. , Anterior cruciate

naturally derived, cytocompatible, and

the biomechanics and histology of gel-

Seo , B.M.; Zhang , L.; Shi , S.; Young ,

ligament regeneration using braided

architecturally optimized scaffold for

collagen sponge constructs used for

biodegradable scaffolds: in vitro

tendon and ligament regeneration" ,

rabbit patellar tendon repair", Tissue

progenitor cells and the role of the

optimization studies. Biomaterials , 26 ,

Biomaterials, 28 , 4321-4329(2007).

Eng. 12 , 369-379(2006).

extracellular matrix in their niche" ,

[17] Lu , H.H.; Cooper, J.A.; Manuel , S.;

4805-4816(2005).

[2 Whitlock

"1dentification of tendon stem/

Nat .Med. 13 ,1219-1227(2007).

[24 ]Bosworth , L.; Clegg , P.; Downes ,

[29]Zhao , C.; Chieh, H.F.; Bakri, K.; 1keda,

[18]Wang , X.; Yucel , T.; Lu , Q. , Silk

S. , "Electrospun nanofibres of

J.; Sun , Y. L.; Moran , S. L.; An , K. N.;

[34]Chen , C.H.; Cao , Y.; Wu , Y. F.; Bais ,

nanospheres and microspheres from

polycaprolactone and their use for

Amadio , P.C. , "The effects of bone

A.J.; Gao , J.S.; Tang , J.B. , "Tendon

silkIP VA blend films for drug delivery.

tendon regeneration" , 1nt. J. Nano and

marrow stromal cell transplants on

healing in vivo: gene expression and

Biomaterials , 31 , 1025-1035(2010).

Biomaterials, 1, 263-279(2008).

tendon healing in vitro" , Med. Eng.

production of multiple growth factors

Phys.31 , 1271-1275(2009).

in early tendon healing period" , J.

[1 Lee K.H.; Baek , D.H.; Ki , C.S. ,

[2 Jeon S.H.; Chung , M.S.; Baek , G.H.;

Preparation and characterization

Lee , Y. H.; Kim , S.H.; Gong , H.S. ,

[30]Dressler, M.R.; Butler, D.L.; Boivin ,

Hand Surg. Am. 33 , 1834-1842(2008).

of wet spun silk fibroin/poly(vinyl

"Comparison of loop-tendon versus

G.P. , Effects of age on the repair

[35]Molloy, T.; Wang, Y.; Murrell , G. A. C. ,

alcohol) blend filaments. 1nt. J. Bio l.

end-weave methods for tendon transfer

ability of mesenchymal stem cells in

"The roles of growth factors in tendon

Macromo l., 41 , 168-172(2007).

or grafting in rabbits" , J. Hand Surg.

rabbit tendon. J. Orthop. Res. 23 , 287-

and ligament healing" , Sports Med.

Am..34,1074-1079(2009).

293(2005).

33 , 381-394(2003).

[20]Li MZ , Lu SZ, Wu ZY, et al. "Structure

and properties of silk fibroin

[26]Be am M.; Ralpl

[36]Hou , Y.; Mao , Z.; Yu , C. , "The roles

J. R. , "The cell

[31]Deng , D.; Liu , W.; Xu , F.; Yang , Y.;

poly(vinyl alcohol) gel" , 1nter J Biol

and developmental biology of tendons

Zhou , G.; Zhang , W.J.; Cui , L.; Cao ,

ofTGF-1

Macro , 2002 , 30(2): 89-94.

and ligaments" , 1nt. Rev. Cyto l. 196 ,

Y., "Engineering human neo-tendon

formation during Achilles tendon

85-130(2000).

tissue in vitro with human dermal

healing" , Biochem. Biophys. Res.

Comm. , 383 , 235-239(2009).

[21]Chen , X.; Qi , Y. Y.; Wang , L.L. ,

52

3692(2008).

"Ligament regeneration using a knitted

[27]Cooper, J.A.; Bailey, L. O.; Carter, J. N.;

fibroblasts under static mechanical

silk scaffold combined with collagen

Castiglioni , C.E.; Kofron , M.D.; Ko ,

strain" , Biomaterials. 30 , 6724-

matrix" , Biomaterials , 29 , 3683-

F. K.; Laurencin , C.T. , "Evaluation of

6730(2009).

228

20148

gene transfer on collagen

[37]Thomopoulos , S.; Harwood , F.L.;

Silva , M.J.; Amiel , D.; Gelberman ,

53

American Machinist

12

Hydraulics & Pneumatics

12

New Equipment Digest

12

Holdcraft , R.W.; Nirmalanandhan ,

Machine Design

21

[3 Huang D.; Balian , G.; Chhab A.B.

V. S.; Butler , D.L. , "!{echanical

Welding

11

"Tendon tissue engineering and

stimulation increases collagen type 1

Electronic Design

28

gene transfer: the future of surgical

and collagen type III gene expression

10

Microwaves & RF

12

treatment" , J. Hand Surg. Am. , 31 ,

of stem cell-collagen sponge

11

Chemical Engineering

12

693-704(2006).

constructs for patellar tendon repair" ,

12

Chemical Week

50

Tissue Eng. 13 , 1219-1226(2007).

13

Modem Plastics World Wide

12

Mason , J.S.; Razzano , P.; Dines , D.;

14

Industry Week

12

Grande , D.A. , "Tendon gene therapy

15

Occupational Hazards

12

modulates the local repair environment

16

Forging

in the shoulder" , J. Am. Osteopath.

17

Foundry Management

12

Assoc. 105 :20-21 (2005).

18

Govemment Procurement

Kang , Q.; Luo , J.; He ,

19

Govemment Product News

13

T.C.; Haydon , R.C.; Mass , D.P. ,

21

Business Week

51

"Characterization of adenovirus-

22

Harvard Business Review

12

mediated gene transfer in rabbit fiexor

24

Aviation Week & Space Technology

52

tendons" , J. Hand Surg. Am. , 30 , 136-

25

Business &Commercial Aviation

12

NT$ 560

141(2005).

26

Overhaul & Maintenance

[41]Dai , Q.; Manfield , L.; Wang , Y.;

27

Dr. Dobb's Jounal

12

Murrell , G. A., "Adenovirus-mediated

28

MSDN

12

NT$ 1000

gene transfer to healing tendon--

41

Information Week

51

enhanced efficiency using a gelatin

47

SQL Server Magazine

12

sponge" , J. Orthop. Res. , 21 , 604-

52

Architectural Record

12

53

ENR-Engineering New Record

52

55

Power

57

Food Management

12

58

Lodging Hospitality

12

60

Air Transport World

12

67

Material Handling Management

12

tissue engineering with a cyclic strain

on canine flexor tendon fibroblast

bioreactor" , J. Hand Surg. Am. , 33 ,

proliferation and collagen synthesis

1388-1396(2008).

in vitro" , J. Hand Surg. Am. , 30 , 441447(2005).

[39]Ugg J.C.; Dines , J.; Uggen , C.W.;

[40]Mehta ,

v.;

609(2003).
[42]Riboh , J.; Chong , A.K.; Pham , H.;

54

R.H. , "Effect of several growth factors

[4 Juncosa-Melv N.; Ma t1 in , K.S.;

NT$ 300

NT$ 500

NT$ 550

NT$ 1800

Longaker , M.; Jacobs , C.; Chang ,

J. , "Optimization of flexor tendon

22 8

NT$ 500

: (02)87125539#686 688
*8-10

American Machinist

12

Hydraulics & Pneumatics

12

New Equipment Digest

12

Holdcraft , R.W.; Nirmalanandhan ,

Machine Design

21

[3 Huang D.; Balian , G.; Chhab A.B.

V. S.; Butler , D.L. , "!{echanical

Welding

11

"Tendon tissue engineering and

stimulation increases collagen type 1

Electronic Design

28

gene transfer: the future of surgical

and collagen type III gene expression

10

Microwaves & RF

12

treatment" , J. Hand Surg. Am. , 31 ,

of stem cell-collagen sponge

11

Chemical Engineering

12

693-704(2006).

constructs for patellar tendon repair" ,

12

Chemical Week

50

Tissue Eng. 13 , 1219-1226(2007).

13

Modem Plastics World Wide

12

Mason , J.S.; Razzano , P.; Dines , D.;

14

Industry Week

12

Grande , D.A. , "Tendon gene therapy

15

Occupational Hazards

12

modulates the local repair environment

16

Forging

in the shoulder" , J. Am. Osteopath.

17

Foundry Management

12

Assoc. 105 :20-21 (2005).

18

Govemment Procurement

Kang , Q.; Luo , J.; He ,

19

Govemment Product News

13

T.C.; Haydon , R.C.; Mass , D.P. ,

21

Business Week

51

"Characterization of adenovirus-

22

Harvard Business Review

12

mediated gene transfer in rabbit fiexor

24

Aviation Week & Space Technology

52

tendons" , J. Hand Surg. Am. , 30 , 136-

25

Business &Commercial Aviation

12

NT$ 560

141(2005).

26

Overhaul & Maintenance

[41]Dai , Q.; Manfield , L.; Wang , Y.;

27

Dr. Dobb's Jounal

12

Murrell , G. A., "Adenovirus-mediated

28

MSDN

12

NT$ 1000

gene transfer to healing tendon--

41

Information Week

51

enhanced efficiency using a gelatin

47

SQL Server Magazine

12

sponge" , J. Orthop. Res. , 21 , 604-

52

Architectural Record

12

53

ENR-Engineering New Record

52

55

Power

57

Food Management

12

58

Lodging Hospitality

12

60

Air Transport World

12

67

Material Handling Management

12

tissue engineering with a cyclic strain

on canine flexor tendon fibroblast

bioreactor" , J. Hand Surg. Am. , 33 ,

proliferation and collagen synthesis

1388-1396(2008).

in vitro" , J. Hand Surg. Am. , 30 , 441447(2005).

[39]Ugg J.C.; Dines , J.; Uggen , C.W.;

[40]Mehta ,

v.;

609(2003).
[42]Riboh , J.; Chong , A.K.; Pham , H.;

54

R.H. , "Effect of several growth factors

[4 Juncosa-Melv N.; Ma t1 in , K.S.;

NT$ 300

NT$ 500

NT$ 550

NT$ 1800

Longaker , M.; Jacobs , C.; Chang ,

J. , "Optimization of flexor tendon

22 8

NT$ 500

: (02)87125539#686 688
*8-10

ATHEROSCLEROSIS

branches

2008

Trialsight medical media

(3(

30~50%

[4]

3~6

56

(restenosis) [6]

(atherosclerosis)

(percutaneous transluminal

1980 1993

[1]

corona angioplasty PTCA)

FDA

(endothelial dysfunction)

PTCA'

(turnover)

(balloon catheter) ,

(cell junction)

(guide wire)

( 2(7])

(leaky

junction)

20~30%[8]

(atherosclerotic plagues)[( 1 [

(tightening pain in the chest)

22 8

20148

PTCA

57

ATHEROSCLEROSIS

branches

2008

Trialsight medical media

(3(

30~50%

[4]

3~6

56

(restenosis) [6]

(atherosclerosis)

(percutaneous transluminal

1980 1993

[1]

corona angioplasty PTCA)

FDA

(endothelial dysfunction)

PTCA'

(turnover)

(balloon catheter) ,

(cell junction)

(guide wire)

( 2(7])

(leaky

junction)

20~30%[8]

(atherosclerotic plagues)[( 1 [

(tightening pain in the chest)

22 8

20148

PTCA

57

2014
| f

Bare-metal stent

Drug-eluting stent

Narrowed
Coronary artery located on

Plaque

Stent
plaorm

the surface of the heart

Polymerc~~~---~
biodegradation

I...,______)

C
A

Aerial i ury

Closed stent

Paclitaxel

Sirolimus

Everolimus

Zotarolimus

Expanded stent
Activation of vascular
smooth-muscle cells

Compressed plaque Increased blood f1 0w

Proliferation and migration

of vascular smooth-muscle

Bindlng 10 -tubulin

Binding to

subunit of microtubules

FKBP12

Polymerization

Inhibition of

oftubulin

mTOR

cells and extracellularmatrix formation

Inhibition
of microtubule
disas~embly

Restenosis
2

(7)

(smooth muscle ceII)[ lll(

(drug-eluting stent)

3A(12 1 )

[I( 3B[12 1 )

58

228

A :8 :C
[12)

20148

59

2014
| f

Bare-metal stent

Drug-eluting stent

Narrowed
Coronary artery located on

Plaque

Stent
plaorm

the surface of the heart

Polymerc~~~---~
biodegradation

I...,______)

C
A

Aerial i ury

Closed stent

Paclitaxel

Sirolimus

Everolimus

Zotarolimus

Expanded stent
Activation of vascular
smooth-muscle cells

Compressed plaque Increased blood f1 0w

Proliferation and migration

of vascular smooth-muscle

Bindlng 10 -tubulin

Binding to

subunit of microtubules

FKBP12

Polymerization

Inhibition of

oftubulin

mTOR

cells and extracellularmatrix formation

Inhibition
of microtubule
disas~embly

Restenosis
2

(7)

(smooth muscle ceII)[ lll(

(drug-eluting stent)

3A(12 1 )

[I( 3B[12 1 )

58

228

A :8 :C
[12)

20148

59

2014
|

Endeavor(zotarolimus luting stent)

Xience V (everolimus luting stent)

FDA [23-

27 1 ( 4(22 1 )

()

31 321

PTCA

(systemic) (i ntrastent)

(hypersensi ti vi ty)

(thrombosis )[14-1 Cypher (sirolimus-

eluting stent) Taxus (paclitaxel-eluting

4(22 1 )

stent)[_211( 4[1)

[]

[29 301

.. Drugs-Sirolimus_ Paclitaxel
Platforlll- Stainles~ steel. lolled
tu lJe design
PolYlllcr- Durable,
Supcrior to BMS in reducmg the
magnitude of neointimal
proliferation and clinical restenosb
Late stent thrombosis i~ more likely
LO occur with thesc stents
4

60

DrugZotarolimus. E\'erolimus
Platforlll- Cobah chromium. thin
struL, stents
Polymer-Persistent
Stent exhihiting c1 early 10 er
thrombosis rates a comflurl!d tn
t1 rst generatinn DES

Bioabsorbablc polymer COalcd DES

Polymer frl!c DES
Bioahsorbable DES
Drugs- Biolimu~. Sirolimus.
E\'erolimu~

Platfoml- ColJah Ghrolllium.

nickel-titanium elC.

[22J

22 8

()

316

polyethy lene-co-vinyl

acetate poly-n-butyl

methacrylate

poly( styrene-b-isobuty lene-b-styrene)

polyurethane

terepthalate ;

45% '

polyglycolic acid

Xience V

polylactic acid

phosphorylcholine hyaluronic acid

20148

silicone polyethylene

61

2014
|

Endeavor(zotarolimus luting stent)

Xience V (everolimus luting stent)

FDA [23-

27 1 ( 4(22 1 )

()

31 321

PTCA

(systemic) (i ntrastent)

(hypersensi ti vi ty)

(thrombosis )[14-1 Cypher (sirolimus-

eluting stent) Taxus (paclitaxel-eluting

4(22 1 )

stent)[_211( 4[1)

[]

[29 301

.. Drugs-Sirolimus_ Paclitaxel
Platforlll- Stainles~ steel. lolled
tu lJe design
PolYlllcr- Durable,
Supcrior to BMS in reducmg the
magnitude of neointimal
proliferation and clinical restenosb
Late stent thrombosis i~ more likely
LO occur with thesc stents
4

60

DrugZotarolimus. E\'erolimus
Platforlll- Cobah chromium. thin
struL, stents
Polymer-Persistent
Stent exhihiting c1 early 10 er
thrombosis rates a comflurl!d tn
t1 rst generatinn DES

Bioabsorbablc polymer COalcd DES

Polymer frl!c DES
Bioahsorbable DES
Drugs- Biolimu~. Sirolimus.
E\'erolimu~

Platfoml- ColJah Ghrolllium.

nickel-titanium elC.

[22J

22 8

()

316

polyethy lene-co-vinyl

acetate poly-n-butyl

methacrylate

poly( styrene-b-isobuty lene-b-styrene)

polyurethane

terepthalate ;

45% '

polyglycolic acid

Xience V

polylactic acid

phosphorylcholine hyaluronic acid

20148

silicone polyethylene

61

2014
| 9

Paclitaxel

C 5 79N 5 0 12 ' 966 Daltons ;

""

everolimus C 53 H 8 0 14 '

phosphorylcholine

Paclitaxel

958 Daltons( 3C[12])

18 032

poly(vinylidene fluoride-co-

00/01

Cypher

hexafluoropropylene)

02/M[12404 1]

sirolimus/ (n-octanol/

Taxus

water)

0~4)

[3

2. (sirolimus)

Sirolimus ' Rapamune'

()

2002 38

[3245]

( )Everolimus

Streptomyces hygroscopicus

PTCA

sirolimus

(Xience)

()

Xience Cypher

Sirolimus

C51H79NO 914

Taxus

( )Si rol i m us(Cypher )

Daltons[42.4( 3C [I)

paclitaxel(Taxus )

[51]

(i ntimal hyperplasia)

XienceTaxus

DMSO

paclitaxel sirolimus

SirolimusmTOR

[5]

zotarolimus everolimus

(mammalian ta of rapamycin)

Cypher

phase (

Cypher[

) DNA

sirolimus sirolimus

[57]

Paclitaxel (Taxus

binding protein (FKBP)

21% 8.6%(p<0.001 )l46]

brevifolia)

FKBP T

Taxus

(T lymphocyte)

(Endeavor)

Paclitaxel C47H51NOl4 '

[41 44]

14 .4% 7 .6% (P <0.00 1)l47]

Endeavor

1. (paclitaxel)

854 Daltons( 30 12 ])

(microtubule)

62

[48 49] meta-analysis

fibrin [3637]

3. (zotarolimus)

(everolimus)

Sirolimt

Xience

( )Zotarolimus

Cypher

Taxus

(positive

14 .4%

remodeling) ,

Zotarolimus everolimus

sirolimus

7.3%(p

~mTOR zotarolimt

Endeavor Taxus

22 8

20148

= 0.0001 )l

63

2014
| 9

Paclitaxel

C 5 79N 5 0 12 ' 966 Daltons ;

""

everolimus C 53 H 8 0 14 '

phosphorylcholine

Paclitaxel

958 Daltons( 3C[12])

18 032

poly(vinylidene fluoride-co-

00/01

Cypher

hexafluoropropylene)

02/M[12404 1]

sirolimus/ (n-octanol/

Taxus

water)

0~4)

[3

2. (sirolimus)

Sirolimus ' Rapamune'

()

2002 38

[3245]

( )Everolimus

Streptomyces hygroscopicus

PTCA

sirolimus

(Xience)

()

Xience Cypher

Sirolimus

C51H79NO 914

Taxus

( )Si rol i m us(Cypher )

Daltons[42.4( 3C [I)

paclitaxel(Taxus )

[51]

(i ntimal hyperplasia)

XienceTaxus

DMSO

paclitaxel sirolimus

SirolimusmTOR

[5]

zotarolimus everolimus

(mammalian ta of rapamycin)

Cypher

phase (

Cypher[

) DNA

sirolimus sirolimus

[57]

Paclitaxel (Taxus

binding protein (FKBP)

21% 8.6%(p<0.001 )l46]

brevifolia)

FKBP T

Taxus

(T lymphocyte)

(Endeavor)

Paclitaxel C47H51NOl4 '

[41 44]

14 .4% 7 .6% (P <0.00 1)l47]

Endeavor

1. (paclitaxel)

854 Daltons( 30 12 ])

(microtubule)

62

[48 49] meta-analysis

fibrin [3637]

3. (zotarolimus)

(everolimus)

Sirolimt

Xience

( )Zotarolimus

Cypher

Taxus

(positive

14 .4%

remodeling) ,

Zotarolimus everolimus

sirolimus

7.3%(p

~mTOR zotarolimt

Endeavor Taxus

22 8

20148

= 0.0001 )l

63

2014

~ ~.--.. ji;,

| ( iX I.

[]

( 7[])

[57] Cypher

1.

Endeavor

VESTAsync

Yukon Choice

Cypher

(hydroxyapatite 6[66])

Taxus

Endeavor[]

[] ;

sirolimus

[67]

W1

()

Yukon Choice

: (1)

(Translul na) 2% sirolimus

; (2)

[]

()

(Polymer-free Drug Coated Stent)

BioFreedom

8ioFreedom(62)

BioFreedom
316L

( 5[])

biolimus A9 sirolimt

o phase

'6]

BioFreedom
Cypher

BioFreedom
Tax

64

VESTAsyncSEM
7

[]

228

ACYukon ChoiceSEM :8D SEM(66)

20148

65

2014

~ ~.--.. ji;,

| ( iX I.

[]

( 7[])

[57] Cypher

1.

Endeavor

VESTAsync

Yukon Choice

Cypher

(hydroxyapatite 6[66])

Taxus

Endeavor[]

[] ;

sirolimus

[67]

W1

()

Yukon Choice

: (1)

(Translul na) 2% sirolimus

; (2)

[]

()

(Polymer-free Drug Coated Stent)

BioFreedom

8ioFreedom(62)

BioFreedom
316L

( 5[])

biolimus A9 sirolimt

o phase

'6]

BioFreedom
Cypher

BioFreedom
Tax

64

VESTAsyncSEM
7

[]

228

ACYukon ChoiceSEM :8D SEM(66)

20148

65

2 014
|

(PLLA)

90 Igaki

(everolimus)

( 1 Q[J)

Tamai Igaki

poly-D L-lactide

Tamai (poly-L

2~3 [77J

lactic acid , PLLA , 183 kDa)

60% ' 67% '

( 8[71 J )

[7074J

DREAMS

Bioabsorbable Therapeutics

REVA Medical

(Biotronik)

(Bioabsorbable Therapeutics Inc

paclitaxel

) poly(anhydride ester)

ReZolve( 11 [)

(71] Igaki-Tamai

salicylic acid()

sirolim

12[J)

(tranilast)

sirolimus

sirolimus

(4%) (7%)

Bioabsorbable Vascular Solutions (BVS)

salicylic acid ' salicylic acid

(Abbott Vascular)

FDA

Nevo (J ohnson &

( 9[ J)

Johnson )

sirolimus poly-D L-lactide

co-glycolide (PLGA)

siroliml '1
10

REVA(70)

Igaki-Tamai (71)

Bioabsorbale Vascular Solutions(73)

( 13[81 J )

Cypher

[7]

66

2.

REVA (REVA Medical

sirolimus[

) tyrosine

derived polycarbonate

Taxus

Nevo

Supralimus

(Sahajanand Medical
11

22 8

20148

ReZolve(78)

Technologies )

67

2 014
|

(PLLA)

90 Igaki

(everolimus)

( 1 Q[J)

Tamai Igaki

poly-D L-lactide

Tamai (poly-L

2~3 [77J

lactic acid , PLLA , 183 kDa)

60% ' 67% '

( 8[71 J )

[7074J

DREAMS

Bioabsorbable Therapeutics

REVA Medical

(Biotronik)

(Bioabsorbable Therapeutics Inc

paclitaxel

) poly(anhydride ester)

ReZolve( 11 [)

(71] Igaki-Tamai

salicylic acid()

sirolim

12[J)

(tranilast)

sirolimus

sirolimus

(4%) (7%)

Bioabsorbable Vascular Solutions (BVS)

salicylic acid ' salicylic acid

(Abbott Vascular)

FDA

Nevo (J ohnson &

( 9[ J)

Johnson )

sirolimus poly-D L-lactide

co-glycolide (PLGA)

siroliml '1
10

REVA(70)

Igaki-Tamai (71)

Bioabsorbale Vascular Solutions(73)

( 13[81 J )

Cypher

[7]

66

2.

REVA (REVA Medical

sirolimus[

) tyrosine

derived polycarbonate

Taxus

Nevo

Supralimus

(Sahajanand Medical
11

22 8

20148

ReZolve(78)

Technologies )

67

2 014
| r

12

A DREAMSSEM ;B(70)

316L

sirolimus PLLA polyvinyl

[29]

pyrrolidone (PVP) PLGA

BioMatrix

( 14[)

[BioMatrix Cypher

sirolimus PLLA-PVP-PLGA '

140

sirolimus '

[87 88]

PVP siroliml

PVP

Ductile hinge

Reservoirs

Supralimus

Venkatraman PLGA

triflusal sirolimus

[]

PLGA Top coat

Infinnium Supralimus

( 16[])

sirolimus;

Infinnium 48

13

A Nevo ;B ;CSEM(80)

BioMatrix 316L
S

bi-phasic drug
release
14

68

Supralimus SEM (66)

228

( 15[) PLLA

biolimus A9
156

20148

15

BioMatrix (85)

69

2 014
| r

12

A DREAMSSEM ;B(70)

316L

sirolimus PLLA polyvinyl

[29]

pyrrolidone (PVP) PLGA

BioMatrix

( 14[)

[BioMatrix Cypher

sirolimus PLLA-PVP-PLGA '

140

sirolimus '

[87 88]

PVP siroliml

PVP

Ductile hinge

Reservoirs

Supralimus

Venkatraman PLGA

triflusal sirolimus

[]

PLGA Top coat

Infinnium Supralimus

( 16[])

sirolimus;

Infinnium 48

13

A Nevo ;B ;CSEM(80)

BioMatrix 316L
S

bi-phasic drug
release
14

68

Supralimus SEM (66)

228

( 15[) PLLA

biolimus A9
156

20148

15

BioMatrix (85)

69

[891

( 17B[901 )

Duraflo heparin

sirolimus

(Duraflo heparin)

( 17 A[ 1)

sirolimus

-F

nD

h\

Duraflo heparin
Sirolimus

Hydrophobic
par

ILC"'"\~

Duraflo

heparin Edwards

A/'

heparin
/
/

Hydrophilic

v pa

Benzalkonium chloride
(binding agent)

Life

Sciences

PTCA

(quatemary

ammonium/heparin complexes)(

17B 1)

Duraflo

Multi-Iayer coating of
Duraflo heparin

17

A Duraflo heparinDsirolimus ;8 Duraflo heparin

(90)

48~53 (2002)

[5]Landau, C.; Lange A. R.; Hillis L. D. ,

"Percutaneous transluminal coronary

angioplasty" , N. Eng l. J. Med. , 330 ,

[1]

' 175~177 '

(2002)
[2]

A sirolimus triflusal ;8;

C D SEM (89)

70

M. W.; Roubin G. S.; King S.

angioplasty. Potential biologic

400 42~4 7

determinats and role of intimal

(2006)

hyperplasia" , Circulation , 79 ,

[4]

22 8

[6]L

(1994).

B. 3rd; "Restenosis after coronary

[3 ]http://decreasecholesterol.blogspot. tw/
16

981~993

' 352

20148

1374~1387

(1 989).

[7]http://www.newsmedica l. net/health/
What are Stents.aspx

71

[891

( 17B[901 )

Duraflo heparin

sirolimus

(Duraflo heparin)

( 17 A[ 1)

sirolimus

-F

nD

h\

Duraflo heparin
Sirolimus

Hydrophobic
par

ILC"'"\~

Duraflo

heparin Edwards

A/'

heparin
/
/

Hydrophilic

v pa

Benzalkonium chloride
(binding agent)

Life

Sciences

PTCA

(quatemary

ammonium/heparin complexes)(

17B 1)

Duraflo

Multi-Iayer coating of
Duraflo heparin

17

A Duraflo heparinDsirolimus ;8 Duraflo heparin

(90)

48~53 (2002)

[5]Landau, C.; Lange A. R.; Hillis L. D. ,

"Percutaneous transluminal coronary

angioplasty" , N. Eng l. J. Med. , 330 ,

[1]

' 175~177 '

(2002)
[2]

A sirolimus triflusal ;8;

C D SEM (89)

70

M. W.; Roubin G. S.; King S.

angioplasty. Potential biologic

400 42~4 7

determinats and role of intimal

(2006)

hyperplasia" , Circulation , 79 ,

[4]

22 8

[6]L

(1994).

B. 3rd; "Restenosis after coronary

[3 ]http://decreasecholesterol.blogspot. tw/
16

981~993

' 352

20148

1374~1387

(1 989).

[7]http://www.newsmedica l. net/health/
What are Stents.aspx

71

3:l

eAUe

annM

ua-UEJ
ui

S.; et a l., "Recent progress in

percutaneous

corona mterventton:

PA

evolution of the drug eluting stents ,

'

NA -mu

rmmc

(2006).

1690~ 1697

182~ 183

mo

in vascular intervention" , Lance t., 361 ,

drug-eluting stents is it the p i11 or the

polymer?" , J. Am. Coll. Cardio 1., 47 ,

[9]Fattori , R.; Piva T. , "Drug eluting stents

M muh-m
dkb

(1998).

1471~1482

-MM

reactions after the implantation of

nc

document on coronary artery stents" ,

-KOaOS
ekdr.
Mmumm
nfjH',

[14]Azarbal , B.; Currier J. W. , "Allergic

"

Faxon D.; et al., "ACC expert consensus

J. Am. Col l. Cardio l., 32 ,

(1 996).

[20]Nebeker, J. R.; Virmani R.; Bennett

focus on the XIENCE V drug-eluting

stent" , Coron. Artery Dis. , 21 , 46-56
(2010).
[2 Joner

M.; Nakazawa G.; Finn A.

[15]Virmani , R.; Guagliumi G.;

C. L.; et a l., "Hypersensitivity

Musumeci G.; et a l., "Localized

cases associated with drug eluting

v.;

hypersensitivity and late coronary

coronary stents a review of available

between comparator polymer-based

expandable stent implantation with

thrombosis secondary to a

cases from the research on adverse

drug-eluting stents" , J. Am. Col 1.

balloon angioplasty in patients with

sirolimus-eluting stent: should we

drug events and reports (RADAR)

Cardio1., 52 , 333-342 (2008).

coronary artery disease" , N. Eng l. J.

be cautious?" , Circulation , 109 ,

pr ect"

Med. , 331 , 489~495 (1994).

701~705

175-181 (2006)

247~249

(2003).

[10]Serru P.

w.; de Jaegere P.; Kiemeneij

F.; et al., "A comprosion of balloon-

[11]Fischman, D. L.; Leon M. B.; Baim

(2004).

[16]Tsimik

J. Am. Col 1. Cardio 1., 47 ,

et a1., "Endothelia1 cell

recove

[26]Lange, R. A.; Hi11 is L. D. , "Secondgeneration drug eluting coronary

S. , "Drug-eluting stents

[21] "DES combats safety and eff-

D. S.; "A randomized comparsion

and late adverse clinical outcomes" ,

icacy concerns is the genous

of coronary-stent p1acement and

J. Am. Coll. Cardio1., 47 , 2112-2115

healing approach the solution?" ,

[27]Lopez , J. J.; Keyes M. J.; Nathan

balloon angiop1asty in the treatment

(2006).

Cardiovascular News 1ntemational ,

S.; et a 1., "Rapid adoption of drug

3, 2006.

eluting stents: clinical practices

of corona

arte disease"

N. Eng1.

J. Med. , 331 , 496~501 (1994).

[1 Stefanini

G. G.; Holmes D. R. Jr. ,

"Drug-eluting coronary-artery
stents" , N. Eng l. J. Med. , 368 ,
254~265

(2013).

[17]Kastrati , A. , "Drug for a while ,

stents" , N. Eng l. J. Med. , 362 ,

1728-1730 (2010).

polymer for life: 1s it a good

[22] Kh an , W.; Farah S.; Domb A. J. ,"Drug

and outcomes from the early drug-

solution?" , Catheter. Cardiovasc.

eluting stents: Developments and

eluting stent era" , Am. Heart J. , 160,

1nterv. , 71 , 340-341 (2008).

current status" , J. Control Release ,

767-774 (2010).

[18]Luscher, T. F.; Steffel J.; Eberli

F. R.; et a l., "Drug eluting

161 , 703-712 (2012).

[2 Sheiban

[28]Jung , F.; Bach R.; Franke R.

I.; Vi11 ata G.; Bollati , M.;

P. , "Effect of crimping on the

[ 1 Nakayama Y.; Ji- Youn K.; Nishi

stent and coronary thrombosis:

et a1., "Next generation drug- e1 uting

contamination of coronary stents" ,

S.; et a l., "Deveploment of high-

biological mechanisms and c1 inical

stents in coronary artery disease:

Eur. Heart J., 20 ,628 (1999).

performance stent: ge1ationous

implications" , Circulation , 115 ,

focus on everolimus eluting stent

photogel coated stent that permits

1051-1058 (2007).

(Xience V)" , Vasc. Health Risk

eluting stents for coronary artery

Manag. , 4 , 31-38 (2008).

disease: a review" , Med. Eng. Phys. ,

drug delivery and gene transfer" , J.

Biomed. Mater. Res. , 57 ,

72

(2001).

MM

[8]Holmes , D. R. J r.; Hirshfeld J. Jr.;

559~566

[1 van

der Giessen , W. J.; Lincoff

A. M.; Schwartz R. S.; et a l.,

228

[24]Doostzadeh, J.; Clark L. N.; Bezenek

20148

[2 Martin

D. M.; Boyle F. J. , "Drug-

33 , 148-163 (2011).

73

3:l

eAUe

annM

ua-UEJ
ui

S.; et a l., "Recent progress in

percutaneous

corona mterventton:

PA

evolution of the drug eluting stents ,

'

NA -mu

rmmc

(2006).

1690~ 1697

182~ 183

mo

in vascular intervention" , Lance t., 361 ,

drug-eluting stents is it the p i11 or the

polymer?" , J. Am. Coll. Cardio 1., 47 ,

[9]Fattori , R.; Piva T. , "Drug eluting stents

M muh-m
dkb

(1998).

1471~1482

-MM

reactions after the implantation of

nc

document on coronary artery stents" ,

-KOaOS
ekdr.
Mmumm
nfjH',

[14]Azarbal , B.; Currier J. W. , "Allergic

"

Faxon D.; et al., "ACC expert consensus

J. Am. Col l. Cardio l., 32 ,

(1 996).

[20]Nebeker, J. R.; Virmani R.; Bennett

focus on the XIENCE V drug-eluting

stent" , Coron. Artery Dis. , 21 , 46-56
(2010).
[2 Joner

M.; Nakazawa G.; Finn A.

[15]Virmani , R.; Guagliumi G.;

C. L.; et a l., "Hypersensitivity

Musumeci G.; et a l., "Localized

cases associated with drug eluting

v.;

hypersensitivity and late coronary

coronary stents a review of available

between comparator polymer-based

expandable stent implantation with

thrombosis secondary to a

cases from the research on adverse

drug-eluting stents" , J. Am. Col 1.

balloon angioplasty in patients with

sirolimus-eluting stent: should we

drug events and reports (RADAR)

Cardio1., 52 , 333-342 (2008).

coronary artery disease" , N. Eng l. J.

be cautious?" , Circulation , 109 ,

pr ect"

Med. , 331 , 489~495 (1994).

701~705

175-181 (2006)

247~249

(2003).

[10]Serru P.

w.; de Jaegere P.; Kiemeneij

F.; et al., "A comprosion of balloon-

[11]Fischman, D. L.; Leon M. B.; Baim

(2004).

[16]Tsimik

J. Am. Col 1. Cardio 1., 47 ,

et a1., "Endothelia1 cell

recove

[26]Lange, R. A.; Hi11 is L. D. , "Secondgeneration drug eluting coronary

S. , "Drug-eluting stents

[21] "DES combats safety and eff-

D. S.; "A randomized comparsion

and late adverse clinical outcomes" ,

icacy concerns is the genous

of coronary-stent p1acement and

J. Am. Coll. Cardio1., 47 , 2112-2115

healing approach the solution?" ,

[27]Lopez , J. J.; Keyes M. J.; Nathan

balloon angiop1asty in the treatment

(2006).

Cardiovascular News 1ntemational ,

S.; et a 1., "Rapid adoption of drug

3, 2006.

eluting stents: clinical practices

of corona

arte disease"

N. Eng1.

J. Med. , 331 , 496~501 (1994).

[1 Stefanini

G. G.; Holmes D. R. Jr. ,

"Drug-eluting coronary-artery
stents" , N. Eng l. J. Med. , 368 ,
254~265

(2013).

[17]Kastrati , A. , "Drug for a while ,

stents" , N. Eng l. J. Med. , 362 ,

1728-1730 (2010).

polymer for life: 1s it a good

[22] Kh an , W.; Farah S.; Domb A. J. ,"Drug

and outcomes from the early drug-

solution?" , Catheter. Cardiovasc.

eluting stents: Developments and

eluting stent era" , Am. Heart J. , 160,

1nterv. , 71 , 340-341 (2008).

current status" , J. Control Release ,

767-774 (2010).

[18]Luscher, T. F.; Steffel J.; Eberli

F. R.; et a l., "Drug eluting

161 , 703-712 (2012).

[2 Sheiban

[28]Jung , F.; Bach R.; Franke R.

I.; Vi11 ata G.; Bollati , M.;

P. , "Effect of crimping on the

[ 1 Nakayama Y.; Ji- Youn K.; Nishi

stent and coronary thrombosis:

et a1., "Next generation drug- e1 uting

contamination of coronary stents" ,

S.; et a l., "Deveploment of high-

biological mechanisms and c1 inical

stents in coronary artery disease:

Eur. Heart J., 20 ,628 (1999).

performance stent: ge1ationous

implications" , Circulation , 115 ,

focus on everolimus eluting stent

photogel coated stent that permits

1051-1058 (2007).

(Xience V)" , Vasc. Health Risk

eluting stents for coronary artery

Manag. , 4 , 31-38 (2008).

disease: a review" , Med. Eng. Phys. ,

drug delivery and gene transfer" , J.

Biomed. Mater. Res. , 57 ,

72

(2001).

MM

[8]Holmes , D. R. J r.; Hirshfeld J. Jr.;

559~566

[1 van

der Giessen , W. J.; Lincoff

A. M.; Schwartz R. S.; et a l.,

228

[24]Doostzadeh, J.; Clark L. N.; Bezenek

20148

[2 Martin

D. M.; Boyle F. J. , "Drug-

33 , 148-163 (2011).

73

2014
|

S. N. , "Sirolimus: its

coronary

arte disease"

N. Eng l. J.

J. Biomed. Mate r. Res. B App l.

design matters: insights from

Biomater. , vo 1. 91B , 441~451 (2009).

discovery, biological properties ,

virtual bench testing" , Expert. Rev.

[36]Mani , G.; Feldman M. D.; Patel D.;

and mechanism of action" ,

[48]Stone , G. W.; Moses J. W.; Ellis S.

613~615

et a l., "Coronary stents: a materials

Transplantation Proceedings , 35

G.; et a l., "Safety and efficacy of

perspective" , Biomaterials , 28 ,

(Supp13A) , 7S~14S (2003).

sirolimus and paclitaxel eluting

Cardiovasc. The r., 8 ,

(2010).

[31]Ako , J.; Bonneau H. N.; Honda Y.,

1689~ 1710

S. 0.; Marks A. R. , "The

[4 Marx

(2007).

et a l., "Design criteria for the ideal

[37]Puskas , J. E.; Munoz-Robledo L. G.;

Development of Rapamycin and Its

drug eluting stent" , Am. J. Cardio l.,

Hoerr R. A.; et a l., "Drug eluting

Application to Stent Restenosis" ,

100 (8B) , 3M~9M (2007).

stent coatings" , Wiley Interdiscip.

Circulation, 104, 852~855 (2001).

Med. , 350 , 221~231 (2004).

coronar

stents" , N. Eng l. J. Med. ,

356 , 998~1008 (2007).

[4 Raber

L.; Magro M.; Stefanini G.

G.; et al., "Very late coronary stent

[44]Kuntz , R. E.; Gibson C. M.;

thrombosis of a newer-generation

Nobuyoshi M.; et a l., "Generalized

everolimus eluting stent compared

Falotico R. ,

model of restenosis after

with early-generation drug-eluting

dysfunction" , JACC Cardiovasc.

"Polymers for drug eluting stents" ,

conventional balloon angioplasty,

stents: a prospective cohort study" ,

Interv. , 2 , 1169~ 1177 (2009).

Curr. Pharm. Des. , 16 ,

3978~3988

stenting and directional

Circulation, 125 ,

[32]Pendyala, L. K.; Yin X.; Li J.; et a l.,

"The first-generation drug eluting
stents and coronary endothelial

[33]Mrowie

C.; Franke R. P.; Seyfert

u. T.; et al., "Haemocompatibility of

Rev. Nanomed. Nanobiotechno l., 1,

451 ~462 (2009).
[38]Parker, T.; Dave

v.;

atherectomy" , J. Am. Coll. Cardio l.,

(2011).
[39]Ga

S.; Serruys P.W. , "Coronary

15~25

stents: a collaborative network meta-

S43~S78

stents" , Adv. Drug Deliv. Rev. , 58 ,

analysis" , Lancet. , 370 ,

(2010).

[40]Donaldson , K. L.; Goolsby G. L.;

[4Burke

437~446

"s
irolimu

1s-elu

Iting
s te

nts

everolimus eluting coronary stent

induced apoptosis" , Cell Growth

versus standard stents in patients

system: a novel second generation

Di

with stenosis in a native

coronar
y

drug-eluting stent" , Exper t. Rev.

Kappert U. , "Do drug-eluting stents

of p34cdc2 coincident with taxol-

J.; et a l.,

influence the spectrum of coronary

artery bypass surgery?" , Herz , 29 ,

ri3

"h

-u

AM

.1

om

fb

sa

4.tvEi

5,

1041~1050

(1 994).

[41]van der Hoeven , B. L; Pires N.

MM-m
;
-m

llqbAU

(2007).

(2006).

[51]Beijk, M. A.; Piek 1. J. , "XIENCE V

Kiener P. A.; et a l., "Activation

Y.; Mandler D.; Weinberger

yJec HGIrA
.12
Edq
VCM
Mdm
iuoa
uv'n
a";

937~948

[46]Moses , J. W.; Leon M. B.; Popma J.

[34]Matschke , K.; Tugtekin S. M.;

[3 Levy

S.; et a l., "Outcomes associated

(1 993).

B. , "Zotarolimus (ABT-578) eluting

Clin. Hemorheo l. Microcirc. , 32 ,

(2004).

[50]Stettler, C.; Wandel S.; Allemann

Col l. Cardio l., 56 (1 0 Supp l.),

as compared to uncoated stents" ,

201~207

(2012).

with drug-eluting and bare-metal

stents: looking forward" , J. Am.

(2005).

21 ,

1110~1121

S. E.; Kuntz R. E.; Schwartz L.

polymer coated stainless steel stents

89~ 103

74

[4 Sehgal

[30]Mortier, P.; Verdonck P. R. , "Stent

M.; Warda H. M.; et a l., "Drug

Med. Devices. , 4,

artery
1315~1323

(2003)

11~21

(2007).

[52]Kedhi , E.; Joesoef K. S.; McFadden

eluting stents: resu1ts , promises and

[47]Stone , G. W.; Ellis S. G.; Cox D. A.;

E.; et a l., "Second generation

9~17

et al., "A polymer-based, paclitaxel-

everolimus eluting and paclitaxel

eluting stent in patients with

eluting stents in real life practice

problems" , In t. 1. Cardio l., 99 ,

(2005).

22 8

20148

75

2014
|

S. N. , "Sirolimus: its

coronary

arte disease"

N. Eng l. J.

J. Biomed. Mate r. Res. B App l.

design matters: insights from

Biomater. , vo 1. 91B , 441~451 (2009).

discovery, biological properties ,

virtual bench testing" , Expert. Rev.

[36]Mani , G.; Feldman M. D.; Patel D.;

and mechanism of action" ,

[48]Stone , G. W.; Moses J. W.; Ellis S.

613~615

et a l., "Coronary stents: a materials

Transplantation Proceedings , 35

G.; et a l., "Safety and efficacy of

perspective" , Biomaterials , 28 ,

(Supp13A) , 7S~14S (2003).

sirolimus and paclitaxel eluting

Cardiovasc. The r., 8 ,

(2010).

[31]Ako , J.; Bonneau H. N.; Honda Y.,

1689~ 1710

S. 0.; Marks A. R. , "The

[4 Marx

(2007).

et a l., "Design criteria for the ideal

[37]Puskas , J. E.; Munoz-Robledo L. G.;

Development of Rapamycin and Its

drug eluting stent" , Am. J. Cardio l.,

Hoerr R. A.; et a l., "Drug eluting

Application to Stent Restenosis" ,

100 (8B) , 3M~9M (2007).

stent coatings" , Wiley Interdiscip.

Circulation, 104, 852~855 (2001).

Med. , 350 , 221~231 (2004).

coronar

stents" , N. Eng l. J. Med. ,

356 , 998~1008 (2007).

[4 Raber

L.; Magro M.; Stefanini G.

G.; et al., "Very late coronary stent

[44]Kuntz , R. E.; Gibson C. M.;

thrombosis of a newer-generation

Nobuyoshi M.; et a l., "Generalized

everolimus eluting stent compared

Falotico R. ,

model of restenosis after

with early-generation drug-eluting

dysfunction" , JACC Cardiovasc.

"Polymers for drug eluting stents" ,

conventional balloon angioplasty,

stents: a prospective cohort study" ,

Interv. , 2 , 1169~ 1177 (2009).

Curr. Pharm. Des. , 16 ,

3978~3988

stenting and directional

Circulation, 125 ,

[32]Pendyala, L. K.; Yin X.; Li J.; et a l.,

"The first-generation drug eluting
stents and coronary endothelial

[33]Mrowie

C.; Franke R. P.; Seyfert

u. T.; et al., "Haemocompatibility of

Rev. Nanomed. Nanobiotechno l., 1,

451 ~462 (2009).
[38]Parker, T.; Dave

v.;

atherectomy" , J. Am. Coll. Cardio l.,

(2011).
[39]Ga

S.; Serruys P.W. , "Coronary

15~25

stents: a collaborative network meta-

S43~S78

stents" , Adv. Drug Deliv. Rev. , 58 ,

analysis" , Lancet. , 370 ,

(2010).

[40]Donaldson , K. L.; Goolsby G. L.;

[4Burke

437~446

"s
irolimu

1s-elu

Iting
s te

nts

everolimus eluting coronary stent

induced apoptosis" , Cell Growth

versus standard stents in patients

system: a novel second generation

Di

with stenosis in a native

coronar
y

drug-eluting stent" , Exper t. Rev.

Kappert U. , "Do drug-eluting stents

of p34cdc2 coincident with taxol-

J.; et a l.,

influence the spectrum of coronary

artery bypass surgery?" , Herz , 29 ,

ri3

"h

-u

AM

.1

om

fb

sa

4.tvEi

5,

1041~1050

(1 994).

[41]van der Hoeven , B. L; Pires N.

MM-m
;
-m

llqbAU

(2007).

(2006).

[51]Beijk, M. A.; Piek 1. J. , "XIENCE V

Kiener P. A.; et a l., "Activation

Y.; Mandler D.; Weinberger

yJec HGIrA
.12
Edq
VCM
Mdm
iuoa
uv'n
a";

937~948

[46]Moses , J. W.; Leon M. B.; Popma J.

[34]Matschke , K.; Tugtekin S. M.;

[3 Levy

S.; et a l., "Outcomes associated

(1 993).

B. , "Zotarolimus (ABT-578) eluting

Clin. Hemorheo l. Microcirc. , 32 ,

(2004).

[50]Stettler, C.; Wandel S.; Allemann

Col l. Cardio l., 56 (1 0 Supp l.),

as compared to uncoated stents" ,

201~207

(2012).

with drug-eluting and bare-metal

stents: looking forward" , J. Am.

(2005).

21 ,

1110~1121

S. E.; Kuntz R. E.; Schwartz L.

polymer coated stainless steel stents

89~ 103

74

[4 Sehgal

[30]Mortier, P.; Verdonck P. R. , "Stent

M.; Warda H. M.; et a l., "Drug

Med. Devices. , 4,

artery
1315~1323

(2003)

11~21

(2007).

[52]Kedhi , E.; Joesoef K. S.; McFadden

eluting stents: resu1ts , promises and

[47]Stone , G. W.; Ellis S. G.; Cox D. A.;

E.; et a l., "Second generation

9~17

et al., "A polymer-based, paclitaxel-

everolimus eluting and paclitaxel

eluting stent in patients with

eluting stents in real life practice

problems" , In t. 1. Cardio l., 99 ,

(2005).

22 8

20148

75

2014
|

(COMPARE): a randomised trial" ,

Lancet., 375 , 201~209 (2010).

et a l., "Comparison of zotarolimus

eluting cypher stent in a porcine

[57]Bangalore , S.; Kumar S.; Fusaro M.;

eluting stents with sirolimus and

model" , Circ Cardiovasc Interv. ,

coronar

3 174~183

(2010).

[53]Stone , G. W.; Rizvi A.; Newman W.;

et al., "Short and long term outcomes

paclitaxel eluting stents for

et a l., "Everolimus-eluting versus

with drug eluting and bare metal

revascularization: the ZEST

paclitaxel eluting stents in coronary

coronary stents: a mixed treatment

(comparison of the efficacy and

biolimus A9 eluting

artery disease" , N. Eng l. J. Med. ,

comparison analysis of 117 762

safety of zotarolimus eluting stent

a next generation drug eluting stent

362 ,

patient years of follow up from

with sirolimus eluting and paclitaxel

for

randomized trials" , Circulation, 125 ,

eluting stent for coronary lesions)

Rev. Med. Devices , 3 ,

randomized trial" , J. Am. Col l.

(2006).

1663~1674

(2010).

[54]Kaiser, C.; Galatius S.; Erne P.; et

a l., "Drug eluting versus bare metal
stents in large coronary arteries" ,

2873~2891

[58]F ad

(2012).

J.; Wijns W.; Laarman G.

Cardio l., 56 ,

1187~1195

(2010).

[64]Grube, E.; Buellesfeld L., "BioMatrix

corona stent:

corona arte disease"

Expert.

731~741

[65]Grube E.; Mueller R.; Schuler G.; et

a l., "Comparison of polymer-free

N. Eng l. J. Med. , 363 , 231 0~2319

J.; et a l., "Randomized , double

[61]Camenzind, E. W.; Wijns W.; Mauri

(2010).

blind , multicenter study of the

L.; et a l., "Stent thrombosis and

BioFreedomTf

[55]Jensen, L. 0.; Thayssen P.; Hansen H.

endeavor zotarolimus eluting

m or

clinical events at 3 years after

polymer Taxus LibertTM stents:

S.; et a l., "Randomized comparison

phosphory lcho line-enca psula ted

zotarolimus eluting or sirolimus

3-Year results from the BioFreedom

of everolimus eluting and sirolimus-

stent for treatment of native

eluting coronary stent implantation:

first in Man trial" , J. Am. Col l.

eluting stents in patients treated with

coronary artery lesions: clinical

a randomised ,

percutaneous

corona mterventlOn:

and angiographic results of the

label , controlled trial" , Lancet., 380

the Scandinavian Organization for

ENDEAVOR 11 trial" , Circulation ,

1396~1405

Randomized Trials with Clinical

114, 798~806 (2006).

multicent open

(2012).

stents with durable

Cardio l., 60 (1 7_S) (2012).

[66]Abizaid , A.; Costa J. R. Jr. , "New
drug-eluting stents: an overview

M. W.; Cruden N. L.

on biodegradable and polymer-free

M. B.; Nikolsky E.; Cutlip D.

M. , "Advances in coronary stent

next-generation stent systems" , Circ.

(2012).

E.; et a l., "Improved late clinical

technology: current expectations

Cardiovasc. Interv. , 3 ,

T.; Morimoto T.; Natsuaki

safety with zotarolimus eluting

and new developments" , Clin. Res.

(2010).

M.; et a l., "Comparison of

stents compared with paclitaxel-

Cardio l., 4 , 85~96 (2013).

everolimus-eluting and sirolimus

eluting stents in patients with de

[63]Tada, N.; Virmani R.; Grant G.; et al.,

R.; et a l., "1-year results of the

eluting coronary stents: 1-year

novo coronary lesions: 3 year

"Polymer-free biolimus A9 coated

hydroxyapatite polymer free

outcomes from the randomized

follow up from the ENDEAVOR IV

stent demonstrates more sustained

sirolimus eluting stent for the

evaluation of sirolimus eluting

trial" , JACC Cardiovasc. Interv. , 3,

intimal inhibition, improved healing ,

treatment of single de novo coronary

versus everolimus eluting stent

1043~1050

(2010).

and reduced inflammation compared

lesions: the VESTASYNC 1 trial" ,

[60]Park , D. W.; Kim Y. H.; Yun S. C.;

with a polymer coated sirolimus

JACC Cardiovasc. Interv. , 2 ,

Outcome IV (SORT OUT IV)" ,

Circulation, 125 ,
[56]Kimu

1246~1255

trial (RESET)" , Circulation , 126 ,

76

(2012).

1225~1236

[5 Leon

228

[6 Wilson

20148

384~393

[67]Costa, J. R. Jr.; Abizaid A.; Costa

77

2014
|

(COMPARE): a randomised trial" ,

Lancet., 375 , 201~209 (2010).

et a l., "Comparison of zotarolimus

eluting cypher stent in a porcine

[57]Bangalore , S.; Kumar S.; Fusaro M.;

eluting stents with sirolimus and

model" , Circ Cardiovasc Interv. ,

coronar

3 174~183

(2010).

[53]Stone , G. W.; Rizvi A.; Newman W.;

et al., "Short and long term outcomes

paclitaxel eluting stents for

et a l., "Everolimus-eluting versus

with drug eluting and bare metal

revascularization: the ZEST

paclitaxel eluting stents in coronary

coronary stents: a mixed treatment

(comparison of the efficacy and

biolimus A9 eluting

artery disease" , N. Eng l. J. Med. ,

comparison analysis of 117 762

safety of zotarolimus eluting stent

a next generation drug eluting stent

362 ,

patient years of follow up from

with sirolimus eluting and paclitaxel

for

randomized trials" , Circulation, 125 ,

eluting stent for coronary lesions)

Rev. Med. Devices , 3 ,

randomized trial" , J. Am. Col l.

(2006).

1663~1674

(2010).

[54]Kaiser, C.; Galatius S.; Erne P.; et

a l., "Drug eluting versus bare metal
stents in large coronary arteries" ,

2873~2891

[58]F ad

(2012).

J.; Wijns W.; Laarman G.

Cardio l., 56 ,

1187~1195

(2010).

[64]Grube, E.; Buellesfeld L., "BioMatrix

corona stent:

corona arte disease"

Expert.

731~741

[65]Grube E.; Mueller R.; Schuler G.; et

a l., "Comparison of polymer-free

N. Eng l. J. Med. , 363 , 231 0~2319

J.; et a l., "Randomized , double

[61]Camenzind, E. W.; Wijns W.; Mauri

(2010).

blind , multicenter study of the

L.; et a l., "Stent thrombosis and

BioFreedomTf

[55]Jensen, L. 0.; Thayssen P.; Hansen H.

endeavor zotarolimus eluting

m or

clinical events at 3 years after

polymer Taxus LibertTM stents:

S.; et a l., "Randomized comparison

phosphory lcho line-enca psula ted

zotarolimus eluting or sirolimus

3-Year results from the BioFreedom

of everolimus eluting and sirolimus-

stent for treatment of native

eluting coronary stent implantation:

first in Man trial" , J. Am. Col l.

eluting stents in patients treated with

coronary artery lesions: clinical

a randomised ,

percutaneous

corona mterventlOn:

and angiographic results of the

label , controlled trial" , Lancet., 380

the Scandinavian Organization for

ENDEAVOR 11 trial" , Circulation ,

1396~1405

Randomized Trials with Clinical

114, 798~806 (2006).

multicent open

(2012).

stents with durable

Cardio l., 60 (1 7_S) (2012).

[66]Abizaid , A.; Costa J. R. Jr. , "New
drug-eluting stents: an overview

M. W.; Cruden N. L.

on biodegradable and polymer-free

M. B.; Nikolsky E.; Cutlip D.

M. , "Advances in coronary stent

next-generation stent systems" , Circ.

(2012).

E.; et a l., "Improved late clinical

technology: current expectations

Cardiovasc. Interv. , 3 ,

T.; Morimoto T.; Natsuaki

safety with zotarolimus eluting

and new developments" , Clin. Res.

(2010).

M.; et a l., "Comparison of

stents compared with paclitaxel-

Cardio l., 4 , 85~96 (2013).

everolimus-eluting and sirolimus

eluting stents in patients with de

[63]Tada, N.; Virmani R.; Grant G.; et al.,

R.; et a l., "1-year results of the

eluting coronary stents: 1-year

novo coronary lesions: 3 year

"Polymer-free biolimus A9 coated

hydroxyapatite polymer free

outcomes from the randomized

follow up from the ENDEAVOR IV

stent demonstrates more sustained

sirolimus eluting stent for the

evaluation of sirolimus eluting

trial" , JACC Cardiovasc. Interv. , 3,

intimal inhibition, improved healing ,

treatment of single de novo coronary

versus everolimus eluting stent

1043~1050

(2010).

and reduced inflammation compared

lesions: the VESTASYNC 1 trial" ,

[60]Park , D. W.; Kim Y. H.; Yun S. C.;

with a polymer coated sirolimus

JACC Cardiovasc. Interv. , 2 ,

Outcome IV (SORT OUT IV)" ,

Circulation, 125 ,
[56]Kimu

1246~1255

trial (RESET)" , Circulation , 126 ,

76

(2012).

1225~1236

[5 Leon

228

[6 Wilson

20148

384~393

[67]Costa, J. R. Jr.; Abizaid A.; Costa

77

422~427(2009).

[68]Mehilli , J.; Kastrati A.; Wessely

R.; et a l., "Intracoronary stenting

et a l., "Novel fully bioabsorbable

in-man BIOSOLVE 1 trial" , Lancet.,

arteries" , JACC Cardiovasc. Interv. ,

salicylate based sirolimus eluting

381 , 836~844 (2013).

2, 312~320 (2009).

stent" , EuroIntervention. , 5 Suppl F,

F58~F64

[81]Ormiston, J. A.; Abizaid A.; Spertus

J.; et a l., "Six month results of the

(2009).

and angiographic restenosis test

[70]Ormiston , J. A.; Serruys P. W. ,

equivalence between 2 drug

"Bioabsorbable coronary stents" ,

[76]Jabara , R. , "Poly-anhydride based

NEVO res-Elution 1 (NEVO RES-I)

eluting stents (ISAR TEST) trial

Circ. Cardiovasc. Interv. , 2, 255~260

on salicylic acid and adipic acid

trial: a randomized , multicenter

investigators. Randomized trial

(2009).

anhydride" , In: Paper presented at:

comparison of the NEVO sirolimus

EuroPCR (2009).

eluting coronary stent with the

of a nonpolymer based rapamycin

[71 ]Tam H.; Igaki K.; Kyo E.; et

eluting stent versus a polymer

a l., "Initial and 6 month results

[77]Grube , R. , "The REVA tyrosine

TAXUS Li bert paclitaxel-eluting

based paclitaxel eluting stent for

of biodegradable poly 1 lactic

derived polycarbonate bioabsorbable

stent in de novo native coronary

the reduction of late lumen loss" ,

acid coronary stents in humans" ,

stent: final results from the

artery lesions" , Circ. Cardiovasc.

Circulation, 113 , 273~279 (2006).

Circulation, 102 , 399~404 (2000).

RESORB First in man clinical trial

Interv. , 3, 556~564 (2010).

R.; Erbel R.; Di Mario

[72]Tsuji , T.; Tamai H.; Igaki K.; et al.,

and next generation designs" , In:

[82]Abizaid, A., "The NEVO res elution

C.; et a l., "Progress 1 year results

"Biodegradable stents as a platform

Paper presented at: Transcatheter

1 study - a randomised milticentre

of the hydroxyapatite polymer

to drug loading" , Int. J. Cardiovasc.

Cardiovascular Therapeutics (2008).

comparison of the NEVO reservoir

free sirolimus eluting stent for the

Intervent., 5,

[78 ]http://sandiego biotechnolo gy.

based sirolimus eluting stent wuth

[6 Waksman

treatment of single de novo coronary

78

implantation in human coronary

[7 Ielasi

13~ 16

(2003).

A.; Latib A.; Colombo A. ,

the Taxus Liberte paclitaxel eluting

coml?attachment id=2138

stent:rst

presentation of 12-month

drug luting

[79]Abizaid , A. , "The REVA tyrosine

technology" , Expert.

derived polycarbonate bioabsorbable

outcomes" , In: Paper presented at:

stent: lessons learned and future

EuroPCR (2010).

lesions: the VESTASYNC 1 trial

"Current and future

AMS (clinical performance and

corona stent

angiographic results of coronary

Rev. Cardiovasc. Ther. , 9,

stenting with absorbable metal

(2011).

485~503

directions" , In: Paper presented

stents) investigators. Early and long

[74]Ormiston , J. A.; Serruys P. W.;

year results of the hydroxyapatite

Regar E.; et a l., "A bioabsorbable

polymer free sirolimus eluting stent

everolimus eluting coronary stent

for the treatment of single de novo

[8 Dani

S.; Kukreja N.; Parikh P.;

at: Transcatheter Cardiovascular

et a l., "Biodegradable polymer-

Therapeutics (2008).

based, sirolimus eluting Supralimus

stent: 6 month angiographic and

system for patients with single

"Safety and performance of the drug

30 month clinical follow up results

coronary lesions: the VESTASYNC

de-novo coronary artery lesions

eluting absorbable metal scaffold

from the Series 1 prospective study" ,

1 trial term intravascular ultrasound

(ABSORB): a prospective open label

(DREAMS) in patients with de-novo

Eurolntervention, 4, 59~63 (2008).

and angiographic findings after

trial" , Lancet., 371 , 899~907 (2008).

coronary lesions: 12 month results

[84]Vranckx , P.; Serruys P.; Gambhir

bioabsorbable magnesium stent

[75]Jabara , R.; Pendyala L.; Geve S.;

multicentre rst-

S.; et a l., "Biodegradable-polymer-

22 8

[80]Haude , M.; Erbel R.; Eme P.; et

of the prospective ,

20148

79

422~427(2009).

[68]Mehilli , J.; Kastrati A.; Wessely

R.; et a l., "Intracoronary stenting

et a l., "Novel fully bioabsorbable

in-man BIOSOLVE 1 trial" , Lancet.,

arteries" , JACC Cardiovasc. Interv. ,

salicylate based sirolimus eluting

381 , 836~844 (2013).

2, 312~320 (2009).

stent" , EuroIntervention. , 5 Suppl F,

F58~F64

[81]Ormiston, J. A.; Abizaid A.; Spertus

J.; et a l., "Six month results of the

(2009).

and angiographic restenosis test

[70]Ormiston , J. A.; Serruys P. W. ,

equivalence between 2 drug

"Bioabsorbable coronary stents" ,

[76]Jabara , R. , "Poly-anhydride based

NEVO res-Elution 1 (NEVO RES-I)

eluting stents (ISAR TEST) trial

Circ. Cardiovasc. Interv. , 2, 255~260

on salicylic acid and adipic acid

trial: a randomized , multicenter

investigators. Randomized trial

(2009).

anhydride" , In: Paper presented at:

comparison of the NEVO sirolimus

EuroPCR (2009).

eluting coronary stent with the

of a nonpolymer based rapamycin

[71 ]Tam H.; Igaki K.; Kyo E.; et

eluting stent versus a polymer

a l., "Initial and 6 month results

[77]Grube , R. , "The REVA tyrosine

TAXUS Li bert paclitaxel-eluting

based paclitaxel eluting stent for

of biodegradable poly 1 lactic

derived polycarbonate bioabsorbable

stent in de novo native coronary

the reduction of late lumen loss" ,

acid coronary stents in humans" ,

stent: final results from the

artery lesions" , Circ. Cardiovasc.

Circulation, 113 , 273~279 (2006).

Circulation, 102 , 399~404 (2000).

RESORB First in man clinical trial

Interv. , 3, 556~564 (2010).

R.; Erbel R.; Di Mario

[72]Tsuji , T.; Tamai H.; Igaki K.; et al.,

and next generation designs" , In:

[82]Abizaid, A., "The NEVO res elution

C.; et a l., "Progress 1 year results

"Biodegradable stents as a platform

Paper presented at: Transcatheter

1 study - a randomised milticentre

of the hydroxyapatite polymer

to drug loading" , Int. J. Cardiovasc.

Cardiovascular Therapeutics (2008).

comparison of the NEVO reservoir

free sirolimus eluting stent for the

Intervent., 5,

[78 ]http://sandiego biotechnolo gy.

based sirolimus eluting stent wuth

[6 Waksman

treatment of single de novo coronary

78

implantation in human coronary

[7 Ielasi

13~ 16

(2003).

A.; Latib A.; Colombo A. ,

the Taxus Liberte paclitaxel eluting

coml?attachment id=2138

stent:rst

presentation of 12-month

drug luting

[79]Abizaid , A. , "The REVA tyrosine

technology" , Expert.

derived polycarbonate bioabsorbable

outcomes" , In: Paper presented at:

stent: lessons learned and future

EuroPCR (2010).

lesions: the VESTASYNC 1 trial

"Current and future

AMS (clinical performance and

corona stent

angiographic results of coronary

Rev. Cardiovasc. Ther. , 9,

stenting with absorbable metal

(2011).

485~503

directions" , In: Paper presented

stents) investigators. Early and long

[74]Ormiston , J. A.; Serruys P. W.;

year results of the hydroxyapatite

Regar E.; et a l., "A bioabsorbable

polymer free sirolimus eluting stent

everolimus eluting coronary stent

for the treatment of single de novo

[8 Dani

S.; Kukreja N.; Parikh P.;

at: Transcatheter Cardiovascular

et a l., "Biodegradable polymer-

Therapeutics (2008).

based, sirolimus eluting Supralimus

stent: 6 month angiographic and

system for patients with single

"Safety and performance of the drug

30 month clinical follow up results

coronary lesions: the VESTASYNC

de-novo coronary artery lesions

eluting absorbable metal scaffold

from the Series 1 prospective study" ,

1 trial term intravascular ultrasound

(ABSORB): a prospective open label

(DREAMS) in patients with de-novo

Eurolntervention, 4, 59~63 (2008).

and angiographic findings after

trial" , Lancet., 371 , 899~907 (2008).

coronary lesions: 12 month results

[84]Vranckx , P.; Serruys P.; Gambhir

bioabsorbable magnesium stent

[75]Jabara , R.; Pendyala L.; Geve S.;

multicentre rst-

S.; et a l., "Biodegradable-polymer-

22 8

[80]Haude , M.; Erbel R.; Eme P.; et

of the prospective ,

20148

79

 8
CIIJIlI

based , paclitaxel eluting Infinnium stent: 9 month clinical and angiographic

follow up results om the SIMPLE II prospective multi centre registry study" ,
Eurolntervention, 2, 31 0~317 (2006).
[ ]Gr S.; Serruys P. W. , "CoronaT stents: looking forward" , J. Am. Col l. Cardiol.
S43~S78

":1:

(2010).

[86]Grube , E.; Hauptman K.; Buellesfeld L.; et al., "Six month results of a randomized

103

study to evaluate safety and efficacy of a biolimus A9 eluting stent with a

biodegradable polymer coating" , Eurolntervention , 1, 53~57 (2005).
[87]Windecker, S.; Serruys P.W.; Wandel S.; et a l., "Biolimus eluting stent with

372 1163~1173

(LEADERS): a randomized non-inferiority trial", Lancet.,

(2008).

[88]Klauss , v., "Leaders: two year follow up from a prospective randomised trial of

biodegradable polymer versus sirolimus eluting stent with durable polymer for
corona revascularisation

................
..u......
,....
..............
.

E...

biolimus A9-eluting stents with a bioabsorbable polymer vs. sirolimus eluting stents
with a durable polymer" , In: Paper presented at: Transcatheter Cardiovascular

nJii

NT$ 350

[89]Huang , Y.; Venkatraman S. S.; Boey F. Y.; et al.1 vitro and in vivo performance of

99

a dual drug eluting stent (DDES)" , Biomaterials , 31 , 4382~4391 (2010).

[90]Su, L. C.; Chen Y. H.; Chen M. C. , "Dual drug eluting stents coated with multi layers
ofhydrophobic heparin and sirolimus" , ACS App l. Mater. Interface , 5, 12944~12953
(2013).

formation with a stent coated with multiple layers of releasable heparin in porcine
J. Cardiovasc. Pharmaco l., 39 ,

513~522

(2002).

....

KSB

[91]Matsumoto , Y.; Shimokawa H.; Morishige K.; et al., "Reduction in neointimal

Aktiengesellschaft

Centrifugal

Pump

Lexicon"

!llil

KSB

80

Therapeutics (2009).

corona arteries"

?J

228

()

www.mmmpc.cow' TEL: 02-87 (6 8)

 8
CIIJIlI

based , paclitaxel eluting Infinnium stent: 9 month clinical and angiographic

follow up results om the SIMPLE II prospective multi centre registry study" ,
Eurolntervention, 2, 31 0~317 (2006).
[ ]Gr S.; Serruys P. W. , "CoronaT stents: looking forward" , J. Am. Col l. Cardiol.
S43~S78

":1:

(2010).

[86]Grube , E.; Hauptman K.; Buellesfeld L.; et al., "Six month results of a randomized

103

study to evaluate safety and efficacy of a biolimus A9 eluting stent with a

biodegradable polymer coating" , Eurolntervention , 1, 53~57 (2005).
[87]Windecker, S.; Serruys P.W.; Wandel S.; et a l., "Biolimus eluting stent with

372 1163~1173

(LEADERS): a randomized non-inferiority trial", Lancet.,

(2008).

[88]Klauss , v., "Leaders: two year follow up from a prospective randomised trial of

biodegradable polymer versus sirolimus eluting stent with durable polymer for
corona revascularisation

................
..u......
,....
..............
.

E...

biolimus A9-eluting stents with a bioabsorbable polymer vs. sirolimus eluting stents
with a durable polymer" , In: Paper presented at: Transcatheter Cardiovascular

nJii

NT$ 350

[89]Huang , Y.; Venkatraman S. S.; Boey F. Y.; et al.1 vitro and in vivo performance of

99

a dual drug eluting stent (DDES)" , Biomaterials , 31 , 4382~4391 (2010).

[90]Su, L. C.; Chen Y. H.; Chen M. C. , "Dual drug eluting stents coated with multi layers
ofhydrophobic heparin and sirolimus" , ACS App l. Mater. Interface , 5, 12944~12953
(2013).

formation with a stent coated with multiple layers of releasable heparin in porcine
J. Cardiovasc. Pharmaco l., 39 ,

513~522

(2002).

....

KSB

[91]Matsumoto , Y.; Shimokawa H.; Morishige K.; et al., "Reduction in neointimal

Aktiengesellschaft

Centrifugal

Pump

Lexicon"

!llil

KSB

80

Therapeutics (2009).

corona arteries"

?J

228

()

www.mmmpc.cow' TEL: 02-87 (6 8)


z
E'

zzti 67;

!.(l

Yannas Burke

[1]

[4] ;

1993

LangerVacanti

Science

(tissue

engineering)

1997 Vacanti

( cells)
(scaffolds) (signals)l IO]

82

22 8

1980

[2] [3]

20148

83


z
E'

zzti 67;

!.(l

Yannas Burke

[1]

[4] ;

1993

LangerVacanti

Science

(tissue

engineering)

1997 Vacanti

( cells)
(scaffolds) (signals)l IO]

82

22 8

1980

[2] [3]

20148

83

2014
|

Cho

(polycaprolactone)

[14-16]

Si
1

[19]

Foaming method)

2_

1 _ (Particulate Leaching

(gas foaming agent)

[17] [18]

(ammonium bicarbonate)

[] ;

[11] :

[12] ;

[1

1_

84

2. (Gas

3_

228

method)

20148

85

2014
|

Cho

(polycaprolactone)

[14-16]

Si
1

[19]

Foaming method)

2_

1 _ (Particulate Leaching

(gas foaming agent)

[17] [18]

(ammonium bicarbonate)

[] ;

[11] :

[12] ;

[1

1_

84

2. (Gas

3_

228

method)

20148

85

2014
|

[21]

[3 1986 Hu l1

3. (Phase

Separation method)

4. (Electrospinning)

[3:

[22]

1981 Komada

[27]

[37-42]

[43-45]

[] ;

[2]

[31]

1 . (Stereo Iith og ra phy

Apparatus , SLA)

86

5.'(Rapid

Prototyping)

1980

22 8

20148

87

2014
|

[21]

[3 1986 Hu l1

3. (Phase

Separation method)

4. (Electrospinning)

[3:

[22]

1981 Komada

[27]

[37-42]

[43-45]

[] ;

[2]

[31]

1 . (Stereo Iith og ra phy

Apparatus , SLA)

86

5.'(Rapid

Prototyping)

1980

22 8

20148

87

2014
|

'

2. (Laminated

Object

Manufacturing , LOM)

Helisys

Feygin 1986 1991

[3 3

47]

3. (Selective Laser

[50.51]

Sintering , SLS)

Deckard 1986

[5]

[][

k""j

88

22 8

20148

89

2014
|

'

2. (Laminated

Object

Manufacturing , LOM)

Helisys

Feygin 1986 1991

[3 3

47]

3. (Selective Laser

[50.51]

Sintering , SLS)

Deckard 1986

[5]

[][

k""j

88

22 8

20148

89

2 014
|

4. (Fused

Deposition

3D

Stratasys

1989

Sachs Haggerty

(ABS)

(polycarbonate) (polyamides)

[ 5

3D[

; 5

Modeling , FDM)
1989 Crump

5.

(3D

Printing , 3DP)

/()
\

)/

90

228

20148

91

2 014
|

4. (Fused

Deposition

3D

Stratasys

1989

Sachs Haggerty

(ABS)

(polycarbonate) (polyamides)

[ 5

3D[

; 5

Modeling , FDM)
1989 Crump

5.

(3D

Printing , 3DP)

/()
\

)/

90

228

20148

91

2014
|

Abbah

[][] []

[] ;

2012

[78]

Seyedn ad []

2012

Miller []

2005

RepRap

Williams []

Mendel'

(extracellular matrix)

(agarose)

[80-8

(alginate) (polyethylene

glyco l)

[]

Williams

(magnetic

2009 Abbah []

resonance imaging)

(computed tomography)

(rhBMP-2)

1980

92

[ 72]

22 8

(anterior

fusion surgery)

20148

lumbar interbody

93

2014
|

Abbah

[][] []

[] ;

2012

[78]

Seyedn ad []

2012

Miller []

2005

RepRap

Williams []

Mendel'

(extracellular matrix)

(agarose)

[80-8

(alginate) (polyethylene

glyco l)

[]

Williams

(magnetic

2009 Abbah []

resonance imaging)

(computed tomography)

(rhBMP-2)

1980

92

[ 72]

22 8

(anterior

fusion surgery)

20148

lumbar interbody

93

2014
|

Human Epithelium" , N. Eng l. J. Med. ,

2010 Park [87]

311 , 448-451 (1 984).

(polyglycolic acid)

P.L.; Bartolo , P. J., "Advanced

[7]Vacanti , C.A.; Bonass L. J.; Vacanti ,

Biofabrication Strategies for

M.P.; Shufflebarger, J. , "Replacement

Skin Regeneration and Repair" ,

of an Avulsed Phalanx with Tissue-

Nanomedicine, 8, 603-621 (2013).

Engineered Bone" , N. Eng l. J. Med. ,

[14]Cao, L.; Duan, P.G.; Wang , H.R. , et al.,

; 2012

[1]Murray, J.E. , "The 50th Anniversary

of the First Successful Human Organ

[8]Hutmacher, D.W., "Scaffolds in Tissue

of a Novel Poly(Lactic Acid) /N ano-

Transplant" , Rev. Inves t. Clin. , 57 , 118-

Engineering Bone and Cartilage" ,

Sized Beta-Tricalcium Phosphate

119 (2005).

Biomaterials , 21 , 2529-2543 (2000).

Scaffold" , Int. J. Nanomedicine , 7 ,

[2]Gotm

344 , 1511-1514 (2001).

"Degradation and Osteogenic Potential

5881-5888 (2012).

1., "Characteristics of Metals

[9]Cao , Y.; Vacanti , lP.; Paige , K. T.; Upton,

Used in Implants" , J. Endouro l., 11 ,

J.; Vacanti, C.A., "Transplantation of

[15]Yoon , S.J.; Kim , S.H.; Ha , H.J. , et a l.,

383-389 (1 997).

Chondrocytes Utilizing a Polymer-Cell

"Reduction of Inflammatory Reaction

[3]Frazer, R.Q.; Byron , R.T.; Osborne ,

Construct to Produce Tissue-Engineered

of Poly(D ,L-Lactic-Co-Glycolic Acid)

P.B.; West , K. P. , "Pmma: An Essential

Cartilage in the Shape of a Human Ear",

Using Demineralized Bone Particles" ,

Dentist J.

Plas t. Reconstr. Surg. , 100 , 297-302;

Tissue Eng. Part A , 14 , 539-547

discussion 303-294 (1997).

(2008).

Material in Medicine and

Long Term Eff. Med. Implants, 15, 629639 (2005).

[10]Nerem , R.M.; Sambanis , A. , "Tissue

[16]Lendlein , A.; Langer , R. ,

'

[4]Yannas , I.v.; Burke , J.F. , "Design of

Engineering: From Biology to

"Biodegradable , Elastic Shape-

an Artificial Skin. 1. Basic Design

Biological Substitutes" , Tissue Eng. , 1,

Memory Polymers for Potential

Principles" , J. Biomed. Mater. Res. , 14,

3-13 (1 995).

Biomedical Applications" , Science,

65-81 (1980).

94

[l3 ]Pereira , R.F.; Barrias , C.C.; Granja ,

[l1 ]O'Brien, F. J., "Biomaterials & Scaffolds

[5]Langer , R.; Vacanti , J.P. , "Tissue

Engineering Science

(1993).

260 , 920-926

for Tissue Engineering" , Mater. Today,

14, 88-95 (2011).
[1 Habraken

296, 1673-1676 (2002).

[17]Thomson , R.C.; Yaszemski , M.J.;
Powe J. M.; Mikos , A.G. ,

W.J.E.M.; Wolke, J.G.C.;

"Fabrication ofBiodegradable Polymer

[6]Gallico , G.G. , 3rd; O'Connor, N.E.;

Jansen, J.A. , "Ceramic Composites

Scaffolds to Engineer Trabecular

Compton , C.C.; Kehinde , 0.; Green ,

as Matrices and Scaffolds for Drug

Bone" , J. Biomater. Sci. Polym. Ed. , 7,

H., "Permanent Coverage of Large Bum

Delivery in Tissue Engineering", Adv.

23-38 (1995).

Wounds with Autologous Cultured

Drug Deliv. Rev., 59, 234-248 (2007).

22 8

20148

[18]Mikos , A.G.; Thorsen , A. J.;

95

2014
|

Human Epithelium" , N. Eng l. J. Med. ,

2010 Park [87]

311 , 448-451 (1 984).

(polyglycolic acid)

P.L.; Bartolo , P. J., "Advanced

[7]Vacanti , C.A.; Bonass L. J.; Vacanti ,

Biofabrication Strategies for

M.P.; Shufflebarger, J. , "Replacement

Skin Regeneration and Repair" ,

of an Avulsed Phalanx with Tissue-

Nanomedicine, 8, 603-621 (2013).

Engineered Bone" , N. Eng l. J. Med. ,

[14]Cao, L.; Duan, P.G.; Wang , H.R. , et al.,

; 2012

[1]Murray, J.E. , "The 50th Anniversary

of the First Successful Human Organ

[8]Hutmacher, D.W., "Scaffolds in Tissue

of a Novel Poly(Lactic Acid) /N ano-

Transplant" , Rev. Inves t. Clin. , 57 , 118-

Engineering Bone and Cartilage" ,

Sized Beta-Tricalcium Phosphate

119 (2005).

Biomaterials , 21 , 2529-2543 (2000).

Scaffold" , Int. J. Nanomedicine , 7 ,

[2]Gotm

344 , 1511-1514 (2001).

"Degradation and Osteogenic Potential

5881-5888 (2012).

1., "Characteristics of Metals

[9]Cao , Y.; Vacanti , lP.; Paige , K. T.; Upton,

Used in Implants" , J. Endouro l., 11 ,

J.; Vacanti, C.A., "Transplantation of

[15]Yoon , S.J.; Kim , S.H.; Ha , H.J. , et a l.,

383-389 (1 997).

Chondrocytes Utilizing a Polymer-Cell

"Reduction of Inflammatory Reaction

[3]Frazer, R.Q.; Byron , R.T.; Osborne ,

Construct to Produce Tissue-Engineered

of Poly(D ,L-Lactic-Co-Glycolic Acid)

P.B.; West , K. P. , "Pmma: An Essential

Cartilage in the Shape of a Human Ear",

Using Demineralized Bone Particles" ,

Dentist J.

Plas t. Reconstr. Surg. , 100 , 297-302;

Tissue Eng. Part A , 14 , 539-547

discussion 303-294 (1997).

(2008).

Material in Medicine and

Long Term Eff. Med. Implants, 15, 629639 (2005).

[10]Nerem , R.M.; Sambanis , A. , "Tissue

[16]Lendlein , A.; Langer , R. ,

'

[4]Yannas , I.v.; Burke , J.F. , "Design of

Engineering: From Biology to

"Biodegradable , Elastic Shape-

an Artificial Skin. 1. Basic Design

Biological Substitutes" , Tissue Eng. , 1,

Memory Polymers for Potential

Principles" , J. Biomed. Mater. Res. , 14,

3-13 (1 995).

Biomedical Applications" , Science,

65-81 (1980).

94

[l3 ]Pereira , R.F.; Barrias , C.C.; Granja ,

[l1 ]O'Brien, F. J., "Biomaterials & Scaffolds

[5]Langer , R.; Vacanti , J.P. , "Tissue

Engineering Science

(1993).

260 , 920-926

for Tissue Engineering" , Mater. Today,

14, 88-95 (2011).
[1 Habraken

296, 1673-1676 (2002).

[17]Thomson , R.C.; Yaszemski , M.J.;
Powe J. M.; Mikos , A.G. ,

W.J.E.M.; Wolke, J.G.C.;

"Fabrication ofBiodegradable Polymer

[6]Gallico , G.G. , 3rd; O'Connor, N.E.;

Jansen, J.A. , "Ceramic Composites

Scaffolds to Engineer Trabecular

Compton , C.C.; Kehinde , 0.; Green ,

as Matrices and Scaffolds for Drug

Bone" , J. Biomater. Sci. Polym. Ed. , 7,

H., "Permanent Coverage of Large Bum

Delivery in Tissue Engineering", Adv.

23-38 (1995).

Wounds with Autologous Cultured

Drug Deliv. Rev., 59, 234-248 (2007).

22 8

20148

[18]Mikos , A.G.; Thorsen , A. J.;

95

2014
|

Czerwonka, L. A. , et a l., "Preparation

321-330 (2007).

[35]Gu

M.; Mlhau R. , "8.04 - Rapid

and Characterization of Poly(L-Lactic

[24]Madihally , S.V.; Matthew , H.W. ,

[30] Rnjak-Kovacina, J.; Wise , S.G.; Li, Z. ,

Prototyping" , In: Matyjaszewski , K. ,

Acid) Foams" , Polymer, 35 , 1068-

"Porous Chitosan Scaffolds for Tissue

et a 1., "Electrospun Synthetic Human

Mller, M. , (Eds.). Polymer Science:

1077 (1994).

Engineering" , Biomaterials , 20 , 1133-

Elastin:Collagen Composite Scaffolds

A Comprehensive Reference.

1142 (1 999).

for Derrnal Tissue Engineering" , Acta

Amsterdam 77-99 (2012).

[19]Cho , Y. S.; Kim , B.-S.; You , H.-K.; Cho ,

Y.-S. , "A Novel Technique for Scaffold

[25]Lu , G.; Zhu , L.; Kong , L., et a 1.,

Fabrication: Slup (Salt Leaching Using

"Porous Chitosan Microcarriers for

Powder)" , Curr. App l. Phys. , 14, 371377 (2014).

[20]Nam , Y. S.; Yoon , J.J.; Park , T.G. ,
"A Novel Fabrication Method of

Biomater. , 8, 3714-3722 (2012).

Elsevi

[36]Yeong , W.-Y.; Chua , C.-K.; Leong ,

D.-G.; Chian , W.; Wang , X.; Li ,

K.-F.; Chandrasekaran , M. , "Rapid

Large Scale Cultivation of Cells for

X.- Y.; Li, Y.; Liao , Y. -Z. , "Linear

Prototyping in Tissue Engineering:

Tissue Engineering: Fabrication and

Drug Release Membrane Prepared by

Challenges and Potential" , Trends

Evaluation" , Tsinghua Sci. Techno l.,

a Modified Coaxial Electrospinning

Biotechnol., 22 , 643 652 (2004).

11 , 427-432 (2006).

Process" , I. Membr. Sci. , 428 0-156

Macroporous Biodegradable Polymer

[26]Baumgarten , P.K. , "E1 ectrostatic

Scaffolds Using Gas Foaming Salt as a

Spinning of Acrylic Microfibers" , J.

Porogen Additive" , J. Biomed. Mater.

Colloid.lnterf. Sci. 36 , 71-79 (1 971).

[31]

[37]Bagaria ,

v.;

Deshpande , S.; Rasalk

D.D.; Kuthe , A.;

(2013).

Paunipag

B.K. ,

L.; Li cht, R.; de Boer, J.; de

"Use of Rapid Prototyping and Three-

Wijn , J.R.; van Blitterswijk , C.A. ,

Dimensional Reconstruction Modeling

[27]Bognitzki , M.; Czado , W.; Frese , T. ,

"Fiber Diameter and Texture of

in the Management of Complex

M. L.; Howard , D. , et

et a 1., "Nanostructured Fibers Via

Electrospun PEOT/PBT Scaffolds

Fractures" , Eur. J. Radio l., 80, 814-820

a1., "Control ofPore Size and Structure

Electrospinning" , Adv. Mater. , 13 , 70-

In f1 uence Human Mesenchymal Stem

(2011).

of Tissue Engineering Scaffolds

72 (2001).

Cell Proliferation and Morphology,

[38]Hutmacher, D.W.; Sittinger, M.;

Res. , 53 , 1-7 (2000).

[21]T: H.; 1ather

[3 Moroni

Produced by Supercritical Fluid

[28]Rho , K.S.; Jeong , L.; Lee , G. , et

and the Release of Incorporated

Risbud , M.V. , "Scaffold-Based Tissue

Processing" , Eur. Cell. Mater. , 14, 64-

a 1., "Electrospinning of Collagen

Compounds" , Biomaterials , 27 , 4911-

Engineering: Rationale for Computer-

77 (2007).

Nanofibers: Effects on the Behavior

4922 (2006).

Aided Design and Solid Free-

[22]Nam , Y. S.; Park, T.G. , "Biodegradable

of Normal Human Keratinocytes

Polymeric Microcellular Foams by

and Ea r1 y-Stage Wound Healing" ,

"Rapid Prototyping: Principles and

Modified Thermally Induced Phase

Biomaterials , 27 , 1452-1461 (2006).

Applications". Wo r1 d Scientific ,

Separation Method" , Biomaterials , 20 ,

[29]Chong , E.J.; Phan , T.T.; Lim , I. J. , et

[3 Chua

C.K.; Leong , K. F.; Lim , C.S. ,

Singapore (2003).

Form Fabrication Systems" , Trends

Biotechno1., 22 , 354-362 (2004).
[3 Li I. P.;

de Wijn , J.R.; Van Blittersw

C.A.; de Groot , K. , "Porous Ti 6A1 4V

a l., "Evaluation of Electrospun P c1 1

[34]Hull, C.W. , "Apparatus for Production

Scaffold Direct1 y Fabricating by Rapid

K.; Thomas , C.H.; Healy,

Gelatin Nanofibrous Scaffold for

of Three-Dimensional Objects by

Prototyping: Preparation and in Vitro

K.E.; Nuber, G. , "A Novel Method to

Wound Healing and Layered Dermal

Stereolithography" , United States

Experiment" , Biomaterials , 27 , 1223-

Fabricate Bioabsorbable Scaffolds" ,

Reconstitution" , Acta Biomater. , 3 ,

Patents , US4575330 A (1 986).

1235 (2006).

1783-1790 (1 999).
[2 Whang

96

Polymer, 36 , 837-842 (1 995).

22 8

20148

97

2014
|

Czerwonka, L. A. , et a l., "Preparation

321-330 (2007).

[35]Gu

M.; Mlhau R. , "8.04 - Rapid

and Characterization of Poly(L-Lactic

[24]Madihally , S.V.; Matthew , H.W. ,

[30] Rnjak-Kovacina, J.; Wise , S.G.; Li, Z. ,

Prototyping" , In: Matyjaszewski , K. ,

Acid) Foams" , Polymer, 35 , 1068-

"Porous Chitosan Scaffolds for Tissue

et a 1., "Electrospun Synthetic Human

Mller, M. , (Eds.). Polymer Science:

1077 (1994).

Engineering" , Biomaterials , 20 , 1133-

Elastin:Collagen Composite Scaffolds

A Comprehensive Reference.

1142 (1 999).

for Derrnal Tissue Engineering" , Acta

Amsterdam 77-99 (2012).

[19]Cho , Y. S.; Kim , B.-S.; You , H.-K.; Cho ,

Y.-S. , "A Novel Technique for Scaffold

[25]Lu , G.; Zhu , L.; Kong , L., et a 1.,

Fabrication: Slup (Salt Leaching Using

"Porous Chitosan Microcarriers for

Powder)" , Curr. App l. Phys. , 14, 371377 (2014).

[20]Nam , Y. S.; Yoon , J.J.; Park , T.G. ,
"A Novel Fabrication Method of

Biomater. , 8, 3714-3722 (2012).

Elsevi

[36]Yeong , W.-Y.; Chua , C.-K.; Leong ,

D.-G.; Chian , W.; Wang , X.; Li ,

K.-F.; Chandrasekaran , M. , "Rapid

Large Scale Cultivation of Cells for

X.- Y.; Li, Y.; Liao , Y. -Z. , "Linear

Prototyping in Tissue Engineering:

Tissue Engineering: Fabrication and

Drug Release Membrane Prepared by

Challenges and Potential" , Trends

Evaluation" , Tsinghua Sci. Techno l.,

a Modified Coaxial Electrospinning

Biotechnol., 22 , 643 652 (2004).

11 , 427-432 (2006).

Process" , I. Membr. Sci. , 428 0-156

Macroporous Biodegradable Polymer

[26]Baumgarten , P.K. , "E1 ectrostatic

Scaffolds Using Gas Foaming Salt as a

Spinning of Acrylic Microfibers" , J.

Porogen Additive" , J. Biomed. Mater.

Colloid.lnterf. Sci. 36 , 71-79 (1 971).

[31]

[37]Bagaria ,

v.;

Deshpande , S.; Rasalk

D.D.; Kuthe , A.;

(2013).

Paunipag

B.K. ,

L.; Li cht, R.; de Boer, J.; de

"Use of Rapid Prototyping and Three-

Wijn , J.R.; van Blitterswijk , C.A. ,

Dimensional Reconstruction Modeling

[27]Bognitzki , M.; Czado , W.; Frese , T. ,

"Fiber Diameter and Texture of

in the Management of Complex

M. L.; Howard , D. , et

et a 1., "Nanostructured Fibers Via

Electrospun PEOT/PBT Scaffolds

Fractures" , Eur. J. Radio l., 80, 814-820

a1., "Control ofPore Size and Structure

Electrospinning" , Adv. Mater. , 13 , 70-

In f1 uence Human Mesenchymal Stem

(2011).

of Tissue Engineering Scaffolds

72 (2001).

Cell Proliferation and Morphology,

[38]Hutmacher, D.W.; Sittinger, M.;

Res. , 53 , 1-7 (2000).

[21]T: H.; 1ather

[3 Moroni

Produced by Supercritical Fluid

[28]Rho , K.S.; Jeong , L.; Lee , G. , et

and the Release of Incorporated

Risbud , M.V. , "Scaffold-Based Tissue

Processing" , Eur. Cell. Mater. , 14, 64-

a 1., "Electrospinning of Collagen

Compounds" , Biomaterials , 27 , 4911-

Engineering: Rationale for Computer-

77 (2007).

Nanofibers: Effects on the Behavior

4922 (2006).

Aided Design and Solid Free-

[22]Nam , Y. S.; Park, T.G. , "Biodegradable

of Normal Human Keratinocytes

Polymeric Microcellular Foams by

and Ea r1 y-Stage Wound Healing" ,

"Rapid Prototyping: Principles and

Modified Thermally Induced Phase

Biomaterials , 27 , 1452-1461 (2006).

Applications". Wo r1 d Scientific ,

Separation Method" , Biomaterials , 20 ,

[29]Chong , E.J.; Phan , T.T.; Lim , I. J. , et

[3 Chua

C.K.; Leong , K. F.; Lim , C.S. ,

Singapore (2003).

Form Fabrication Systems" , Trends

Biotechno1., 22 , 354-362 (2004).
[3 Li I. P.;

de Wijn , J.R.; Van Blittersw

C.A.; de Groot , K. , "Porous Ti 6A1 4V

a l., "Evaluation of Electrospun P c1 1

[34]Hull, C.W. , "Apparatus for Production

Scaffold Direct1 y Fabricating by Rapid

K.; Thomas , C.H.; Healy,

Gelatin Nanofibrous Scaffold for

of Three-Dimensional Objects by

Prototyping: Preparation and in Vitro

K.E.; Nuber, G. , "A Novel Method to

Wound Healing and Layered Dermal

Stereolithography" , United States

Experiment" , Biomaterials , 27 , 1223-

Fabricate Bioabsorbable Scaffolds" ,

Reconstitution" , Acta Biomater. , 3 ,

Patents , US4575330 A (1 986).

1235 (2006).

1783-1790 (1 999).
[2 Whang

96

Polymer, 36 , 837-842 (1 995).

22 8

20148

97

[40]McCullough, E.J.; Yadavalli, V. K. ,

"Surface 1odification

of Fused

Deposition Modeling ABS to Enable

Rapid Prototyping of Biomedical
Microdevices J.

Mater. Process.

Tech. , 213 , 947-954 (2013).

[41]Ryan, G.E.; Pandit, A.S.; Apatsidis,
D.P. , "Porous Titanium Scaffolds

Tooling" , J. Mater. Process. Tech. ,

Indian. J. Plas t. Surg. , 42 , 85-93

132 , 42-48 (2003).

[46]Kodama, H. , "Automatic Method for

K.H.; Wiria , F.E.; Cheah , C.M. ,

Selective Laser Sintering" , Appl. Surf.

Fabricating a Three-Dimensional

"Development of Tissue Scaffolds

Sci. , 254, 989-992 (2007).

Plastic Model with Photo-Hardening

Using Selective Laser Sintering of

[57]Masood , S.H.; Song , W.Q. ,

Polymer", Rev. Sci. Ins. Trum. , 52,

Polyvinyl Alcoho l/ Hydroxyapatite

"Development of New MetallPolymer

1770-1773 (1 981).

Biocomposite for Craniofacial and

Materials for Rapid Tooling Using

Joint Defects" , J. Mater. Sci. Mater.

Fused Deposition Modelling" , Mater.

Med. , 15 , 1113-1121 (2004).

Design. , 25 , 587-594 (2004).

and Powder Metallurgy Technique" ,

Planning Effect for the Accuracy of

Biomaterials , 29 , 3625-3635 (2008).

Rapid Prototyping System" , Int. J.

Architecture Design and Freeform

Goeuriot, P.; Smurov, 1., "Ceramic

Components Manufacturing by

[47]Huang , Y.-M.; Lan, H.- Y. , "Path

D. , "New Paradigms in Internal

[56]Bertrand, P.; Bayle, F.; Combe, C.;

[52]Chua , C.K.; Leong , K.F.; Tan ,

(2009).

Fabricated Using a Rapid Prototyping

[4 Yoo

[53]Salmoria, G. v.;

J. L.; Ahrens,

[58]Greul, M.; Pintat, T.; Greulich, M. ,

Adv. Manu f. Technol., 30, 233-246

C.H.; Lago , A.; Pires , A.T.N. ,

"Rapid Prototyping of Functional

(2006).

"Rapid Manufacturing of PA/HDPE

Metallic Parts", Comput. Ind. , 28, 2328 (1995).

Lei

Fabrication of Tissue Engineering

[48]Tari, M.J.; Bals, A.; Park, J.; Lin, M. Y.;

Blend Specimens by Selective

Porous Scaffolds" , Med. Eng. Phys. ,

Thomas Hahn , H. , "Rapid Prototyping

Laser Sintering: Microstructural

[59]Pham , D.T.; Gault , R.S. , "A

34, 762-776 (2012).

of Composite Parts Using Resin

Characterization" , Polymer Testing ,

Comparison of Rapid Prototyping

Potamian

Transfer Molding and Laminated

26 , 361-368 (2007).

Technologies" , In t. J. Mach. Tool.

P.; Goodger, N.M. , "Rapid Prototyping

Object Manufacturing" , Composites

Techniques for Anatomical Modelling

Part A, 29 , 651-661 (1 998).

[43]McGu

M.; Amis, A.A.;

in Medicine" , Ann. R. Col l. Surg.

Engl., 79, 169-174 (1 997).
[44]Hoque , M.E. , "Advanced Applications
of Rapid Prototyping Technology in
Modern Engineering". InTech , Rijeka
(2011).
[45]Chaware, S.M.; Bagaria, v.; Kuthe, A.,
"Application of the Rapid

98

Treat Temporomandibular Ankylosis" ,

Protorpmg

[54]Nakamoto, T.; Shirakawa, N.; Miyata,

Manu. , 38 , 1257-1287 (1 998).

H. , "Selective Laser Sintering

[60]Cima, M.J.; Haggerty, J.S.; Sachs,

C.R. , "Method and Apparatus

of High Carbon Steel Powders Studied

E.M.; Williams , P.A. , "Three-

for Producing Parts by Selective

as a Function of Carbon Content" , J.

Dimensional Printing Techniques" ,

Sintering" , United States Patents , US

Mater. Process. Tech. , 209 , 5653-5660

United States Patents , US 5204055 A

4863538 A (1 989).

(2009).

(1 993).

[4 Deckard

[50]Kathuria , Y. P. , "Microstructuring by

Y.;Im

[55]Yu, P.;

Schaffi

G.B., "Microstructural

[61]Sachs, E.; Cima, M.; Williams, P.;

Corn

Selective Laser Sintering of Metallic

Evolution During Pressureless

Brancazio , D.;

Powder", Surf. Coat. Tech., 116-119,

Infiltration of Aluminium Alloy

Dimensional Printing: Rapid Tooling

643-647 (1 999).

Parts Fabricated by Selective Laser

and Prototypes Directly from a Cad

Sintering", Acta Mater., 57, 163-170

Model", J. Manuf. Sci. E., 114, 481-

(2009).

488 (1 992).

Technique to Design a Customized

[51]King, D.; Tansey, T., "Rapid Tooling:

Temporomandibular J oint U sed to

Selective Laser Sintering Injection

228

20148

J. , "Three

99

[40]McCullough, E.J.; Yadavalli, V. K. ,

"Surface 1odification

of Fused

Deposition Modeling ABS to Enable

Rapid Prototyping of Biomedical
Microdevices J.

Mater. Process.

Tech. , 213 , 947-954 (2013).

[41]Ryan, G.E.; Pandit, A.S.; Apatsidis,
D.P. , "Porous Titanium Scaffolds

Tooling" , J. Mater. Process. Tech. ,

Indian. J. Plas t. Surg. , 42 , 85-93

132 , 42-48 (2003).

[46]Kodama, H. , "Automatic Method for

K.H.; Wiria , F.E.; Cheah , C.M. ,

Selective Laser Sintering" , Appl. Surf.

Fabricating a Three-Dimensional

"Development of Tissue Scaffolds

Sci. , 254, 989-992 (2007).

Plastic Model with Photo-Hardening

Using Selective Laser Sintering of

[57]Masood , S.H.; Song , W.Q. ,

Polymer", Rev. Sci. Ins. Trum. , 52,

Polyvinyl Alcoho l/ Hydroxyapatite

"Development of New MetallPolymer

1770-1773 (1 981).

Biocomposite for Craniofacial and

Materials for Rapid Tooling Using

Joint Defects" , J. Mater. Sci. Mater.

Fused Deposition Modelling" , Mater.

Med. , 15 , 1113-1121 (2004).

Design. , 25 , 587-594 (2004).

and Powder Metallurgy Technique" ,

Planning Effect for the Accuracy of

Biomaterials , 29 , 3625-3635 (2008).

Rapid Prototyping System" , Int. J.

Architecture Design and Freeform

Goeuriot, P.; Smurov, 1., "Ceramic

Components Manufacturing by

[47]Huang , Y.-M.; Lan, H.- Y. , "Path

D. , "New Paradigms in Internal

[56]Bertrand, P.; Bayle, F.; Combe, C.;

[52]Chua , C.K.; Leong , K.F.; Tan ,

(2009).

Fabricated Using a Rapid Prototyping

[4 Yoo

[53]Salmoria, G. v.;

J. L.; Ahrens,

[58]Greul, M.; Pintat, T.; Greulich, M. ,

Adv. Manu f. Technol., 30, 233-246

C.H.; Lago , A.; Pires , A.T.N. ,

"Rapid Prototyping of Functional

(2006).

"Rapid Manufacturing of PA/HDPE

Metallic Parts", Comput. Ind. , 28, 2328 (1995).

Lei

Fabrication of Tissue Engineering

[48]Tari, M.J.; Bals, A.; Park, J.; Lin, M. Y.;

Blend Specimens by Selective

Porous Scaffolds" , Med. Eng. Phys. ,

Thomas Hahn , H. , "Rapid Prototyping

Laser Sintering: Microstructural

[59]Pham , D.T.; Gault , R.S. , "A

34, 762-776 (2012).

of Composite Parts Using Resin

Characterization" , Polymer Testing ,

Comparison of Rapid Prototyping

Potamian

Transfer Molding and Laminated

26 , 361-368 (2007).

Technologies" , In t. J. Mach. Tool.

P.; Goodger, N.M. , "Rapid Prototyping

Object Manufacturing" , Composites

Techniques for Anatomical Modelling

Part A, 29 , 651-661 (1 998).

[43]McGu

M.; Amis, A.A.;

in Medicine" , Ann. R. Col l. Surg.

Engl., 79, 169-174 (1 997).
[44]Hoque , M.E. , "Advanced Applications
of Rapid Prototyping Technology in
Modern Engineering". InTech , Rijeka
(2011).
[45]Chaware, S.M.; Bagaria, v.; Kuthe, A.,
"Application of the Rapid

98

Treat Temporomandibular Ankylosis" ,

Protorpmg

[54]Nakamoto, T.; Shirakawa, N.; Miyata,

Manu. , 38 , 1257-1287 (1 998).

H. , "Selective Laser Sintering

[60]Cima, M.J.; Haggerty, J.S.; Sachs,

C.R. , "Method and Apparatus

of High Carbon Steel Powders Studied

E.M.; Williams , P.A. , "Three-

for Producing Parts by Selective

as a Function of Carbon Content" , J.

Dimensional Printing Techniques" ,

Sintering" , United States Patents , US

Mater. Process. Tech. , 209 , 5653-5660

United States Patents , US 5204055 A

4863538 A (1 989).

(2009).

(1 993).

[4 Deckard

[50]Kathuria , Y. P. , "Microstructuring by

Y.;Im

[55]Yu, P.;

Schaffi

G.B., "Microstructural

[61]Sachs, E.; Cima, M.; Williams, P.;

Corn

Selective Laser Sintering of Metallic

Evolution During Pressureless

Brancazio , D.;

Powder", Surf. Coat. Tech., 116-119,

Infiltration of Aluminium Alloy

Dimensional Printing: Rapid Tooling

643-647 (1 999).

Parts Fabricated by Selective Laser

and Prototypes Directly from a Cad

Sintering", Acta Mater., 57, 163-170

Model", J. Manuf. Sci. E., 114, 481-

(2009).

488 (1 992).

Technique to Design a Customized

[51]King, D.; Tansey, T., "Rapid Tooling:

Temporomandibular J oint U sed to

Selective Laser Sintering Injection

228

20148

J. , "Three

99

2014
|

[62]Sachs, E.; Wylonis, E.; Allen, S.; Cima,

M.; Guo , H. , "Production of Injection

[67]Holzapfel , B.M.;

Reiche

J.C.;

Molding Tooling with Conformal

Schantz, J.-T. , et al., "How Smart

Cooling Channels U sing the Three

Do Biomaterials Need to Be? A

Dimensional Printing Process" , Polym.

Eng. Sci. , 40 , 1232-1247 (2000).
[6 Curodeau

A.; Sachs, E.; Caldarise,

Biomimetic Microvascular Networks

"Repair of Segmental Defects in Rabbit

for Efficient Fluid Transport" , Soft

Humeri with Titanium Fiber Mesh

Matter, 6, 739-742 (2010).

Cylinders Containing Recombinant

W.; DeConinck, A.; Lewis ,

Human Bone Morphogenetic Protein-2

Translational Science and Clinical

J.A. , "Omnidirectional Printing of

(Rhbmp-2) and a Synthetic Polymer" ,

Point ofView" , Adv. Drug Deliv. Rev. ,

3D Microvascular Networks" , Adv.

J. Biomed. Mater. Res. , 62 , 169-174

65 , 581-603 (2013).

Mater. , 23 , 178-183 (2011).

(2002).

[7 Wu

[7 Miller

J.S.; Stevens, K. R.; Yang, M.T.,

[77]Yang, J.; Chen, H.J.; Zhu, X.D., et al.,

Tissue Engineering Scaffolds Work.

et al., "Rapid Casting of Patterned

"Enhanced Repair of a Critical-Sized

Surface Textures from 3-D Printed

Review: The Application of Solid

Vascular Networks for Perfusable

Segmental Bone Defect in Rabbit

Ceramic Shell" , J. Biomed. Mater.

Freeform Fabrication Technology to

Engineered Three-DimensionaI

Femur by Surface Microstructured

Res. , 53 , 525-535 (2000).

the Production of Tissue Engineering

Tissues" , Nat. Mater., 11 , 768-774

Porous Titanium" , J. Mater. Sci. Mater.

(2012).

Med. , in press (2014).

S. , "Design and Fabrication of Cast

[68]Sachlos, E.; Czernuszka, J.T., "Making

Orthopedic Implants with Freeform

[64 ]Pfister, A.;

Lande

R.; Laib, A.;

Scaffolds", Eur.

Cell. 1ater.

5, 29-40

[74]Okafuji, N.; Shimizu, T.; Watanabe,

[78]Cao, L.; Werkmeister, J.A.; Wang ,

D.; Wh ite, S. R.; Lewis, J.A.,

T. , et a l., "Tissue Reaction to

J.; Glattauer, V.; McLean , K.M.;

Prototyping for Tissue-Engineering

"Chaotic Mixing in Three-Dimensional

Poly (Lactic-Co-Glycolic Acid)

Liu , C. , "Bone Regeneration

Applications: 3D Bioplotting Versus

Microvascular Networks Fabricated by

Copolymer Membrane in Rhbmp

Using Photocrosslinked Hydrogel

3d Printing" , J. Polym. Sci. Po l.

Direct-Write Assembly" , Nat. Mater. ,

Used Rabbit ExperimentaI Mandibular

Incorporating Rhbmp-2 Loaded 2-N ,

Chem. , 42 , 624-638 (2004).

2, 265-271 (2003).

Reconstruction", Eur. J. Med. Res. , 11 ,

6-0-Sulfated Chitosan Nanoparti c1 es" ,

394-396 (2006).

Biomaterials , 35 , 2730-2742 (2014).

Hbner , U.; Schmelzeisen , R.;

Mlhaupt , R. , "Biofunctional Rapid

(2003).
[6 Theiault

[65]Yang, S.; Leong, K.F.; Du, Z.; Chua,

[70]Bellan, L. M.; Singh, S.P.; Henderson,

C.K. , "The Design of Scaffolds for

P.W.; Porri , T.J.; Craighead , H.G.;

Use in Tissue Engineering. Part II.

Spector , J.A. , "Fabrication of an

S.; Cheng , L., "Biocompatibility

R. 1

Rapid Prototyping Techniques" , Tissue

Artificial 3-Dimensional Vascular

and Osteogenesis of Biomimetic

Using Polycaprolactone Scaffolds

Eng. , 8, 1-11 (2002).

Network Using Sacrificial Sugar

Nano-Hydroxyapatite/Polyamide

Fabricated Via Selective Laser

Structures", Soft Matter, 5, 1354-1357

Composite Scaffolds for Bone Tissue

Sintering", Biomaterials, 26, 4817-

(2009).

Engineering", Biomaterials, 28, 3338-

4827 (2005).

[66]Billiet , T.; Vandenhaute , M.;

Schelfhout , J.; Van Vlierberghe , S.;

100

Biomaterials , 33 , 6020-6041 (2012).

[7 Wang

H.; Li, Y.; Zuo, Y.; Li, J.; Ma,

Dubruel , P. , "A Review of Trends

[71]Wu, W.; Hansen, C.J.; Aragon, A.M.;

and Limitations in Hydrogel-Rapid

Geubelle, P.H.; White, S.R.; Lewis,

[76]Murakami, N.; Saito, N.; Horiuchi, H.;

Prototyping for Tissue Engineering" ,

J.A. , "Direct- Write Assembly of

Okada, T.; Nozaki, K.; Takaoka, K. ,

228

3348 (2007).

20148

[7 Williams

J.M.; Adewunmi, A.;

Sch

et al., "Bone Tissue Engineering

[80]Chandra , R.; Rustgi , R. ,

"Biodegradable Polymers" , Prog.
Polym. Sc i., 23 , 1273-1335 (1 998).

101

2014
|

[62]Sachs, E.; Wylonis, E.; Allen, S.; Cima,

M.; Guo , H. , "Production of Injection

[67]Holzapfel , B.M.;

Reiche

J.C.;

Molding Tooling with Conformal

Schantz, J.-T. , et al., "How Smart

Cooling Channels U sing the Three

Do Biomaterials Need to Be? A

Dimensional Printing Process" , Polym.

Eng. Sci. , 40 , 1232-1247 (2000).
[6 Curodeau

A.; Sachs, E.; Caldarise,

Biomimetic Microvascular Networks

"Repair of Segmental Defects in Rabbit

for Efficient Fluid Transport" , Soft

Humeri with Titanium Fiber Mesh

Matter, 6, 739-742 (2010).

Cylinders Containing Recombinant

W.; DeConinck, A.; Lewis ,

Human Bone Morphogenetic Protein-2

Translational Science and Clinical

J.A. , "Omnidirectional Printing of

(Rhbmp-2) and a Synthetic Polymer" ,

Point ofView" , Adv. Drug Deliv. Rev. ,

3D Microvascular Networks" , Adv.

J. Biomed. Mater. Res. , 62 , 169-174

65 , 581-603 (2013).

Mater. , 23 , 178-183 (2011).

(2002).

[7 Wu

[7 Miller

J.S.; Stevens, K. R.; Yang, M.T.,

[77]Yang, J.; Chen, H.J.; Zhu, X.D., et al.,

Tissue Engineering Scaffolds Work.

et al., "Rapid Casting of Patterned

"Enhanced Repair of a Critical-Sized

Surface Textures from 3-D Printed

Review: The Application of Solid

Vascular Networks for Perfusable

Segmental Bone Defect in Rabbit

Ceramic Shell" , J. Biomed. Mater.

Freeform Fabrication Technology to

Engineered Three-DimensionaI

Femur by Surface Microstructured

Res. , 53 , 525-535 (2000).

the Production of Tissue Engineering

Tissues" , Nat. Mater., 11 , 768-774

Porous Titanium" , J. Mater. Sci. Mater.

(2012).

Med. , in press (2014).

S. , "Design and Fabrication of Cast

[68]Sachlos, E.; Czernuszka, J.T., "Making

Orthopedic Implants with Freeform

[64 ]Pfister, A.;

Lande

R.; Laib, A.;

Scaffolds", Eur.

Cell. 1ater.

5, 29-40

[74]Okafuji, N.; Shimizu, T.; Watanabe,

[78]Cao, L.; Werkmeister, J.A.; Wang ,

D.; Wh ite, S. R.; Lewis, J.A.,

T. , et a l., "Tissue Reaction to

J.; Glattauer, V.; McLean , K.M.;

Prototyping for Tissue-Engineering

"Chaotic Mixing in Three-Dimensional

Poly (Lactic-Co-Glycolic Acid)

Liu , C. , "Bone Regeneration

Applications: 3D Bioplotting Versus

Microvascular Networks Fabricated by

Copolymer Membrane in Rhbmp

Using Photocrosslinked Hydrogel

3d Printing" , J. Polym. Sci. Po l.

Direct-Write Assembly" , Nat. Mater. ,

Used Rabbit ExperimentaI Mandibular

Incorporating Rhbmp-2 Loaded 2-N ,

Chem. , 42 , 624-638 (2004).

2, 265-271 (2003).

Reconstruction", Eur. J. Med. Res. , 11 ,

6-0-Sulfated Chitosan Nanoparti c1 es" ,

394-396 (2006).

Biomaterials , 35 , 2730-2742 (2014).

Hbner , U.; Schmelzeisen , R.;

Mlhaupt , R. , "Biofunctional Rapid

(2003).
[6 Theiault

[65]Yang, S.; Leong, K.F.; Du, Z.; Chua,

[70]Bellan, L. M.; Singh, S.P.; Henderson,

C.K. , "The Design of Scaffolds for

P.W.; Porri , T.J.; Craighead , H.G.;

Use in Tissue Engineering. Part II.

Spector , J.A. , "Fabrication of an

S.; Cheng , L., "Biocompatibility

R. 1

Rapid Prototyping Techniques" , Tissue

Artificial 3-Dimensional Vascular

and Osteogenesis of Biomimetic

Using Polycaprolactone Scaffolds

Eng. , 8, 1-11 (2002).

Network Using Sacrificial Sugar

Nano-Hydroxyapatite/Polyamide

Fabricated Via Selective Laser

Structures", Soft Matter, 5, 1354-1357

Composite Scaffolds for Bone Tissue

Sintering", Biomaterials, 26, 4817-

(2009).

Engineering", Biomaterials, 28, 3338-

4827 (2005).

[66]Billiet , T.; Vandenhaute , M.;

Schelfhout , J.; Van Vlierberghe , S.;

100

Biomaterials , 33 , 6020-6041 (2012).

[7 Wang

H.; Li, Y.; Zuo, Y.; Li, J.; Ma,

Dubruel , P. , "A Review of Trends

[71]Wu, W.; Hansen, C.J.; Aragon, A.M.;

and Limitations in Hydrogel-Rapid

Geubelle, P.H.; White, S.R.; Lewis,

[76]Murakami, N.; Saito, N.; Horiuchi, H.;

Prototyping for Tissue Engineering" ,

J.A. , "Direct- Write Assembly of

Okada, T.; Nozaki, K.; Takaoka, K. ,

228

3348 (2007).

20148

[7 Williams

J.M.; Adewunmi, A.;

Sch

et al., "Bone Tissue Engineering

[80]Chandra , R.; Rustgi , R. ,

"Biodegradable Polymers" , Prog.
Polym. Sc i., 23 , 1273-1335 (1 998).

101

......
f Www.mmmoc.com.tw E-mail: ann566tlmmmoc.com.tw
[81]Sant , S.; Hwang , C.M.; Lee , S.H.;
Khademhosseini , A. , "Hybrid

Pgsc1

Microfibrous Scaffolds with Improved

Mechanical and Biological Properties" ,
J. Tissue. Eng.

Regen. 1:ed.

5 , 283-

291 (2011).

Fusion (ALIF) Surgery in Patients

with Discogenic Low Back Pain" ,
Yonsei Med. J. , 55 , 487-492 (2014).
[86]Seyedn ad
R.

H.; Gawlitta , D.; Kuiper,

et a l., "In Vivo Biocompatibility

and Biodegradation of 3D-Printed

[82]Liao , G.- Y.; Chen , L.; Zeng , X.- Y.,

Porous Scaffolds Based on a HydroxylPoly(-Caprolactone)" ,

et a l., "Electrospun Poly(L-Lactide)/

Functionalized

Poly(-Caprolactone)

Biomaterials, 33 , 4309-4318 (2012).

Blend Fibers and

Their Cellular Response to Adipose-

[87]Park , C.H.; Rios , H. F.; Jin , Q. , et a l.,

Derived Stem Cells" , J. App l. Polym.

"Biomimetic Hybrid Scaffolds for

Sci. , 120 , 2154-2165 (2011).

Engineering Human Tooth- Li gament

[83]Porter, J.R.;

Ruc1

: 105 51 3

TEL : 02-8712-5539 # 566

FAX:

02~8712-6567

.............................................................................................................................................................................................................
-
*:(/ E-mail)

8 000-10 000
:( 100-500)(3-5)
(:.. 1 2... 1.1 1.2
...)///
/ J

:Word

Word() 350dpi (*.JPG *.TIF)

//( )

1 2 1 2.. 1-1 2-1 1-1 2-1...

;(:iI (11 (2 1 ...)
D()/

T.T.; Popat, K. C. ,

"Bone Tissue Engineering: A Review

Interfaces" , Biomaterials , 31 , 5945-

J () J (

1999)//( 80/ )

5952 (2010).

in Bone Biomimetics and Drug

[88]Park , C.H.; Rios , H.F.; Jin , Q. , et a l.,

Delivery Strategies" , Biotechno l.

"Tissue Engineering Bone-Ligament

Prog. , 25 , 1539-1560 (2009).

Complexes Using Fiber-Guiding

[84]Abbah , S.A.; Lam , C.X.; Hutmacher,

D.W.; Goh , J.C.; Wong , H.K. ,

Scaffolds" , Biomaterials , 33 , 137-145

(2012).

"Biological Performance of a

a Large Animal Model of Spinal

[85]Kimura , S.; Ohtori , S.;

after Anterior Lumbar Interbody

'/"

()

et a l.,

Space to Detect Painful Nonunion

[1] 8uzuki , 1.; Komatsu H.; Yagi H.; Hirata M., "Formation and Prediction of Quaternary Vapor-Li quid
EquilibriaAccompanied by Esterification" , J. Chem. Engng. , 3, 152-157(1970).
[2] rJ '33 86-92 '(1995)

[1][2][3]...

"Injection of Bupivacaine into Disc

/:

G~()

Orita

/ r J

Used as Fusion Cage Device in

30 , 5086-5093 (2009).

:(:iI)

:/

Polycaprolactone-Based Scaffold

Reconstructive Surgery" , Biomaterials ,

:
:

// s

()
(3)

(21 )

102

22 8

()

......
f Www.mmmoc.com.tw E-mail: ann566tlmmmoc.com.tw
[81]Sant , S.; Hwang , C.M.; Lee , S.H.;
Khademhosseini , A. , "Hybrid

Pgsc1

Microfibrous Scaffolds with Improved

Mechanical and Biological Properties" ,
J. Tissue. Eng.

Regen. 1:ed.

5 , 283-

291 (2011).

Fusion (ALIF) Surgery in Patients

with Discogenic Low Back Pain" ,
Yonsei Med. J. , 55 , 487-492 (2014).
[86]Seyedn ad
R.

H.; Gawlitta , D.; Kuiper,

et a l., "In Vivo Biocompatibility

and Biodegradation of 3D-Printed

[82]Liao , G.- Y.; Chen , L.; Zeng , X.- Y.,

Porous Scaffolds Based on a HydroxylPoly(-Caprolactone)" ,

et a l., "Electrospun Poly(L-Lactide)/

Functionalized

Poly(-Caprolactone)

Biomaterials, 33 , 4309-4318 (2012).

Blend Fibers and

Their Cellular Response to Adipose-

[87]Park , C.H.; Rios , H. F.; Jin , Q. , et a l.,

Derived Stem Cells" , J. App l. Polym.

"Biomimetic Hybrid Scaffolds for

Sci. , 120 , 2154-2165 (2011).

Engineering Human Tooth- Li gament

[83]Porter, J.R.;

Ruc1

: 105 51 3

TEL : 02-8712-5539 # 566

FAX:

02~8712-6567

.............................................................................................................................................................................................................
-
*:(/ E-mail)

8 000-10 000
:( 100-500)(3-5)
(:.. 1 2... 1.1 1.2
...)///
/ J

:Word

Word() 350dpi (*.JPG *.TIF)

//( )

1 2 1 2.. 1-1 2-1 1-1 2-1...

;(:iI (11 (2 1 ...)
D()/

T.T.; Popat, K. C. ,

"Bone Tissue Engineering: A Review

Interfaces" , Biomaterials , 31 , 5945-

J () J (

1999)//( 80/ )

5952 (2010).

in Bone Biomimetics and Drug

[88]Park , C.H.; Rios , H.F.; Jin , Q. , et a l.,

Delivery Strategies" , Biotechno l.

"Tissue Engineering Bone-Ligament

Prog. , 25 , 1539-1560 (2009).

Complexes Using Fiber-Guiding

[84]Abbah , S.A.; Lam , C.X.; Hutmacher,

D.W.; Goh , J.C.; Wong , H.K. ,

Scaffolds" , Biomaterials , 33 , 137-145

(2012).

"Biological Performance of a

a Large Animal Model of Spinal

[85]Kimura , S.; Ohtori , S.;

after Anterior Lumbar Interbody

'/"

()

et a l.,

Space to Detect Painful Nonunion

[1] 8uzuki , 1.; Komatsu H.; Yagi H.; Hirata M., "Formation and Prediction of Quaternary Vapor-Li quid
EquilibriaAccompanied by Esterification" , J. Chem. Engng. , 3, 152-157(1970).
[2] rJ '33 86-92 '(1995)

[1][2][3]...

"Injection of Bupivacaine into Disc

/:

G~()

Orita

/ r J

Used as Fusion Cage Device in

30 , 5086-5093 (2009).

:(:iI)

:/

Polycaprolactone-Based Scaffold

Reconstructive Surgery" , Biomaterials ,

:
:

// s

()
(3)

(21 )

102

22 8

()

2014
|

2007

[2] 0

(stem cells)

(undifferentiated)

(James A. Thomson)

(self-renewal)

[3]

2007

(adult stem cells)

2012

(bone

stem cells , BMSCs)

marrow stromal

(umbilical cord blood stem cells)

220

(processed lipoaspirate cells);

(i nduced

2006 (Shinya Yamanaka)

iPSCs) 1

(reprogram)

(pluripotent) (induced

pluripotent stem cells , iPSCs) [I] (embryonic stem cells , ESCs)

(conditioned medium)

: (1) (totipotent

(growth factor)

stem cells) :

; (2) (pluripotent stem

cells)

104

228

20148

pluripotent stem cells ,

:;

105

2014
|

2007

[2] 0

(stem cells)

(undifferentiated)

(James A. Thomson)

(self-renewal)

[3]

2007

(adult stem cells)

2012

(bone

stem cells , BMSCs)

marrow stromal

(umbilical cord blood stem cells)

220

(processed lipoaspirate cells);

(i nduced

2006 (Shinya Yamanaka)

iPSCs) 1

(reprogram)

(pluripotent) (induced

pluripotent stem cells , iPSCs) [I] (embryonic stem cells , ESCs)

(conditioned medium)

: (1) (totipotent

(growth factor)

stem cells) :

; (2) (pluripotent stem

cells)

104

228

20148

pluripotent stem cells ,

:;

105

2 0 14
|

Blastocyst

Bone marrow

Inner cell mass

Oct3/4 , Sox-2 ,

Embryonic stem cells

c-Myc , Klf4

i. e.

Induced pluripotent stem cells

Mesenchymal stem cells

(neuron)

(oligodendroc))l5-7] ;

12

(non tissue-specific stem

cell)

P (insulin

brain-derived

producing

neurotrophic factor (BDNF)

epithelium) [ll]

BDNF

[12 1

[8]

(bone

marrow

T8

Adult stem cells

(3) (multipotent stem cells) :

106

()

(lung

mesenchymal stem cell , BMSCs)

()
1

cells)

(hematopoietic stem

cells , HSCs) (mesenchymal

(plasticity)

(blastcyst) (inner

stem cells , MSCs)

(reversibility)

cell mass)

(endothelial progenitor stem cells)

1998

(neural stem cells , NSCs) ;

(James

(4) (unipotent stem cells ,

(tissue-specific stem

USCs) :

cells)

[10]

SRY box-containing gene 2 (SOX2)

(average

tumour suppressor

[4] ;

population-doubling time) 36/J

(F4)proto-oncogene C-MYC (or non-

22 8

20148

A.

Thomson)

()

octamer

3/4 (OCT4)

Kruppe like

factor 4

107

2 0 14
|

Blastocyst

Bone marrow

Inner cell mass

Oct3/4 , Sox-2 ,

Embryonic stem cells

c-Myc , Klf4

i. e.

Induced pluripotent stem cells

Mesenchymal stem cells

(neuron)

(oligodendroc))l5-7] ;

12

(non tissue-specific stem

cell)

P (insulin

brain-derived

producing

neurotrophic factor (BDNF)

epithelium) [ll]

BDNF

[12 1

[8]

(bone

marrow

T8

Adult stem cells

(3) (multipotent stem cells) :

106

()

(lung

mesenchymal stem cell , BMSCs)

()
1

cells)

(hematopoietic stem

cells , HSCs) (mesenchymal

(plasticity)

(blastcyst) (inner

stem cells , MSCs)

(reversibility)

cell mass)

(endothelial progenitor stem cells)

1998

(neural stem cells , NSCs) ;

(James

(4) (unipotent stem cells ,

(tissue-specific stem

USCs) :

cells)

[10]

SRY box-containing gene 2 (SOX2)

(average

tumour suppressor

[4] ;

population-doubling time) 36/J

(F4)proto-oncogene C-MYC (or non-

22 8

20148

A.

Thomson)

()

octamer

3/4 (OCT4)

Kruppe like

factor 4

107

2 014
|

Reprogramming factors :
Oct4 , SOX2 , KLF4 , C-MTC

X0<
t

Obtain cells

Correct mutation
Adult fibroblast cells
Reprogramming cells

Growth factors

/
/

[Afr 1

// J CS\\

Cardiomyocytes

Adipocytes

Dopaminergic
neurons

(a)

(b)

(c)

(d)

Blood cells
Pancreatic -cells

Neural cells

Motoneurons

108

12 (a) 1 (b) 3 (c) 5 (d) 7

tumourigenic substitute L-MYC)

( 3(c)) 3(d)

( 2)[1]

(mouse bone marrow cells)[I]

(colony)

(hepatocytes )[14] (gastric

epithelial cells) (pancreatic

3(b) )

cells )f 15] (lymphocytes)f 16]

(teratomas) 3 12

(adult

(iPSC colony)

22 8

20148

neural stem cells)f 17.

109

2 014
|

Reprogramming factors :
Oct4 , SOX2 , KLF4 , C-MTC

X0<
t

Obtain cells

Correct mutation
Adult fibroblast cells
Reprogramming cells

Growth factors

/
/

[Afr 1

// J CS\\

Cardiomyocytes

Adipocytes

Dopaminergic
neurons

(a)

(b)

(c)

(d)

Blood cells
Pancreatic -cells

Neural cells

Motoneurons

108

12 (a) 1 (b) 3 (c) 5 (d) 7

tumourigenic substitute L-MYC)

( 3(c)) 3(d)

( 2)[1]

(mouse bone marrow cells)[I]

(colony)

(hepatocytes )[14] (gastric

epithelial cells) (pancreatic

3(b) )

cells )f 15] (lymphocytes)f 16]

(teratomas) 3 12

(adult

(iPSC colony)

22 8

20148

neural stem cells)f 17.

109

2 0 14
|

110

()

(4)

(biocompatibility)

1954

(inflammion)

DNA

(John Merril) (Joseph E. Murray)

(cytotoxici ty)

DNA

(autograft)

(allograft) (xenograft)

C-MYC KLF4

C-MYC

KLF4 SOX2

OCT4

C-MYC

[21)

2000

(scaffolds) (cells) (sials)l

(tetratomas)

228

Cells

Scaffold

Culture in 3D structure

Bioartificial tissue

Transplant

20148

111

2 0 14
|

110

()

(4)

(biocompatibility)

1954

(inflammion)

DNA

(John Merril) (Joseph E. Murray)

(cytotoxici ty)

DNA

(autograft)

(allograft) (xenograft)

C-MYC KLF4

C-MYC

KLF4 SOX2

OCT4

C-MYC

[21)

2000

(scaffolds) (cells) (sials)l

(tetratomas)

228

Cells

Scaffold

Culture in 3D structure

Bioartificial tissue

Transplant

20148

111

(polyethyleneimine

PEI)

(poly(lactic-co-glycolic

(adhesion)l25 J (proliferation)

acid , PLGA)

bFGF

: (1) :

(differentiation) (migration)

PC12

[3637J

[47J

; (2) :

basic domains

(growth factor)

[3]

(nerve growth factor ,

NGF) -3 (neurotrophin-3 ,

NT-3) 49J

Taylor heparin

Hu

based delivery system (HBDS)

platelet-derived growth factor-AA (PDGF-

NT-3

AA) insulin-like

HBDS NT-3

NT3 '

; (3) :

112

()

(heparin)

()

growth factor 1 (IGFl)

[50J

[51J

(4) :

(polycaprolactone , PCL)/

(RA)dimethyl sulfoxide (DMSO)

(D-glucosamine) L-

(poly-3-hydroxybutyrate , PHB)

smooth

; (5)

(L-iduronide) D- (D-glucuronic

muscle cells (SMCs)

acid)(aggrecan) 6

3D

good manufacturing practice (GMP)

(glycosaminoglycan GAG)

5)

[27J

(phase separation)

(protein)

[ (gas foaming)[

(freeze-drying)[3 IJ

[4 (basic

(porogen leaching)l32

fibroblast growth factors ,

(fibro bonding)l34 J

(heparin-binding protein)

( electrospun)[35 J

Park

bFGF (L)(poly(L

lysine) , PLL)

Xie retinoid acid

bFGF)

22 8

Heparin conjugated

Porous structure

20148

iPSC culture

Differentiation

113

(polyethyleneimine

PEI)

(poly(lactic-co-glycolic

(adhesion)l25 J (proliferation)

acid , PLGA)

bFGF

: (1) :

(differentiation) (migration)

PC12

[3637J

[47J

; (2) :

basic domains

(growth factor)

[3]

(nerve growth factor ,

NGF) -3 (neurotrophin-3 ,

NT-3) 49J

Taylor heparin

Hu

based delivery system (HBDS)

platelet-derived growth factor-AA (PDGF-

NT-3

AA) insulin-like

HBDS NT-3

NT3 '

; (3) :

112

()

(heparin)

()

growth factor 1 (IGFl)

[50J

[51J

(4) :

(polycaprolactone , PCL)/

(RA)dimethyl sulfoxide (DMSO)

(D-glucosamine) L-

(poly-3-hydroxybutyrate , PHB)

smooth

; (5)

(L-iduronide) D- (D-glucuronic

muscle cells (SMCs)

acid)(aggrecan) 6

3D

good manufacturing practice (GMP)

(glycosaminoglycan GAG)

5)

[27J

(phase separation)

(protein)

[ (gas foaming)[

(freeze-drying)[3 IJ

[4 (basic

(porogen leaching)l32

fibroblast growth factors ,

(fibro bonding)l34 J

(heparin-binding protein)

( electrospun)[35 J

Park

bFGF (L)(poly(L

lysine) , PLL)

Xie retinoid acid

bFGF)

22 8

Heparin conjugated

Porous structure

20148

iPSC culture

Differentiation

113

2014
|

myocardin smoothelin SM22a

NGF

SMMHC' RA

6(a)

6( c )-( d)

III tubulin Pax6tyrosine

DMSORA

NGF

NGF iPS cells

NGF

NGF

iPS cells 6(b) NGF 4h

1~2

NGF

48 h

NGF TrkA'

mitogen-activated

protein

kinase (MAPK) MAPK

'NGF

Chen

(c)

NGF;5 ng/mL

(c) 24

114

(d)

h (d)

. (a) 4 h (b) 12 h

48 h

of pluripotent stem cells from mouse

9 OCT4 '

embryonic and adult fibroblast cultures by

defined factors" , Cell , 126 , 663~676(2006).

[2]Takahashi , K.; Tanabe , K.; Ohnuki , M.;

OCT4

Nari

Yamana

[ Haque

cells from adult human fibroblasts by defined

factors" , Cell , 131 , 861 ~872(2007).

N-cadherin

228

[1]Takahashi , K.; Yamanaka , S. , "Induction

20148

[3]Yu , J.;

M.; Ichisaka , T.; Tomoda , K.;

S. , "Induction of pluripotent stem

Vodyanil

M. A.; Smuga-Otto , K.;

115

2014
|

myocardin smoothelin SM22a

NGF

SMMHC' RA

6(a)

6( c )-( d)

III tubulin Pax6tyrosine

DMSORA

NGF

NGF iPS cells

NGF

NGF

iPS cells 6(b) NGF 4h

1~2

NGF

48 h

NGF TrkA'

mitogen-activated

protein

kinase (MAPK) MAPK

'NGF

Chen

(c)

NGF;5 ng/mL

(c) 24

114

(d)

h (d)

. (a) 4 h (b) 12 h

48 h

of pluripotent stem cells from mouse

9 OCT4 '

embryonic and adult fibroblast cultures by

defined factors" , Cell , 126 , 663~676(2006).

[2]Takahashi , K.; Tanabe , K.; Ohnuki , M.;

OCT4

Nari

Yamana

[ Haque

cells from adult human fibroblasts by defined

factors" , Cell , 131 , 861 ~872(2007).

N-cadherin

228

[1]Takahashi , K.; Yamanaka , S. , "Induction

20148

[3]Yu , J.;

M.; Ichisaka , T.; Tomoda , K.;

S. , "Induction of pluripotent stem

Vodyanil

M. A.; Smuga-Otto , K.;

115

2014
|

H. , "Bone marrow stromal

Ichisaka , T.; Okita, K.; Takahashi , K.;

reprogramming with two factors" ,

A.; Ruotti ,

cell transplantation preserves

Chiba, T.; Yamanaka , S. , "Generation

Nature , 454 , 646-654(2008).

Stewart, R.; Slukvin 1. 1.; Thomson

gammaaminobutyric acid receptor

of pluripotent stem cells from adult

i ured

mouse liver and stomach cells" ,

M.; Arauzo-Bravo , M. J.; Sasse , P.;

Science , 321 , 699-702(2008).

Gentile , L.; Ko , K.; Ruau , D.; Ehrich ,

Antosiewicz- Bourg J.; Frane , J. L.;

Tian , S.; Nie , J.;

v.;

Jonsdott G.

J. A. , "Induced pluripotent stem cell

function in the

lines derived from human somatic cells" ,

Neurotrauma , 23 , 1682-1692(2006).

J. B.;

Sebastiano Wu

G.

[10]Thomson , J. A.; It skovitz-Eldor,

[15]Stadtfeld , M.; Brennand , K.;

M.; van den Boom , D.; Meyer, J.;

[4]Erices , A.; Conget, P.; Minguell , J. J. ,

J.; Shapiro , S. S.; Waknitz , M. A.;

Hochedlinger, K. , "Reprogramming

Hubner, K.; Bememann, C.; Ortmeier,

"Mesenchymal progenitor cells in human

Swiergiel , J. J.; Marshall , V. S.; Jones ,

of pancreatic beta cells into induced

C.; Zenke , M.; Fleischmann , B.

umbilical cord blood" , Br. J. Haemato l.,

J. M. , "Embryonic stem cell lines

pluripotent stem cells" , Current

K.; Zaehres , H.; Scholer , H. R. ,

109 , 235-242(2000).

derived from human blastocysts" ,

Biology, 18 , 890-894(2008).

"Oct4-induced pluripotency in

Science, 318 , 1917-1920(2007).

[5]Lim, J. Y.; Jeun, S. S.; Lee , K. J.; Oh , J.

Science, 282 , 1145-1147(1 998).

[16]Hanna , J.; Markoulaki , S.; Schorderet,

P.; Carey, B. W.; Beard , C.; Wemig ,

adult neural stem cells" , Cell , 2136 ,

411-419(2009).

H.; Kim , S. M.; Park, S. 1.; Jeong , C. H.;

[11]Vazin T.; Freed W. J. , "Human

Kang , S. G. , "Multiple stem cell traits of

embryonic stem cells: derivation ,

1.; Creyghton I{.

expanded rat bone maow stromal cells" ,

culture , and differentiation: a

Cassady, J. P.; Foreman, R.; Lengner,

Ding , D. C.; Chen , L. H.; Chang , Y. L.;

Exp. Neuro l., 199 , 416-426(2006).

review" , Restor Neurol Neurosci. , 28 ,

C. J.; Dausman , J. A.; Jaenisch , R. ,

Chen , L. K.; Chiou , S. H. , "Induced

589-603(2010).

"Direct reprogramming of terminally

pluripotent stem cells and regenerative

[12]Wang , D.; Haviland , D. L.; Burns ,

differentiated mature B lymphocytes

medicine" , J. Clin. Geronto l.

A. R.; Zsigmond , E.; Wetsel , R. A. ,

to pluripotency" , Cell , 133 ,

2, 1-6(2011).

[7]Davis , A. A.; Temple , S. , "A self-

"A pure population of lung alveolar

250-264(2008).

renewing multipotential stem cell in

epithelial type 11 cells derived from

[17]Silva , J.; Barrandon , 0.; Nichols ,

Guo , W.; Eijkelen-Boom , A.; Chen ,

embryonic rat cerebral cortex" , Nature ,

human embryonic stem cells" , Proc

J.; Kawaguchi , J.; Theunissen ,

S.; Muhlestein , W.; Melton , D. A. ,

372 , 263-266(1994).

.Nat l. Acad. Sc i. U. S. A. , 104 ,

T. W.; Smith , A. , "Promotion of

"Induction of pluripotent stem cells

4449-4454(2007).

reprogramming to ground state

from primary human fibroblasts with

pluripotency by signal inhibition" ,

only Oct4 and Sox2" , Nat. Biotechnol.,

Plos Biology, 6, 2237-2247(2008).

26 , 1269-1275(2008).

[6]McK

R. , "Stem cells in the central

nervous system" , Science , 276 ,

66-71 (1997).

[8]Xuan , A. G.; Long , D. H.; Gu , H. G.;

Yang , D. D.; Hong , L. P.; Leng , S.

[13]We

D. J.; Bertoncello , 1.; Bor

P.; Steine , E. J.;

L. , "BDNF improves the effects of

Z.; Kim , C.; Panoskaltsis-Mortari, A.;

neural stem cells on the rat model of

Reynolds , S.;

Alzheimer's disease with unilateral

Warburton , D.; Prockop , D. J. , "Stem

Gentile , L.; Ko , K.; Sebastiano ,

lesion offimbria-fomix" , Neurosc i. Lett.,

440 , 331-335(2008).
[9]Yano , S.; Kuroda , S.; Shichinohe ,
H.; Seki , T.; Ohnishi , T.; Tamagami ,

116

spinal cord" , J.

[1 Kim

[20]Chen , Y. C.; Tsai , K. L.; Hung , C.

[21]Huang

D.; Osafune , K.;

w.;

Geriat

Mael R.;

[18]Kim , J. B.; Zaehres , H.; Wu , G. M.;

[22]Chen , G.; Ushida , T.; Tateishi , T. ,

v.;

"Development of biodegradable

cells and cell therapies in lung biology

Arauzo-Bravo , M. J.; Ruau , D.;

porous scaffolds for tissue

and lung diseases" , Proc. Am. Thorac.

Han , D. W.; Zenke , M.; Scholer, H.

engineering" , Mater. Sci. Eng. C, 17,

Soc. , 8, 223-272(2011).

R. , "Pluripotent stem cells induced

63-69(2001).

M.; Stripp , B.;

[14]Aoi , T.; Yae , K.; Nakagawa , M.;

228

from adult neural stem cells by

20148

[2 Lanza

R.; Langer, R.; Vacanti , J. P. ,

117

2014
|

H. , "Bone marrow stromal

Ichisaka , T.; Okita, K.; Takahashi , K.;

reprogramming with two factors" ,

A.; Ruotti ,

cell transplantation preserves

Chiba, T.; Yamanaka , S. , "Generation

Nature , 454 , 646-654(2008).

Stewart, R.; Slukvin 1. 1.; Thomson

gammaaminobutyric acid receptor

of pluripotent stem cells from adult

i ured

mouse liver and stomach cells" ,

M.; Arauzo-Bravo , M. J.; Sasse , P.;

Science , 321 , 699-702(2008).

Gentile , L.; Ko , K.; Ruau , D.; Ehrich ,

Antosiewicz- Bourg J.; Frane , J. L.;

Tian , S.; Nie , J.;

v.;

Jonsdott G.

J. A. , "Induced pluripotent stem cell

function in the

lines derived from human somatic cells" ,

Neurotrauma , 23 , 1682-1692(2006).

J. B.;

Sebastiano Wu

G.

[10]Thomson , J. A.; It skovitz-Eldor,

[15]Stadtfeld , M.; Brennand , K.;

M.; van den Boom , D.; Meyer, J.;

[4]Erices , A.; Conget, P.; Minguell , J. J. ,

J.; Shapiro , S. S.; Waknitz , M. A.;

Hochedlinger, K. , "Reprogramming

Hubner, K.; Bememann, C.; Ortmeier,

"Mesenchymal progenitor cells in human

Swiergiel , J. J.; Marshall , V. S.; Jones ,

of pancreatic beta cells into induced

C.; Zenke , M.; Fleischmann , B.

umbilical cord blood" , Br. J. Haemato l.,

J. M. , "Embryonic stem cell lines

pluripotent stem cells" , Current

K.; Zaehres , H.; Scholer , H. R. ,

109 , 235-242(2000).

derived from human blastocysts" ,

Biology, 18 , 890-894(2008).

"Oct4-induced pluripotency in

Science, 318 , 1917-1920(2007).

[5]Lim, J. Y.; Jeun, S. S.; Lee , K. J.; Oh , J.

Science, 282 , 1145-1147(1 998).

[16]Hanna , J.; Markoulaki , S.; Schorderet,

P.; Carey, B. W.; Beard , C.; Wemig ,

adult neural stem cells" , Cell , 2136 ,

411-419(2009).

H.; Kim , S. M.; Park, S. 1.; Jeong , C. H.;

[11]Vazin T.; Freed W. J. , "Human

Kang , S. G. , "Multiple stem cell traits of

embryonic stem cells: derivation ,

1.; Creyghton I{.

expanded rat bone maow stromal cells" ,

culture , and differentiation: a

Cassady, J. P.; Foreman, R.; Lengner,

Ding , D. C.; Chen , L. H.; Chang , Y. L.;

Exp. Neuro l., 199 , 416-426(2006).

review" , Restor Neurol Neurosci. , 28 ,

C. J.; Dausman , J. A.; Jaenisch , R. ,

Chen , L. K.; Chiou , S. H. , "Induced

589-603(2010).

"Direct reprogramming of terminally

pluripotent stem cells and regenerative

[12]Wang , D.; Haviland , D. L.; Burns ,

differentiated mature B lymphocytes

medicine" , J. Clin. Geronto l.

A. R.; Zsigmond , E.; Wetsel , R. A. ,

to pluripotency" , Cell , 133 ,

2, 1-6(2011).

[7]Davis , A. A.; Temple , S. , "A self-

"A pure population of lung alveolar

250-264(2008).

renewing multipotential stem cell in

epithelial type 11 cells derived from

[17]Silva , J.; Barrandon , 0.; Nichols ,

Guo , W.; Eijkelen-Boom , A.; Chen ,

embryonic rat cerebral cortex" , Nature ,

human embryonic stem cells" , Proc

J.; Kawaguchi , J.; Theunissen ,

S.; Muhlestein , W.; Melton , D. A. ,

372 , 263-266(1994).

.Nat l. Acad. Sc i. U. S. A. , 104 ,

T. W.; Smith , A. , "Promotion of

"Induction of pluripotent stem cells

4449-4454(2007).

reprogramming to ground state

from primary human fibroblasts with

pluripotency by signal inhibition" ,

only Oct4 and Sox2" , Nat. Biotechnol.,

Plos Biology, 6, 2237-2247(2008).

26 , 1269-1275(2008).

[6]McK

R. , "Stem cells in the central

nervous system" , Science , 276 ,

66-71 (1997).

[8]Xuan , A. G.; Long , D. H.; Gu , H. G.;

Yang , D. D.; Hong , L. P.; Leng , S.

[13]We

D. J.; Bertoncello , 1.; Bor

P.; Steine , E. J.;

L. , "BDNF improves the effects of

Z.; Kim , C.; Panoskaltsis-Mortari, A.;

neural stem cells on the rat model of

Reynolds , S.;

Alzheimer's disease with unilateral

Warburton , D.; Prockop , D. J. , "Stem

Gentile , L.; Ko , K.; Sebastiano ,

lesion offimbria-fomix" , Neurosc i. Lett.,

440 , 331-335(2008).
[9]Yano , S.; Kuroda , S.; Shichinohe ,
H.; Seki , T.; Ohnishi , T.; Tamagami ,

116

spinal cord" , J.

[1 Kim

[20]Chen , Y. C.; Tsai , K. L.; Hung , C.

[21]Huang

D.; Osafune , K.;

w.;

Geriat

Mael R.;

[18]Kim , J. B.; Zaehres , H.; Wu , G. M.;

[22]Chen , G.; Ushida , T.; Tateishi , T. ,

v.;

"Development of biodegradable

cells and cell therapies in lung biology

Arauzo-Bravo , M. J.; Ruau , D.;

porous scaffolds for tissue

and lung diseases" , Proc. Am. Thorac.

Han , D. W.; Zenke , M.; Scholer, H.

engineering" , Mater. Sci. Eng. C, 17,

Soc. , 8, 223-272(2011).

R. , "Pluripotent stem cells induced

63-69(2001).

M.; Stripp , B.;

[14]Aoi , T.; Yae , K.; Nakagawa , M.;

228

from adult neural stem cells by

20148

[2 Lanza

R.; Langer, R.; Vacanti , J. P. ,

117

2 014
|

Prabhakaran ,

microparticles for the delivery of

[30]Lee , J. E.; Kim , K. E.; Kwon , 1. C.;

M. P.; Morshed , M.; Nasr-Esfaha

polypeptides and proteins" , Adv. Drug

Ahn , H. J.; Lee , S. H.; Cho , H.; Kim ,

M. H.; Ramakrishna , S. , "Electrospun

Deliv. Rev. , 10 , 141-162(1 993).

H. J.; Seong , S. C.; Lee , M. C. ,

p 0 ly( G -c apro 1ac tone)/ ge 1a tin

[41]Chappell , J. C.; Song , J.; Burke , C.

"Effects of the controlled-released

nanofibrous scaffolds for nerve tissue

W.; Klibanov , A. L.; Price , R. J. ,

the mechanical properties of chitosan

TGF 1

engineering" , Biomaterials , 29 ,

"Targeted delivery of nanoparticles

films by the addition of poly( ethylene

on chondrocytes cultured in a collagen!

4532-4539(2008).

bearing fibroblast growth factor-2 by

oxide)" , Polym. Eng. Sci. , 40 ,

chitosarglycosaminoglycan

1211-1215(2000).

Biomaterials , 25 , 4163-4173(2004).

"Principles of Tissue Engineering" ,

Mater. Res. , 42 , 396-402(1 998).

Academic Press , Burlington ,

671-682(1 999).
[24]Alexeev , V. L.; Kelberg , E. A.;
Evmenenko , G.

A. mprovement

of

[25]Zhao, K.; Deng , Y.; Chen , J. C.; Chen ,

scaffold" ,

Z. S.; Zhang , M. Q. , "Chitosan-

G. Q. , "Polyhydroxyalkanoate (PHA)

alginate as scaffolding material

scaffolds with good mechanical

for cartilage tissue engineering" ,

properties and biocompatibility" ,

Biomaterials , 24 , 1041-1045(2003).

[36]Babensee, J. E.; McIntire , L. V.; Mikos ,

ultrasonic microbubble destruction for

A. G. , "Growth factor delivery for

therapeutic arteriogenesis" , Small , 4 ,

tissue engineering" , Pharm. Res. , 17 ,

1769-1777(2008).
[4 Cushing

497-504(2000).

M. C.; Liao , J. T.; Anseth , K.

"Polypeptide growth

S. , "Activation of valvular interstitial

J. Biomed. Mate r. Res. , 75A ,

factors: targeted delivery systems" ,

cells is mediated by transforming

485-493(2005).

Biomaterials

growth factor-beta 1 interactions with

[37]Nim M.

1201-1225(1997).

matrix molecules" , Matrix Biology,

S.; Radisic ,

[32]Wan , Y.; Wu , H.; Wen , D. , "Porous-

[38]Golden , J. D.; Jones , A. L.; Bucholz ,

M. , "Vascular endothelial growth

conductive chitosan scaffolds for

R. W.; Bosse , M. J.; Lyon , T. R.;

factor immobilized in collagen

tissue engineering , preparation and

Webb , L. X.; Valentin-Opran , A. ,

[43]Pufe , T.; Groth , G.; Goldring , M. B.;

scaffold promotes penetration and

characterization" , Macromo l. Biosci. ,

"Recombinant human BMP-2 and

Tillmann , B.; Mentlein , R. , "Effects

proliferation of endothelial cells" , Acta

4 , 882-890(2004).

allograft compared with autogenous

of pleiotrophin , a heparin-binding

[33]Ishaug-Riley, S. L.; Crane-Kruger,

bone graft for reconstruction of

growth factor , on human primary

Mik

diaphyseal tibial fractures with cortical

and immortalized chondrocytes" ,

scaffolds for tissue engineering" ,

A. G. , "Three-dimensional culture

defects" , J. Bone Joint Surg. Am. , 90,

Osteoarthritis Cartilage , 15 ,

Mater. Today, 14 , 88-95(2011).

of rat calvarial osteoblasts in

1168-1169(2008).

155-162(2007).

[26]Shen , Y. H.;

Shoich.

Biomater. , 4, 477-489(2008).
[27]O'Brien , F. J. , "Biomaterials &

[28]Nam , Y. S.; Park , T. G. , "Porous

biodegradable polymeric scaffolds

G. M.; Yaszemski , M. J.;

porous biodegradable polymers" ,

Biomaterials, 19 , 1405-1412(1 998).

24 , 428-437(2005).

E. R.; Nugent , M. A.;

[44]Freeman , 1.; Kedem , A.; Cohen , S. ,

Karnovsky , M. J., "Perivascular

"The effect of sulfation of alginate

[3 Edelman

prepared by thermally induced phase

[34]Mooney , D. J.; Mazzoni , C. L.;

and intravenous administration

hydrogels on the specific binding

separation" , J. Biomed. Mater. Res. ,

Breuer, C.; McNamara , K.; Hem , D.;

of basic fibroblast growth factor:

and controlled release of heparin-

47 , 8-17(1 999).

Vacanti , J. P.; Langer, R. , "Stabilized

vascular and solid organ deposition" ,

binding proteins" , Biomaterials , 29 ,

L. D.; Kim , B. S.; Mooney, D.

polyglycolic acid fibre-based tubes for

Proc. Nat l. Acad. Sci. U. S. A. , 90 ,

3260-3268(2008).

J., "Open pore biodegradable matrices

tissue engineering" , Biomaterials , 17 ,

1513-1517(1 993).

formed with gas foaming" , J. Biomed.

115-124(1 996).

[2 Ha

118

I]Li

from chitosan microspheres

[3 Ghasemi-Mobarakeh L.;

[40]Couvreur, P.; Puisieux , F. , "Nano- and

228

20148

[45]Rajangam , K.; Arnold , M. S.;

Rocco , M. A.; Stupp , S. 1., "Peptide

119

2 014
|

Prabhakaran ,

microparticles for the delivery of

[30]Lee , J. E.; Kim , K. E.; Kwon , 1. C.;

M. P.; Morshed , M.; Nasr-Esfaha

polypeptides and proteins" , Adv. Drug

Ahn , H. J.; Lee , S. H.; Cho , H.; Kim ,

M. H.; Ramakrishna , S. , "Electrospun

Deliv. Rev. , 10 , 141-162(1 993).

H. J.; Seong , S. C.; Lee , M. C. ,

p 0 ly( G -c apro 1ac tone)/ ge 1a tin

[41]Chappell , J. C.; Song , J.; Burke , C.

"Effects of the controlled-released

nanofibrous scaffolds for nerve tissue

W.; Klibanov , A. L.; Price , R. J. ,

the mechanical properties of chitosan

TGF 1

engineering" , Biomaterials , 29 ,

"Targeted delivery of nanoparticles

films by the addition of poly( ethylene

on chondrocytes cultured in a collagen!

4532-4539(2008).

bearing fibroblast growth factor-2 by

oxide)" , Polym. Eng. Sci. , 40 ,

chitosarglycosaminoglycan

1211-1215(2000).

Biomaterials , 25 , 4163-4173(2004).

"Principles of Tissue Engineering" ,

Mater. Res. , 42 , 396-402(1 998).

Academic Press , Burlington ,

671-682(1 999).
[24]Alexeev , V. L.; Kelberg , E. A.;
Evmenenko , G.

A. mprovement

of

[25]Zhao, K.; Deng , Y.; Chen , J. C.; Chen ,

scaffold" ,

Z. S.; Zhang , M. Q. , "Chitosan-

G. Q. , "Polyhydroxyalkanoate (PHA)

alginate as scaffolding material

scaffolds with good mechanical

for cartilage tissue engineering" ,

properties and biocompatibility" ,

Biomaterials , 24 , 1041-1045(2003).

[36]Babensee, J. E.; McIntire , L. V.; Mikos ,

ultrasonic microbubble destruction for

A. G. , "Growth factor delivery for

therapeutic arteriogenesis" , Small , 4 ,

tissue engineering" , Pharm. Res. , 17 ,

1769-1777(2008).
[4 Cushing

497-504(2000).

M. C.; Liao , J. T.; Anseth , K.

"Polypeptide growth

S. , "Activation of valvular interstitial

J. Biomed. Mate r. Res. , 75A ,

factors: targeted delivery systems" ,

cells is mediated by transforming

485-493(2005).

Biomaterials

growth factor-beta 1 interactions with

[37]Nim M.

1201-1225(1997).

matrix molecules" , Matrix Biology,

S.; Radisic ,

[32]Wan , Y.; Wu , H.; Wen , D. , "Porous-

[38]Golden , J. D.; Jones , A. L.; Bucholz ,

M. , "Vascular endothelial growth

conductive chitosan scaffolds for

R. W.; Bosse , M. J.; Lyon , T. R.;

factor immobilized in collagen

tissue engineering , preparation and

Webb , L. X.; Valentin-Opran , A. ,

[43]Pufe , T.; Groth , G.; Goldring , M. B.;

scaffold promotes penetration and

characterization" , Macromo l. Biosci. ,

"Recombinant human BMP-2 and

Tillmann , B.; Mentlein , R. , "Effects

proliferation of endothelial cells" , Acta

4 , 882-890(2004).

allograft compared with autogenous

of pleiotrophin , a heparin-binding

[33]Ishaug-Riley, S. L.; Crane-Kruger,

bone graft for reconstruction of

growth factor , on human primary

Mik

diaphyseal tibial fractures with cortical

and immortalized chondrocytes" ,

scaffolds for tissue engineering" ,

A. G. , "Three-dimensional culture

defects" , J. Bone Joint Surg. Am. , 90,

Osteoarthritis Cartilage , 15 ,

Mater. Today, 14 , 88-95(2011).

of rat calvarial osteoblasts in

1168-1169(2008).

155-162(2007).

[26]Shen , Y. H.;

Shoich.

Biomater. , 4, 477-489(2008).
[27]O'Brien , F. J. , "Biomaterials &

[28]Nam , Y. S.; Park , T. G. , "Porous

biodegradable polymeric scaffolds

G. M.; Yaszemski , M. J.;

porous biodegradable polymers" ,

Biomaterials, 19 , 1405-1412(1 998).

24 , 428-437(2005).

E. R.; Nugent , M. A.;

[44]Freeman , 1.; Kedem , A.; Cohen , S. ,

Karnovsky , M. J., "Perivascular

"The effect of sulfation of alginate

[3 Edelman

prepared by thermally induced phase

[34]Mooney , D. J.; Mazzoni , C. L.;

and intravenous administration

hydrogels on the specific binding

separation" , J. Biomed. Mater. Res. ,

Breuer, C.; McNamara , K.; Hem , D.;

of basic fibroblast growth factor:

and controlled release of heparin-

47 , 8-17(1 999).

Vacanti , J. P.; Langer, R. , "Stabilized

vascular and solid organ deposition" ,

binding proteins" , Biomaterials , 29 ,

L. D.; Kim , B. S.; Mooney, D.

polyglycolic acid fibre-based tubes for

Proc. Nat l. Acad. Sci. U. S. A. , 90 ,

3260-3268(2008).

J., "Open pore biodegradable matrices

tissue engineering" , Biomaterials , 17 ,

1513-1517(1 993).

formed with gas foaming" , J. Biomed.

115-124(1 996).

[2 Ha

118

I]Li

from chitosan microspheres

[3 Ghasemi-Mobarakeh L.;

[40]Couvreur, P.; Puisieux , F. , "Nano- and

228

20148

[45]Rajangam , K.; Arnold , M. S.;

Rocco , M. A.; Stupp , S. 1., "Peptide

119

2014
|

UM

An-H

QU

3d

-4ELIl

FB4E

-hu.

:.

-11nu

nO

+1n

na

U4.L

t--:
KmN
unuM
an"
mdJ
eoku
pcb
E--t
ear
neo
dh2
np}
1if
,

3298-3305(2008).
[46]Rapraeger, A. C.; Kru fka, A.; Olwin, B.
B. , "Requirement of heparan sulfate
for bFGF-mediated fibroblast growth

into motor neurons" , Science, 321 ,

A.; Tagawa , Y.; Akaike , T. ,

C. , "Neural differentiation of human

1218-1221(2008).

"Characterization and neural

induced pluripotent stem cells follows

[56]Ebe

A. D.; Yu, J.; Rose, F. F.; Mattis,

differentiation of mouse embryonic

developmental principles but with

v.

B.; Lorson , C. L.; Thomson , J. A.;

and induced pluripotent stem cells

variable potency" , Proc. Nat l. Acad.

Svendsen, C. N. , "Induced pluripotent

on cadherin-based substrata" ,

Sci. U. S. A. , 107 , 4335-4340(2010).

stem cells from a spinal muscular

Biomaterials, 33 , 5094-5106(2012).

[52]X C.;

Hu, J.; Ma, H.; Zhang, J.;

and myoblast dierentiation" Science ,

Chang, L. J.;

252 , 1705-1708 (1 991).

"Three-dimensional growth of iPS

Ch

Y. E.; Ma, P. X. ,

atrophy patient" , Nature , 457 ,

277-281(2009).
[57]Wernig, M.; Zhao, J. P.;

Prusz

J.;

[47]Park , K. H.; Kim , H.; Na , K. ,

cell-derived smooth muscle cells on

Hedlund , E.; Fu , D.; Soldner, F.;

"Neuronal differentiation of PC12

nano fi brous scaffolds" , Biomaterials,

Broccoli, V.; Paton, M. C.; Isacson, 0.;

cells cultured on growth dactor-

32 , 4369-4375(2011).

Jaenisch , R. , "Neurons derived from

loaded nanoparticles coated on

[53]Li, Z.; Theus, M. H.; Wei, L., "Role

reprogrammed fibroblasts functionally

PLGA microspheres" , J. Microbio l.

of ERK 112 signaling in neuronal

integrate into the fetal brain and

Biotechno l., 19 , 1490-1495(2009).

differentiation of cultured embryonic

improve symptoms of rats with

stem cells" , Develop. Growth Differ. ,

Parkinson's disease" , Proc. Natl. Acad.

48 , 513-523(2006).

Sci. U. S. A. , 105 , 5856-5861(2008).

[48]Sakiyama-Elbe S. E.; Hubbell, J. A.,

"Development of fibrin derivatives for
controlled release of heparin-binding

[54]Marchetto , M. C.N.; Carromeu , C.;

w.; Mu, Y.;

[58]Park , 1. H.; Arora , N.; Huo , H.;

growth factors" , J. Contro l. Release ,

Acab, A.; Yu, D.; Yeo, G.

65 , 389-402(2000).

Chen, G.; Gage, F. H.; Muotri, A. R.,

A.; Lensch , M. W.; Cowan , C.;

S. E.; Hubbell, J. A.,

"A Model for Neural Development and

Hochedlinger , K.; Daley , G.

"Controlled release of nerve growth

Treatment of Rett Syndrome Using

Q. , "Disease-Specific Induced

factor from a heparin-containing

Human Induced Pluripotent Stem

Pluripotent Stem Cells" , Cell, 134,

fibrin-based cell ingrowth matrix" , J.

Cells", Cell, 143, 527-539(2010).

877-886(2008).

[4 Sakiyama-Elbe

Contro l. Release , 69 , 149-158(2000).

[5 Dimos

Rodol

Maherali, N.; Ahfeldt, T.;

Shimamu

K. T.; Niakan, K.

[59]Chen, G. Y.; Pang, D. W. P.; Hwang,

K.; Weisenthal , L. M.; Mitsumoto , H.;

S. M.; Tuan , H. Y.; Hu , Y. C. , "A

Sakiyama-Elbert , S. E. , "Controlled

Chung, w.;

G. F.; Saphier, G.;

graphene-based platforrn for induced

release of neurotrophin-3 from fibrin

Leibel, R.; Goland, R.; Wichterle, H.;

pluripotent stem cells culture and

gels for spinal cord injury" , J. Contro l.

Henderson, C. E.; Eggan, K., "Induced

differentiation" , Biomaterials, 33 ,

Release , 98 , 281-294(2004).

pluripotent stem cells generated from

418-427(2012).

[50]Taylor , S. J.; McDonald , J. W.;

[51]Hu , B.; Weick, J.; Yu, J.; Ma, L.;

120

Zhang, x.; Thomson, J. A.; Zhang, S.

J. T.;

Cro

patients with ALS can be dierentiated

228

[60]Haque, A.; Yue, X. S.; Motazedian,

20148

121

2014
|

UM

An-H

QU

3d

-4ELIl

FB4E

-hu.

:.

-11nu

nO

+1n

na

U4.L

t--:
KmN
unuM
an"
mdJ
eoku
pcb
E--t
ear
neo
dh2
np}
1if
,

3298-3305(2008).
[46]Rapraeger, A. C.; Kru fka, A.; Olwin, B.
B. , "Requirement of heparan sulfate
for bFGF-mediated fibroblast growth

into motor neurons" , Science, 321 ,

A.; Tagawa , Y.; Akaike , T. ,

C. , "Neural differentiation of human

1218-1221(2008).

"Characterization and neural

induced pluripotent stem cells follows

[56]Ebe

A. D.; Yu, J.; Rose, F. F.; Mattis,

differentiation of mouse embryonic

developmental principles but with

v.

B.; Lorson , C. L.; Thomson , J. A.;

and induced pluripotent stem cells

variable potency" , Proc. Nat l. Acad.

Svendsen, C. N. , "Induced pluripotent

on cadherin-based substrata" ,

Sci. U. S. A. , 107 , 4335-4340(2010).

stem cells from a spinal muscular

Biomaterials, 33 , 5094-5106(2012).

[52]X C.;

Hu, J.; Ma, H.; Zhang, J.;

and myoblast dierentiation" Science ,

Chang, L. J.;

252 , 1705-1708 (1 991).

"Three-dimensional growth of iPS

Ch

Y. E.; Ma, P. X. ,

atrophy patient" , Nature , 457 ,

277-281(2009).
[57]Wernig, M.; Zhao, J. P.;

Prusz

J.;

[47]Park , K. H.; Kim , H.; Na , K. ,

cell-derived smooth muscle cells on

Hedlund , E.; Fu , D.; Soldner, F.;

"Neuronal differentiation of PC12

nano fi brous scaffolds" , Biomaterials,

Broccoli, V.; Paton, M. C.; Isacson, 0.;

cells cultured on growth dactor-

32 , 4369-4375(2011).

Jaenisch , R. , "Neurons derived from

loaded nanoparticles coated on

[53]Li, Z.; Theus, M. H.; Wei, L., "Role

reprogrammed fibroblasts functionally

PLGA microspheres" , J. Microbio l.

of ERK 112 signaling in neuronal

integrate into the fetal brain and

Biotechno l., 19 , 1490-1495(2009).

differentiation of cultured embryonic

improve symptoms of rats with

stem cells" , Develop. Growth Differ. ,

Parkinson's disease" , Proc. Natl. Acad.

48 , 513-523(2006).

Sci. U. S. A. , 105 , 5856-5861(2008).

[48]Sakiyama-Elbe S. E.; Hubbell, J. A.,

"Development of fibrin derivatives for
controlled release of heparin-binding

[54]Marchetto , M. C.N.; Carromeu , C.;

w.; Mu, Y.;

[58]Park , 1. H.; Arora , N.; Huo , H.;

growth factors" , J. Contro l. Release ,

Acab, A.; Yu, D.; Yeo, G.

65 , 389-402(2000).

Chen, G.; Gage, F. H.; Muotri, A. R.,

A.; Lensch , M. W.; Cowan , C.;

S. E.; Hubbell, J. A.,

"A Model for Neural Development and

Hochedlinger , K.; Daley , G.

"Controlled release of nerve growth

Treatment of Rett Syndrome Using

Q. , "Disease-Specific Induced

factor from a heparin-containing

Human Induced Pluripotent Stem

Pluripotent Stem Cells" , Cell, 134,

fibrin-based cell ingrowth matrix" , J.

Cells", Cell, 143, 527-539(2010).

877-886(2008).

[4 Sakiyama-Elbe

Contro l. Release , 69 , 149-158(2000).

[5 Dimos

Rodol

Maherali, N.; Ahfeldt, T.;

Shimamu

K. T.; Niakan, K.

[59]Chen, G. Y.; Pang, D. W. P.; Hwang,

K.; Weisenthal , L. M.; Mitsumoto , H.;

S. M.; Tuan , H. Y.; Hu , Y. C. , "A

Sakiyama-Elbert , S. E. , "Controlled

Chung, w.;

G. F.; Saphier, G.;

graphene-based platforrn for induced

release of neurotrophin-3 from fibrin

Leibel, R.; Goland, R.; Wichterle, H.;

pluripotent stem cells culture and

gels for spinal cord injury" , J. Contro l.

Henderson, C. E.; Eggan, K., "Induced

differentiation" , Biomaterials, 33 ,

Release , 98 , 281-294(2004).

pluripotent stem cells generated from

418-427(2012).

[50]Taylor , S. J.; McDonald , J. W.;

[51]Hu , B.; Weick, J.; Yu, J.; Ma, L.;

120

Zhang, x.; Thomson, J. A.; Zhang, S.

J. T.;

Cro

patients with ALS can be dierentiated

228

[60]Haque, A.; Yue, X. S.; Motazedian,

20148

121

2014
|

000
5 000

: in vivo ex vivo

2003

(growth factor) (cytokine)

: in vivo( ) ex vivo()

( 2)

(recombinant protein)

[1]

(scaffold)
( 1)

122

228

in

vivo

(transgene)

in vivo

20148

123

2014
|

000
5 000

: in vivo ex vivo

2003

(growth factor) (cytokine)

: in vivo( ) ex vivo()

( 2)

(recombinant protein)

[1]

(scaffold)
( 1)

122

228

in

vivo

(transgene)

in vivo

20148

123

2014
|

Ex vivo gene therapy

In vivo

gene therapy

Current vectors
with therapeutic gene

<

O O (>

Host cells

DNA RNA

35 kb

(episome)

1. (retrovirus)

Engineered cells containing

therapeutic gene

RNA

7-12 kb

10 kb

DNA

(proto-

(capsid protein) T

ex vivo

ex vivo

oncogene) (tumor

suppressor gene)

ex vivo() vivo()

(http://www.bmj.com/conten t/315/7118/1289/F1.large.jpg)

in vivo

ex vivo

(lentivirus)

3. (adeno-associated

virus , AAV)
(AAV) DNA

(parovirus)

124

2. (adenovirus)

22 8

(envelop) DNA

AAV

20148

125

2014
|

Ex vivo gene therapy

In vivo

gene therapy

Current vectors
with therapeutic gene

<

O O (>

Host cells

DNA RNA

35 kb

(episome)

1. (retrovirus)

Engineered cells containing

therapeutic gene

RNA

7-12 kb

10 kb

DNA

(proto-

(capsid protein) T

ex vivo

ex vivo

oncogene) (tumor

suppressor gene)

ex vivo() vivo()

(http://www.bmj.com/conten t/315/7118/1289/F1.large.jpg)

in vivo

ex vivo

(lentivirus)

3. (adeno-associated

virus , AAV)
(AAV) DNA

(parovirus)

124

2. (adenovirus)

22 8

(envelop) DNA

AAV

20148

125

2 014
|

AAV

(AcMNPV) ) 134 kb

(l igand)

H (cell

in

(recombinant

peptide)

AAV, rAAV)

lipofectamine

in vivo

rAAV 11

(Invitrogene) Superfect (Qiagen)

rAAV-2 '

5.

vivo

AAV

(complex)

(polylysine)

rAAV

(polyethyleneimine)

(chitosan)

( 3)

rAAV

(l iposome)

ex vivo

(amphiphilic)

50~1000 nm

DNA

(Autographa

() ()

califomica multiple nucleopolyhedrovirus

ex vivo

(2)

4. (Baculovirus)

126

penetrating

228

20148

127

2 014
|

AAV

(AcMNPV) ) 134 kb

(l igand)

H (cell

in

(recombinant

peptide)

AAV, rAAV)

lipofectamine

in vivo

rAAV 11

(Invitrogene) Superfect (Qiagen)

rAAV-2 '

5.

vivo

AAV

(complex)

(polylysine)

rAAV

(polyethyleneimine)

(chitosan)

( 3)

rAAV

(l iposome)

ex vivo

(amphiphilic)

50~1000 nm

DNA

(Autographa

() ()

califomica multiple nucleopolyhedrovirus

ex vivo

(2)

4. (Baculovirus)

126

penetrating

228

20148

127

2014
|

IGF-l

IGF-l

(mesenchymal stem

cells)

2.

3.

BMPs

(fibrin)

(collagne) (hylauronic acid)

(conduction)

ex vivo BMPs

[3]

in vivo

ex vivo

(induction)

BMPs

BMPs

[]

BMPs

(iliac

crest) TGF- l

(epidermal

(transforming growth factor-

factor , EGF) IGF-l

BMP

) BMPs IGF-l

(insulin-like growth

(platelet-derived growth factor ,

factor-l ')

PDGF)

BMPs

(osteoblast)

[9]

(bone morphogenic proteins

(mineralization) (osteo c1ast)

TGF-l

(proteoglycan)

ex vivo

20

[6] BMP-7

FDA BMP-2 BMP-7

(poly(glycolic acid) , PGA)

BMPs

(hyaline

(remodeling)

BMP

(mineralization) [7]

[10]

1.

128

-....::

228

20148

cartilage) ,

growth

129

2014
|

IGF-l

IGF-l

(mesenchymal stem

cells)

2.

3.

BMPs

(fibrin)

(collagne) (hylauronic acid)

(conduction)

ex vivo BMPs

[3]

in vivo

ex vivo

(induction)

BMPs

BMPs

[]

BMPs

(iliac

crest) TGF- l

(epidermal

(transforming growth factor-

factor , EGF) IGF-l

BMP

) BMPs IGF-l

(insulin-like growth

(platelet-derived growth factor ,

factor-l ')

PDGF)

BMPs

(osteoblast)

[9]

(bone morphogenic proteins

(mineralization) (osteo c1ast)

TGF-l

(proteoglycan)

ex vivo

20

[6] BMP-7

FDA BMP-2 BMP-7

(poly(glycolic acid) , PGA)

BMPs

(hyaline

(remodeling)

BMP

(mineralization) [7]

[10]

1.

128

-....::

228

20148

cartilage) ,

growth

129

2014
|

(in situ)

(blood-brain barrier)

EGF

(satellite cells)

Ex ivo in vivo

EGF[11]

[17]

[1

[18]

MyoD Myf5

Myf6 [13]

IGF

[14]

[1

[ vivo

BMP-

2 BMP-12 IGF-l

PDGF

[1

7.

8.

[16]

4.

6.

(integration)

NGF (nerve growth factor '

) B D NF (brain -derived

VEGF

(vascular endothelial

) IGF-l PDGF

growth factor ')

PDGF bFGF (basic fibroblast growth

factor' )

[]

neurotrophic factors
5.

130

'

228

20148

PDX-l

131

2014
|

(in situ)

(blood-brain barrier)

EGF

(satellite cells)

Ex ivo in vivo

EGF[11]

[17]

[1

[18]

MyoD Myf5

Myf6 [13]

IGF

[14]

[1

[ vivo

BMP-

2 BMP-12 IGF-l

PDGF

[1

7.

8.

[16]

4.

6.

(integration)

NGF (nerve growth factor '

) B D NF (brain -derived

VEGF

(vascular endothelial

) IGF-l PDGF

growth factor ')

PDGF bFGF (basic fibroblast growth

factor' )

[]

neurotrophic factors
5.

130

'

228

20148

PDX-l

131

2014
|

[2]Jang, J.H.; Houchin, T. L. Shea, L. D. ,

[7] Grande , D.A.; Mason , J.; Light , E.

"Gene delivery from polymer scaffolds

Dines , D. , "Stem cells as platforms for

MafANeuroD1

for tissue engineering" , Expert Review of

delivery of genes to enhance cartilage

Medical Devices. 1(1), 127-138 (2004).

repair" , Journal of Bone and Joint

Surgery-American Volume. 85A , 111-

[3] Lieberman, J.R.; Daluiski, A.; Stevenson,

S.; Wu, L.; McAllister, P.; Lee , Y. P.;

Kabo, J.M.; Finerman, G.A.M.;

1(induced pluripotent stem cells , iPSCs)

-(1 3)

(galactose-(1 3) residue)

Be

[8] Nixon, A.J.; Brower-Toland, B.D.; Bent,

A.J.Witte , O.N. , "The effect of regional

S.J.; Saxer, R.A.; Wilke, M.J.; Robbins,

gene therapy with bone morphogenetic

P.D. Evans , C.H. , "lnsulinlike growth

protein-2-producing bone-marrow cells

factor-l gene therapy applications for

on the repair of segmental femoral

cartilage repair" , Clinical Orthopaedics

defects in rats" , Journal of Bone and

and Related Research. (379) , S201-S213

Joint Surgery-American Volume. 81A(7) ,

(2000).
[9]Eming, S.A.; Snow, R.G.; Yarmush ,

905-917 (1999).
[4]Hu, W.W.; Wang , Z.; Hollister, S.J.

M. L. Morgan , J.R. , "Targeted expression

Krebsbach , P.H. , "Localized viral vector

of insulin-like growth factor to human

delivery to enhance in situ regenerative

keratinocytes: Modification of the

gene therapy" , Gene Therapy. 14( 11) ,

autocrine control of keratinocyte

891-901 (2007).

proliferation" , Journal of lnvestigative

[]

MHC-II (major

histocompatibility complex '

[6]Lee, J.Y.; Hall , R.; Pelinkovic , D.;

Cassinelli, E.; Usas, A.; Gilbertson, L.;

[11] Andree , C.; Voigt, M.; Wenger, A.;

Huard, J.Kang, J., "New use of a three-

Erichsen, T.; Bittner, K.; Schaefer, D.;

dimensional pellet culture system for

Walgenbach, K.J.; Borges, J.; Horch,

human intervertebral disc cells: initial

R.E.; Eriksson, E. Stark, B., "Plasmid

[1]Langer, R.Vacanti , J.P. , "Tissue

characterization and potential use for

gene delivery to human keratinocytes

engineering" , Science. 260 (5110) , 920-6

tissue engineering" , Spine (Phila Pa

through a fibrin-mediated transfection

(1993).

1976).26(21), 2316-22 (2001).

system" , Tissue Engineering. 7(6) , 757-

[24]

~~E

132

116 (2003).

228

[5]Hu , W.W.; Ward , B.B.;

Wa

Dermatology. 107(1), 113-120 (1 996).

Z. Krebsbach , P.H. , "Bone Regeneration

[10] Svensjo, T.; Yao , F.; Pomahac, B.;

in Defects Compromised by Radio-

Winkler, T.Eriksson, E. , "Cultured

therapy" , Journal of Dental Research.

autologous fibroblasts augment

89(1) , 77-81 (2010).

epidermal repair" , Transplantation.

20148

73(7) , 1033-1041 (2002).

133

2014
|

[2]Jang, J.H.; Houchin, T. L. Shea, L. D. ,

[7] Grande , D.A.; Mason , J.; Light , E.

"Gene delivery from polymer scaffolds

Dines , D. , "Stem cells as platforms for

MafANeuroD1

for tissue engineering" , Expert Review of

delivery of genes to enhance cartilage

Medical Devices. 1(1), 127-138 (2004).

repair" , Journal of Bone and Joint

Surgery-American Volume. 85A , 111-

[3] Lieberman, J.R.; Daluiski, A.; Stevenson,

S.; Wu, L.; McAllister, P.; Lee , Y. P.;

Kabo, J.M.; Finerman, G.A.M.;

1(induced pluripotent stem cells , iPSCs)

-(1 3)

(galactose-(1 3) residue)

Be

[8] Nixon, A.J.; Brower-Toland, B.D.; Bent,

A.J.Witte , O.N. , "The effect of regional

S.J.; Saxer, R.A.; Wilke, M.J.; Robbins,

gene therapy with bone morphogenetic

P.D. Evans , C.H. , "lnsulinlike growth

protein-2-producing bone-marrow cells

factor-l gene therapy applications for

on the repair of segmental femoral

cartilage repair" , Clinical Orthopaedics

defects in rats" , Journal of Bone and

and Related Research. (379) , S201-S213

Joint Surgery-American Volume. 81A(7) ,

(2000).
[9]Eming, S.A.; Snow, R.G.; Yarmush ,

905-917 (1999).
[4]Hu, W.W.; Wang , Z.; Hollister, S.J.

M. L. Morgan , J.R. , "Targeted expression

Krebsbach , P.H. , "Localized viral vector

of insulin-like growth factor to human

delivery to enhance in situ regenerative

keratinocytes: Modification of the

gene therapy" , Gene Therapy. 14( 11) ,

autocrine control of keratinocyte

891-901 (2007).

proliferation" , Journal of lnvestigative

[]

MHC-II (major

histocompatibility complex '

[6]Lee, J.Y.; Hall , R.; Pelinkovic , D.;

Cassinelli, E.; Usas, A.; Gilbertson, L.;

[11] Andree , C.; Voigt, M.; Wenger, A.;

Huard, J.Kang, J., "New use of a three-

Erichsen, T.; Bittner, K.; Schaefer, D.;

dimensional pellet culture system for

Walgenbach, K.J.; Borges, J.; Horch,

human intervertebral disc cells: initial

R.E.; Eriksson, E. Stark, B., "Plasmid

[1]Langer, R.Vacanti , J.P. , "Tissue

characterization and potential use for

gene delivery to human keratinocytes

engineering" , Science. 260 (5110) , 920-6

tissue engineering" , Spine (Phila Pa

through a fibrin-mediated transfection

(1993).

1976).26(21), 2316-22 (2001).

system" , Tissue Engineering. 7(6) , 757-

[24]

~~E

132

116 (2003).

228

[5]Hu , W.W.; Ward , B.B.;

Wa

Dermatology. 107(1), 113-120 (1 996).

Z. Krebsbach , P.H. , "Bone Regeneration

[10] Svensjo, T.; Yao , F.; Pomahac, B.;

in Defects Compromised by Radio-

Winkler, T.Eriksson, E. , "Cultured

therapy" , Journal of Dental Research.

autologous fibroblasts augment

89(1) , 77-81 (2010).

epidermal repair" , Transplantation.

20148

73(7) , 1033-1041 (2002).

133

2014
|

White, J.J., "From scrawny to brawny:

adult retinal ganglion cell survival

M. L.; Betthauser, J.; Carter, D.B.;

[12] Qin , R.F.; Mao , T.Q.; Gu , X.M.;

the quest for neomusculogenesis; smart

and axonal

regeneration" 101ecular

Greenstein , J. L.; Hao , Y. H.; 1m, G.S.;

Hu , K.J.; Liu , Y.P.; Chen , J.W. Nie ,

surfaces and scaffolds for muscle

Therapy. 11 (6) , 906-915 (2005).

Liu , Z.H.; Mell , G.D.;

X. , "Regulation of skeletal muscle

tissue engineering" , Expert Review

Dur

P.F.; Newman , K.D.; Jones ,

Park , K.W.; Rieke , A.; Ryan , D.J.J.;

differentiation in fibroblasts by

of Medical Devices. 4(5) , 709-728

M.; Yamada , 1.; Shayani , V.; Virmani ,

Sachs , D.H.; Forsberg , E.J.; Prather,

exogenous MyoD gene in vitro and

(2007).

R.Dichek , D.A. , "Seeding of vascular

R.S. Hawley, R.J. , "Production of

766 (2001).

C.N.;

in vivo" , Molecular and Cellular

[17] Quigley, A. F.; Bulluss , K.J.; Kyratzis ,

grafts with genetically modified

alpha-l ,3-galactosyltransferase null

Biochemistry. 302 (1 -2) , 233-239

I.L. B.; Gilmore , K.; Mysore , T.;

endothelial cells - Secretion of

pigs by means of nuclear transfer

(2007).

Schirmer, K.S.U.; Kennedy , E. L.;

recombinant TPA results in decreased

with fibroblasts bearing loss of

Truong , Y. B.; Edwards ,

seeded cell retention in vitro and in

heterozygosity mutations", Proceedings

vivo" , Circulation. 93(7) , 1439-1446

of the N ational Academy of Sciences of

(1 996).

the United States of America. 101 (1 9),

[1 Goncalves

M.A.F.V.; Swildens , J.;

O'She1.;

Peete

Holkers , M.; Narain , A.; van Nierop ,

S. L.;

G.P.; van de Watering , M.J.M.; Kn aan-

J.M.; Campbell , T.E.; Lowes , K.N.;

Shanzer, S.de Vries , A.A. F., "Genetic

Higgins , M. J.; Moulton , S.E.;

[21] Gu , D. L.; Nguyen , T.; Gonzalez , A.M.;

complementation of human muscle

Murphy , M.A.; Cook , M.J.; Clark ,

Printz, M.A.; Pierce, G. F.; Sosnowski,

[24] Tian , C.; Ansari , M. J.I.; Paez-

cells via directed stem cell fusion" ,

G.M.; Wallace , G.G. Kapsa , R.M. 1.,

B.A.; Phillips , M. L. Chandler, L.A. ,

Cortez , J.; Bagley, J.; Godwin , J.;

Molecular Therapy. 16(4) , 741-748

"Engineering a multimodal nerve

"Adenovirus encoding human platelet-

Donnarumma , M.; Sayegh , M.H.

(2008).

conduit for repair of injured peripheral

derived growth factor-B delivered in

Lacomini "Induction

nerve" , Joumal of Neural Engineering.

collagen exhibits safety, biodistribution,

diabetes resistance and prevention of

10(1) (2013).

and immunogenicity profiles favorable

recurrent type 1 diabetes following

for clinical use" , Molecular Therapy.

islet transplantation by gene therapy" ,

9(5) , 699-711 (2004).

Joumalo fI mmunology. 179 (1 0) , 6762-

[14] Lynch , G.S.; Schertzer, J.D. Ryall ,

J.G. , "Anabolic agents for improving

G.; Herwig , P.; Razal ,

muscle regeneration and function after

[18] Natsume , A.; Wolfe , D.; Hu , J.; Huang ,

injury" , Clinical and Experimental

S.H.; Puskovic, v.; Glorioso , J.C.; Fink

Pharmacology and Physiology. 35(7),

D.J. Mata, M. , "Enhanced functional

852-858 (2008).

recovery after proximal nerve root

Lai , S.H.;

T.; Yang , S.; Konig ,

injury by vector-mediated gene

R.T.H.; Tan , S. Y.; Lee , S.Y.; Tan ,

S.;Chauveau , C.; Anegon , 1.;

transfer" , Experimental N eurology.

M.E.H.; Sivalingam, J.; Chow, P.K.H.

Home

ye

r"

184(2), 878-886 (2003).

Kon , O. L., "Nonvirally Modified

[1 Laumonier

mediated HO-l gene transfer enhances

[1 Hu

[22] Chen, N.K. F.; Wong , J.S.; Kee , 1. H.C.;

Th

C.H.; Ng ,

W.;

Autologous Primary Hepatocytes

precursor cell survival after

Hendriks , W. T.J.; Niclou , S .P.;

Correct Diabetes and Prevent Target

autologous transplantation in pig" ,,

Molecular Therapy. 16(2) , 404-410

Verhaagen , J.; Harvey, A.R. Cui , Q. ,

Organ Injury in a Large Preclinical

"Lentiviral-mediated transfer of CNTF

Model", Plos One. 3(3) (2008).

(2008).

to Schwann cells within reconstructed

[16] Rowlands , A.S.; Hudson , J.E. Cooper-

peripheral nerve grafts enhances

22 8

[23]

Kolber-Simon

D.; Lai , L. X.; Watt ,

S. R.; Denaro , M.; Am , S.; Augenstein ,

20148

7335-7340 (2004).

of robust

6769 (2007).

Ng ,

Y.; Leaver , S.G.; Plant , G.W.;

myogeni
c

134

[20]

Muhy

:
:
:

135

2014
|

White, J.J., "From scrawny to brawny:

adult retinal ganglion cell survival

M. L.; Betthauser, J.; Carter, D.B.;

[12] Qin , R.F.; Mao , T.Q.; Gu , X.M.;

the quest for neomusculogenesis; smart

and axonal

regeneration" 101ecular

Greenstein , J. L.; Hao , Y. H.; 1m, G.S.;

Hu , K.J.; Liu , Y.P.; Chen , J.W. Nie ,

surfaces and scaffolds for muscle

Therapy. 11 (6) , 906-915 (2005).

Liu , Z.H.; Mell , G.D.;

X. , "Regulation of skeletal muscle

tissue engineering" , Expert Review

Dur

P.F.; Newman , K.D.; Jones ,

Park , K.W.; Rieke , A.; Ryan , D.J.J.;

differentiation in fibroblasts by

of Medical Devices. 4(5) , 709-728

M.; Yamada , 1.; Shayani , V.; Virmani ,

Sachs , D.H.; Forsberg , E.J.; Prather,

exogenous MyoD gene in vitro and

(2007).

R.Dichek , D.A. , "Seeding of vascular

R.S. Hawley, R.J. , "Production of

766 (2001).

C.N.;

in vivo" , Molecular and Cellular

[17] Quigley, A. F.; Bulluss , K.J.; Kyratzis ,

grafts with genetically modified

alpha-l ,3-galactosyltransferase null

Biochemistry. 302 (1 -2) , 233-239

I.L. B.; Gilmore , K.; Mysore , T.;

endothelial cells - Secretion of

pigs by means of nuclear transfer

(2007).

Schirmer, K.S.U.; Kennedy , E. L.;

recombinant TPA results in decreased

with fibroblasts bearing loss of

Truong , Y. B.; Edwards ,

seeded cell retention in vitro and in

heterozygosity mutations", Proceedings

vivo" , Circulation. 93(7) , 1439-1446

of the N ational Academy of Sciences of

(1 996).

the United States of America. 101 (1 9),

[1 Goncalves

M.A.F.V.; Swildens , J.;

O'She1.;

Peete

Holkers , M.; Narain , A.; van Nierop ,

S. L.;

G.P.; van de Watering , M.J.M.; Kn aan-

J.M.; Campbell , T.E.; Lowes , K.N.;

Shanzer, S.de Vries , A.A. F., "Genetic

Higgins , M. J.; Moulton , S.E.;

[21] Gu , D. L.; Nguyen , T.; Gonzalez , A.M.;

complementation of human muscle

Murphy , M.A.; Cook , M.J.; Clark ,

Printz, M.A.; Pierce, G. F.; Sosnowski,

[24] Tian , C.; Ansari , M. J.I.; Paez-

cells via directed stem cell fusion" ,

G.M.; Wallace , G.G. Kapsa , R.M. 1.,

B.A.; Phillips , M. L. Chandler, L.A. ,

Cortez , J.; Bagley, J.; Godwin , J.;

Molecular Therapy. 16(4) , 741-748

"Engineering a multimodal nerve

"Adenovirus encoding human platelet-

Donnarumma , M.; Sayegh , M.H.

(2008).

conduit for repair of injured peripheral

derived growth factor-B delivered in

Lacomini "Induction

nerve" , Joumal of Neural Engineering.

collagen exhibits safety, biodistribution,

diabetes resistance and prevention of

10(1) (2013).

and immunogenicity profiles favorable

recurrent type 1 diabetes following

for clinical use" , Molecular Therapy.

islet transplantation by gene therapy" ,

9(5) , 699-711 (2004).

Joumalo fI mmunology. 179 (1 0) , 6762-

[14] Lynch , G.S.; Schertzer, J.D. Ryall ,

J.G. , "Anabolic agents for improving

G.; Herwig , P.; Razal ,

muscle regeneration and function after

[18] Natsume , A.; Wolfe , D.; Hu , J.; Huang ,

injury" , Clinical and Experimental

S.H.; Puskovic, v.; Glorioso , J.C.; Fink

Pharmacology and Physiology. 35(7),

D.J. Mata, M. , "Enhanced functional

852-858 (2008).

recovery after proximal nerve root

Lai , S.H.;

T.; Yang , S.; Konig ,

injury by vector-mediated gene

R.T.H.; Tan , S. Y.; Lee , S.Y.; Tan ,

S.;Chauveau , C.; Anegon , 1.;

transfer" , Experimental N eurology.

M.E.H.; Sivalingam, J.; Chow, P.K.H.

Home

ye

r"

184(2), 878-886 (2003).

Kon , O. L., "Nonvirally Modified

[1 Laumonier

mediated HO-l gene transfer enhances

[1 Hu

[22] Chen, N.K. F.; Wong , J.S.; Kee , 1. H.C.;

Th

C.H.; Ng ,

W.;

Autologous Primary Hepatocytes

precursor cell survival after

Hendriks , W. T.J.; Niclou , S .P.;

Correct Diabetes and Prevent Target

autologous transplantation in pig" ,,

Molecular Therapy. 16(2) , 404-410

Verhaagen , J.; Harvey, A.R. Cui , Q. ,

Organ Injury in a Large Preclinical

"Lentiviral-mediated transfer of CNTF

Model", Plos One. 3(3) (2008).

(2008).

to Schwann cells within reconstructed

[16] Rowlands , A.S.; Hudson , J.E. Cooper-

peripheral nerve grafts enhances

22 8

[23]

Kolber-Simon

D.; Lai , L. X.; Watt ,

S. R.; Denaro , M.; Am , S.; Augenstein ,

20148

7335-7340 (2004).

of robust

6769 (2007).

Ng ,

Y.; Leaver , S.G.; Plant , G.W.;

myogeni
c

134

[20]

Muhy

:
:
:

135

2 0 14
| 4

[1]

1965 A.

D.

and Drug

Bangham lecithin

Administration; FDA)

1970

(conventional liposomes)

[3]

(l ong

circulating liposomes) [2]

(l iposome)

(poly(ethylene glycol); PEG)

(Food

1.

-.

1986 EPR EPR

(vascular permeability factor)

40 kDa

136

228

(A) ; (8); (C)-;

(0); (E)[2J

20148

137

2 0 14
| 4

[1]

1965 A.

D.

and Drug

Bangham lecithin

Administration; FDA)

1970

(conventional liposomes)

[3]

(l ong

circulating liposomes) [2]

(l iposome)

(poly(ethylene glycol); PEG)

(Food

1.

-.

1986 EPR EPR

(vascular permeability factor)

40 kDa

136

228

(A) ; (8); (C)-;

(0); (E)[2J

20148

137

2014
|

138

2. ()

NON-PEGYLATED
(CONVENTIONAL)

"OPSONINS"

: (opsonins)

(complement component) []

FDA

(mononuclear phagocyte system;

MPS)

(polyethylene glycol; PEG)

(reticuloendothelial system;RES)

[2 1

distearoyl phosphatidyl

EPR

ethanolasmi DSPE)

[] ;

DSPC [12 15] ;

2000 5000 [16]

- 4-6 mol%

PEGYLATED
(STERICALLY STABI Ll ZED)

[ 11]

3 5 nm

(mushroom)

[10 11]

[17 , 18]

[6 12] 0

(stealth liposomes) 2 [19] ;

doxorubicin

A , Gabizon

( distearoyl

48

phophatidylcholine; DSPC)

55:45 66:33

EPR

[2]

(environment responsive liposomes)

[20] 'D. NeedhamPEG

[12]

(active

L. D , Meyer DSPC

:45

[21]

) microbubble

24 1] [12 13]

: Caelyx Caelyx

doxorubicin-

[25 ,26]

HDL

OOJCJ

RES

~d

Ll VER

RAPID
CLEARANCE

RES[19]

22 8

73 9

20148

triggered liposomes)

139

2014
|

138

2. ()

NON-PEGYLATED
(CONVENTIONAL)

"OPSONINS"

: (opsonins)

(complement component) []

FDA

(mononuclear phagocyte system;

MPS)

(polyethylene glycol; PEG)

(reticuloendothelial system;RES)

[2 1

distearoyl phosphatidyl

EPR

ethanolasmi DSPE)

[] ;

DSPC [12 15] ;

2000 5000 [16]

- 4-6 mol%

PEGYLATED
(STERICALLY STABI Ll ZED)

[ 11]

3 5 nm

(mushroom)

[10 11]

[17 , 18]

[6 12] 0

(stealth liposomes) 2 [19] ;

doxorubicin

A , Gabizon

( distearoyl

48

phophatidylcholine; DSPC)

55:45 66:33

EPR

[2]

(environment responsive liposomes)

[20] 'D. NeedhamPEG

[12]

(active

L. D , Meyer DSPC

:45

[21]

) microbubble

24 1] [12 13]

: Caelyx Caelyx

doxorubicin-

[25 ,26]

HDL

OOJCJ

RES

~d

Ll VER

RAPID
CLEARANCE

RES[19]

22 8

73 9

20148

triggered liposomes)

139

2014
|

pKa

[]

( oleic acid cholesteryl

carboxyl acrylic acid

"

hemisuccinate)

(aggregate)

P. S. Uster D. W. Deamer

- D. Needham

polyhistidine

poly( ethylacrylic acid)(PEAA)

[2]

[31]

; G. D. Eytan pol)sme

(M.W.=30000) cholesterol

5% mole PEG-DSPE

pH(

pH 5.0 polysine

pH 6.0

6.5_6.8)[24.25]

[];

Tirrell PEAA Michael

pH 5-6.5 (endosomes)

: (1)

addition

pH 4-5

(polycation) , (2)

pH 6]

(lysosomes) 3 [

po ly(meth acry 1i c

(polyanion)[30]

acid-co-stearyl methacrylate)

( poly (l ysine)

- (3 7]

succinylated poly(glycidol)s

PEG

polyethylenimine(PEI)

DNA siRNA'

K. Kono

( Lipofectamine)l PEI

methylglutarylated poly(glycidol)

endosome lysosome

PEI[34]

1. -

early endosome (pH

2-5 min

=6.5)

lale endosome (pH =5.0-6.0)

10-15 min

pH 5-6.5 ;

pH pH

140

4_5 125]

228

D. A.

E. C. Cho

[384

pH

T. O'Halloran S. B. Nguyen

20148

141

2014
|

pKa

[]

( oleic acid cholesteryl

carboxyl acrylic acid

"

hemisuccinate)

(aggregate)

P. S. Uster D. W. Deamer

- D. Needham

polyhistidine

poly( ethylacrylic acid)(PEAA)

[2]

[31]

; G. D. Eytan pol)sme

(M.W.=30000) cholesterol

5% mole PEG-DSPE

pH(

pH 5.0 polysine

pH 6.0

6.5_6.8)[24.25]

[];

Tirrell PEAA Michael

pH 5-6.5 (endosomes)

: (1)

addition

pH 4-5

(polycation) , (2)

pH 6]

(lysosomes) 3 [

po ly(meth acry 1i c

(polyanion)[30]

acid-co-stearyl methacrylate)

( poly (l ysine)

- (3 7]

succinylated poly(glycidol)s

PEG

polyethylenimine(PEI)

DNA siRNA'

K. Kono

( Lipofectamine)l PEI

methylglutarylated poly(glycidol)

endosome lysosome

PEI[34]

1. -

early endosome (pH

2-5 min

=6.5)

lale endosome (pH =5.0-6.0)

10-15 min

pH 5-6.5 ;

pH pH

140

4_5 125]

228

D. A.

E. C. Cho

[384

pH

T. O'Halloran S. B. Nguyen

20148

141

2014
|

\
H\

Cholesterol-terminated poly
(acrylic acid)

succinylated poly(glycidol)s-(39)

(polymer-caged liposome)

(l ower critical solution

temperature )(LCST) 32 C '

5 poly(acrylic

LCST poly(NIPAM)

acid)

; LCST

poly(acrylic acid)

--

coil-to-globule

poly(acrylic acid)

6 poly(NIPAM)

LCST' K.

Kono poly(NIPAM)

Polymer-Incorporated
Li posome (PIL)

Bare Li posome
(BL)

Polymer-Caged
(PCL)

Li posome

[ l

[]

2. -

142

poly(NIPAM)
. T. Tagami

O.5 C

Brij78(polyoxyethylene(~20 units ,

MW~880) stearyl ether) poly(NIPAM)

.7

poly(N -iso-prepropylacrylamide)

[1

(poly (N IPAM) )

(2-hydroxypropyl)methacrylamide mono/

. poly(NIPAM)

dilactate)"

T < LCST

L. Paasonnen poly

228

20148

LCST<T

- LCST (42)

143

2014
|

\
H\

Cholesterol-terminated poly
(acrylic acid)

succinylated poly(glycidol)s-(39)

(polymer-caged liposome)

(l ower critical solution

temperature )(LCST) 32 C '

5 poly(acrylic

LCST poly(NIPAM)

acid)

; LCST

poly(acrylic acid)

--

coil-to-globule

poly(acrylic acid)

6 poly(NIPAM)

LCST' K.

Kono poly(NIPAM)

Polymer-Incorporated
Li posome (PIL)

Bare Li posome
(BL)

Polymer-Caged
(PCL)

Li posome

[ l

[]

2. -

142

poly(NIPAM)
. T. Tagami

O.5 C

Brij78(polyoxyethylene(~20 units ,

MW~880) stearyl ether) poly(NIPAM)

.7

poly(N -iso-prepropylacrylamide)

[1

(poly (N IPAM) )

(2-hydroxypropyl)methacrylamide mono/

. poly(NIPAM)

dilactate)"

T < LCST

L. Paasonnen poly

228

20148

LCST<T

- LCST (42)

143

2014

r.- -~}

| I-~)C;'"';

Drug release profile

100

cn

30 C

80
~

60

37 C

40

40C

<=

20
0

42C

.0

10

20

30

Incubation time (min)

Brij78.[441

[ (1 )-
:(2)-

[]

; (3):

(4); (5):

) PEG

trastuzumab (Herceptin)

J. C. Leroux

(active targeting)( 8 )

doxorubicin [4.51]

NIPAM methacrylic

EPR

acid methacrylic

M. Sugano

acid

anti

1 integrins

polyNIPAM

doxorubicin (non-small

[52]

cell lung carcinomas)[49] ; T. Hamaguchi

1. .

GAH doxorubicin

2. "

J. C. Kim Poly (l~

isopropylacrylamide-co-acrylic

by stander k i1l ing effect

acid) .

PEG-DSPE

J. W. Park

ialoglycoprotein

( PEG maleimide

anti HER2/nu

[]

144

(6)

228

20148

145

2014

r.- -~}

| I-~)C;'"';

Drug release profile

100

cn

30 C

80
~

60

37 C

40

40C

<=

20
0

42C

.0

10

20

30

Incubation time (min)

Brij78.[441

[ (1 )-
:(2)-

[]

; (3):

(4); (5):

) PEG

trastuzumab (Herceptin)

J. C. Leroux

(active targeting)( 8 )

doxorubicin [4.51]

NIPAM methacrylic

EPR

acid methacrylic

M. Sugano

acid

anti

1 integrins

polyNIPAM

doxorubicin (non-small

[52]

cell lung carcinomas)[49] ; T. Hamaguchi

1. .

GAH doxorubicin

2. "

J. C. Kim Poly (l~

isopropylacrylamide-co-acrylic

by stander k i1l ing effect

acid) .

PEG-DSPE

J. W. Park

ialoglycoprotein

( PEG maleimide

anti HER2/nu

[]

144

(6)

228

20148

145

2014
| f

Y. Hattori

[ R.Xie

azidosugar '

azidosugar

azide

[54]

pH
3. .

(folic

[] 10

acid)

gamma

carboxyl amino-PEG-DSPE

A. Gabizon

0.2-0.5% mole folate

PEG-DSPE

[57 58]

EPR

60] J. M. Saul

[ A. Gabizon

[]( 9

[]

146

(1)

[62)

Prevent protein adsorption

2 -J (2) rom

(4) Biotin-receptor
interaction to improve
cell uptake

Biotin receptor

:\:/Je

pH 6.8 -

6.5

10

Tumor extracellular matrix

Passive targeting

Cancer cell
Active targeting

[l]Matsumura , Y.; Maeda , H. , "A

New Concept for Macromolecular

228

10

20148

- [61)

147

2014
| f

Y. Hattori

[ R.Xie

azidosugar '

azidosugar

azide

[54]

pH
3. .

(folic

[] 10

acid)

gamma

carboxyl amino-PEG-DSPE

A. Gabizon

0.2-0.5% mole folate

PEG-DSPE

[57 58]

EPR

60] J. M. Saul

[ A. Gabizon

[]( 9

[]

146

(1)

[62)

Prevent protein adsorption

2 -J (2) rom

(4) Biotin-receptor
interaction to improve
cell uptake

Biotin receptor

:\:/Je

pH 6.8 -

6.5

10

Tumor extracellular matrix

Passive targeting

Cancer cell
Active targeting

[l]Matsumura , Y.; Maeda , H. , "A

New Concept for Macromolecular

228

10

20148

- [61)

147

2014
|

Therapeutics in Cancer
Chemotherapy: Mechanism of

[8]Petel , H. , "Serum Opsonins and Liposomes:

Tumoritropic Accumulation of

Their Interaction and Opsonophagocytosis" ,

Proteins and the Antitumor Agent

Cri t. Rev. Ther. Drug Carrier Sys t., 9, 39-

SMANCS" , Cancer Res. , 46 , 6387-

90 (1 992).

Polyethylene-glycol Coated

Circulate so Long" , J. Liposome Res. ,

Liposome" , Cancer Res. , 54 , 987-

4 , 725-739 (1 994).
[1 Zambo

992(1994).

C. , "Liposomal, nanoparti c1 e,

[14]Gabizon , A.; Goren , D.; Fuks , Z.;

and conjugated formulations of

Barenholz , Y.; Dagan , A.; Meshorer,

anticancer agents" , Clin. Cancer Res.

[9]Semple , S.; Chonn , A.; Cullis , P. ,

A. , "Enhancement of Adriamycin

11 , 8230-8234(2005).

[2]Torchilin , v., "Recent Advances

"Interactions of Liposomes and Lipid-

Delivery to Liver Metastatic Cells

[20]Gabizon , A.; Goren , D.; Horowitz ,

with Liposomes as Pharmaceutical

based Carrier Systems with Blood Proteins:

with Increased Tumoricidal Effect

A.; Tzemach , D.; Lossos A. , "Long-

Carriers" , Nature Rev. Drug Discov. ,

Relation to Clearance Behaviour in Vivo" ,

Using Liposomes as Drug Carriers" ,

circulating Liposomes for Drug

4 , 145-160(2005).

Adv. Drug Deliver. Rev. , 32 , 3-17(1998).

Cancer Res. 43 , 4730- 4735(1983).

Delivery in Cancer Therapy: a Review

J. , "Stealth

[15]Papahadjopoulos , D.; Allen , T.;

of Biodistribution Studies in Tumor-

Liposomes for Drug Delivery:

Liposomes and Long Circulating

Gabizon , A.; Mayhew, E.; Matthay,

bearing Animals" Adv. Drug Deliver.

Progress and Problems" , Trends

Nanoparti c1 es:critical Issues in

K.; Huang , S.; Lee , K.; Woodle , M.;

Rev. , 24 , 337-344 (1 997).

Biotechno1., 13 , 527-537 (1 995).

Pharmacokinetics , Opsonization and

Lasic , D.; Redemann , C. , "Sterically

[21]Tali Siegal Needham , D.; Mclntosh ,

Protein-binding Properties" , Prog. Lipid

Stabilized Liposomes: Improvements

T.; Lasic , D. , "Repulsive Interactions

Res. , 42 , 463-478(2003).

in Pharmacokinetics and Antitumor

and Mechanical Stability of Polymer-

6392( 1986).

[3] Gregoriadis , G. , "Engineering

[4]Cattel , M. , "Stealth Liposomes:

Review of the Basic Science ,

[10]Moghimi , S.;

Szebe

Eicacy"

Rationale , and Clinical Applications ,

[11]Gabizon , A. , "Liposome Circulation

Existing and Potential" , In t. 1.

Time and Tumor Targeting: Implications

Sci USA , 88 , 11460-11464(1 991).

Nanomedicine , 1, 297-315(2006).

for Cancer Chemotherapy" , Adv. Drug

[16]Photos , P.; Bacakova , L.; Discher,

[22]Daemen , T.; Hofstede , G.; Ten

B.; Bates , F.; Discher, D. , "Polymer

Kate , M.; Bakker-Woudenberg ,

D.; Meyer, 0.; Hong , K.;

Vesi c1 es in Vivo: Correlations with

1.; Scherphof, G. , "Liposomal

Curr. Opin. Colloid Interface Sci. 6 ,

Kirpotin , D.; Papahadjopoulos , D. ,

PEG Molecular Weight" , J. Contro 1.

Doxorubicin-induced Toxicity:

66-77(2001).

"Optimizing Liposomes for Delivery

Release 90 , 323-334(2003).

Depletion and Impairment of

[5]Barenholz , Y.; "Liposome

Application: Problems and Prospects" ,

Deliver. Rev. ,16, 285-294 (1 995).

[1 Drummond

Therapeutic

Proc Nat1 Acad

grafted Lipid Membrane" , Biochim.

Biophys. Acta. , 1108 , 40-48 (1 992).

[6]Lian , T.; Ho , R. , "Trends and

of Chemotheapeutic Agents to Solid

[17]Torchilin , v.; Omelyyaneke , v.;

Phagocytic Activity of Liver

Developments in Liposome Drug

Tumors" , Pharmaco l. Rev. 51 , 691-

Papisov, M.; "Poly(ethylene glycol)

Macrophages" , In t. J. Cancer 61 , 716-

Delivery Systems" , J. Pharm. Sci. , 6 ,

743 (1 999).

721 (1 995).

the Liposome Surface: on the

[23]Daemen , T.;

Reg

J.; Meesters , M.;

A.; Catane , R.; Uziely , B.;

Mechanism of Polymer-coated

[7]Scherphof , G. , "Uptake and

Kaufman , B.; Safra , T. , "Prolonged

Liposomes Longevity" , Biochim.

Ten Kate , M.; Bakker-Woudenberg ,

Intracellular Processing of Targeted

Circulation Time and Enhanced

Biophys. Acta. , 1195 , 11-20(1 994).

1.; Scherphof. G. , "Toxicity of

and Nontargeted Li posomes by Rat

Accumulation in Malignant Exudates

[18]Torchilin , V.; Papisov, M. , "Why Do

Doxorubicin Entrapped Within Long-

Kupper Cells in Vivo and in Vitro" ,

of Doxorubicin Encapsulated in

Polyethylene glycol-coated Liposomes

circulating Liposomes ," J. Contro l.

667-679(2001).

148

Ann. N. Y. Acad. Sci. , 446 , 368-384(1985).

[1 Gabizon

228

20148

149

2014
|

Therapeutics in Cancer
Chemotherapy: Mechanism of

[8]Petel , H. , "Serum Opsonins and Liposomes:

Tumoritropic Accumulation of

Their Interaction and Opsonophagocytosis" ,

Proteins and the Antitumor Agent

Cri t. Rev. Ther. Drug Carrier Sys t., 9, 39-

SMANCS" , Cancer Res. , 46 , 6387-

90 (1 992).

Polyethylene-glycol Coated

Circulate so Long" , J. Liposome Res. ,

Liposome" , Cancer Res. , 54 , 987-

4 , 725-739 (1 994).
[1 Zambo

992(1994).

C. , "Liposomal, nanoparti c1 e,

[14]Gabizon , A.; Goren , D.; Fuks , Z.;

and conjugated formulations of

Barenholz , Y.; Dagan , A.; Meshorer,

anticancer agents" , Clin. Cancer Res.

[9]Semple , S.; Chonn , A.; Cullis , P. ,

A. , "Enhancement of Adriamycin

11 , 8230-8234(2005).

[2]Torchilin , v., "Recent Advances

"Interactions of Liposomes and Lipid-

Delivery to Liver Metastatic Cells

[20]Gabizon , A.; Goren , D.; Horowitz ,

with Liposomes as Pharmaceutical

based Carrier Systems with Blood Proteins:

with Increased Tumoricidal Effect

A.; Tzemach , D.; Lossos A. , "Long-

Carriers" , Nature Rev. Drug Discov. ,

Relation to Clearance Behaviour in Vivo" ,

Using Liposomes as Drug Carriers" ,

circulating Liposomes for Drug

4 , 145-160(2005).

Adv. Drug Deliver. Rev. , 32 , 3-17(1998).

Cancer Res. 43 , 4730- 4735(1983).

Delivery in Cancer Therapy: a Review

J. , "Stealth

[15]Papahadjopoulos , D.; Allen , T.;

of Biodistribution Studies in Tumor-

Liposomes for Drug Delivery:

Liposomes and Long Circulating

Gabizon , A.; Mayhew, E.; Matthay,

bearing Animals" Adv. Drug Deliver.

Progress and Problems" , Trends

Nanoparti c1 es:critical Issues in

K.; Huang , S.; Lee , K.; Woodle , M.;

Rev. , 24 , 337-344 (1 997).

Biotechno1., 13 , 527-537 (1 995).

Pharmacokinetics , Opsonization and

Lasic , D.; Redemann , C. , "Sterically

[21]Tali Siegal Needham , D.; Mclntosh ,

Protein-binding Properties" , Prog. Lipid

Stabilized Liposomes: Improvements

T.; Lasic , D. , "Repulsive Interactions

Res. , 42 , 463-478(2003).

in Pharmacokinetics and Antitumor

and Mechanical Stability of Polymer-

6392( 1986).

[3] Gregoriadis , G. , "Engineering

[4]Cattel , M. , "Stealth Liposomes:

Review of the Basic Science ,

[10]Moghimi , S.;

Szebe

Eicacy"

Rationale , and Clinical Applications ,

[11]Gabizon , A. , "Liposome Circulation

Existing and Potential" , In t. 1.

Time and Tumor Targeting: Implications

Sci USA , 88 , 11460-11464(1 991).

Nanomedicine , 1, 297-315(2006).

for Cancer Chemotherapy" , Adv. Drug

[16]Photos , P.; Bacakova , L.; Discher,

[22]Daemen , T.; Hofstede , G.; Ten

B.; Bates , F.; Discher, D. , "Polymer

Kate , M.; Bakker-Woudenberg ,

D.; Meyer, 0.; Hong , K.;

Vesi c1 es in Vivo: Correlations with

1.; Scherphof, G. , "Liposomal

Curr. Opin. Colloid Interface Sci. 6 ,

Kirpotin , D.; Papahadjopoulos , D. ,

PEG Molecular Weight" , J. Contro 1.

Doxorubicin-induced Toxicity:

66-77(2001).

"Optimizing Liposomes for Delivery

Release 90 , 323-334(2003).

Depletion and Impairment of

[5]Barenholz , Y.; "Liposome

Application: Problems and Prospects" ,

Deliver. Rev. ,16, 285-294 (1 995).

[1 Drummond

Therapeutic

Proc Nat1 Acad

grafted Lipid Membrane" , Biochim.

Biophys. Acta. , 1108 , 40-48 (1 992).

[6]Lian , T.; Ho , R. , "Trends and

of Chemotheapeutic Agents to Solid

[17]Torchilin , v.; Omelyyaneke , v.;

Phagocytic Activity of Liver

Developments in Liposome Drug

Tumors" , Pharmaco l. Rev. 51 , 691-

Papisov, M.; "Poly(ethylene glycol)

Macrophages" , In t. J. Cancer 61 , 716-

Delivery Systems" , J. Pharm. Sci. , 6 ,

743 (1 999).

721 (1 995).

the Liposome Surface: on the

[23]Daemen , T.;

Reg

J.; Meesters , M.;

A.; Catane , R.; Uziely , B.;

Mechanism of Polymer-coated

[7]Scherphof , G. , "Uptake and

Kaufman , B.; Safra , T. , "Prolonged

Liposomes Longevity" , Biochim.

Ten Kate , M.; Bakker-Woudenberg ,

Intracellular Processing of Targeted

Circulation Time and Enhanced

Biophys. Acta. , 1195 , 11-20(1 994).

1.; Scherphof. G. , "Toxicity of

and Nontargeted Li posomes by Rat

Accumulation in Malignant Exudates

[18]Torchilin , V.; Papisov, M. , "Why Do

Doxorubicin Entrapped Within Long-

Kupper Cells in Vivo and in Vitro" ,

of Doxorubicin Encapsulated in

Polyethylene glycol-coated Liposomes

circulating Liposomes ," J. Contro l.

667-679(2001).

148

Ann. N. Y. Acad. Sci. , 446 , 368-384(1985).

[1 Gabizon

228

20148

149

2014
|

Re1ease 44 , 1-9(1 997).

[24]Gerasimov, 0.; Boomer, J.; Qualls ,
M.; Thompson , D. , "Cytoso1ic Drug

glyco1) on pH-induced Re1ease of

R. , "Destabi1ization of Liposomes

Time" , Adv. Drug De1iver. Rev. ,56 ,

Contents from Liposomes by Po1y(2-

by Uncharged Hydrophi1ic and

947-965(2004).

ethy1acry1ic acid)" , J. Liposome Res.

Amphiphi1ic Po1ymers" , J. Phys.

9, 275-290(1 999).

Chem. B 108 , 7763-7770(2004).

De1ivery Using pH- and Light-

[30]Drummond, D.; Zignani , M.; Leroux ,

sensitive Liposomes" , Adv. Drug

J. , "Current Status of pH-sensitive

De1iver. Rev. , 38 , 317-338(1 999).

[25]Sharma , A.; Sharma, U. , "Liposomes

Tirrell

[4 1]Lee , S.; Chen , H.; Dettmer , C.;

Liposomes in Drug De1ivery" , Prog.

"H. -Induced Re1ease of Contents of

O'Halloran, T.; Nguyen , S. , "Po1ymer-

Lipid Res. 39 , 409-460(2000).

Phosphatidylcho1ine Vesicles Bearing

caged Lipsomes: a pH-responsive

[36]Maeda , M.; Kumano , A.;

in Drug De1ivery: Progress and

[31]U ster, P.; Deamer, D. , "pH -Dependent

Surface-bound Po1ye1ectro1yte

De1ivery System with High Stabi1ity" ,

Limitations" , In t. J. Pharmaceut. 154,

Fusion of Liposomes Using Titratab1e

Chains" , J. Am. Chem. Soc. 110 ,

J. Am. Chem. Soc. 129 , 15096-

123-140 (1 997).

Po1ycations" , Biochemistry 24 ,

7455-7459(1 988).

15097(2007) ,.

[26]Kibanov, A.; Schevchenko , T.;

R u

1-8(1 985).

[37]Cho , E.; Lim H.; Kim , H.; Son , E.;

[42]Kono , K. , "Thermosensitive Po1ymer-

B.; Seip , R.; Chin , C. , "Ultrasound-

[32]Gad , A.; Si1ver , B.; Eytan , G. ,

Choi ,H.; Park , J.; Kim , J.;Kim J. ,

modified Liposomes" , Adv. Drug

trigger Re1ease of Materia1s Entrapped

"Po1ycation-induced Fusion of

"Ro1e of pH-sensitive Po1ymer-

De1iver. Rev 53 , 307-319(2001).

in a Microbubb1e-1ipoosme Contructs:

Negative1y Charged Vesicles" ,

1iposome Comp1ex in Enhancing

A Too1 for Targeted Drug De1ivery" , J.

Biochim. Biophys. Acta. , 690 , 124-

Cellu1ar Uptake of Bio1ogically Active

"Temperature-sensitive Liposomes:

Contro l. Re1ease , 148 , 13-17(2010).

132(1 982).

Drugs" , Mater. Sci. Eng. C, 29 , 774-

Liposomes Bearing Po1y(N-

778(2009).

isopropy1acry1amide)" , J. Contro l.

[27]Geers , B.; Lentacker, 1.; Sander, N.;

[33]Yamazaki , Y.; Nango , M.;

Matsuu

[4 Kono

K.; Hayashi , H.; Takagishi , T. ,

Re1ease 30, 69-75(1 994).

Demeester, J.; Meairs , S.; Se Smedt,

M.; Hasegawa , Y.; Hasegawa , M.;

[38]Kono , K.; Zenitani , K.; Takagish , T. ,

S. , "Se1f-assemb1ed Liposome-1oaded

Oku , N. , "Po1ycation Liposomes ,

"Nove1 pH-sensitive Liposomes:

Microbubb1es: The Missing Link for

a N ove1 N onvira1 Gene Transfer

Liposomes Bearing a Po1y(ethy1ene

Nanopartic1e , and Conjugated

Safe and Efficient Ultrasound Trigger

System, Constructed from Cety1ated

glyco1) Derivative with Carboxy1

Formu1ations of Anticancer Agents" ,

Drug De1ivery" , J. Contro l. Re1ease ,

Po1yethy1enimine" , Gene Ther. , 13 ,

Groups" , BBA-biomembranes , 1193 ,

C1in. Cancer Res. 11 , 8230-

152 , 249-256(2011).

1148-1155(2000).

1-9(1 994).

8234(2005).

[28]Eng

K.; Leeper , D.; Cater , J.;

[34] Schfera , J.;

Hbe1

S.; Bakowsky,

[3 Yuba

[44]Zamboni ,

V.

"Liposoma1 ,

E.; Kojima C.; Harada , A.;

[45]Paasonen , L.; Romberg , B.; Storm, G.;

Thist1ethwaite , A.; Tupchong L. ,

U.; Aigner , A. , "Liposome

Tana ;

S.; Kono , K. , "pH-

Yiperttu1a , M.; Uriti , A.; Hennink ,

McFarlane , J. , "Extracellu1ar pH

po1yethy1enimine Comp1exes for

Sensitive Fusogenic Po1ymer-modified

W. , "Temperature-sensitive Po1y(N-

Distribution in Human Tumours" , Int.

Enhanced DNA and siRNA De1ivery" ,

Liposomes as a Carrier of Antigenic

(2-hydroxypropy1)methacry1amide

J. Hyperthermia , 11 , 211-216(1995).

Biomateria1s , 31 , 6892-6900(2010).

Proteins for Activation of Cellu1ar

mono/di1actate )-Coated Liposomes

Immunity" , Biomateria1s 31 , 943-

for Triggered Contents Re1ease" ,

951(2010).

Bioconjugate Chem. , 18 , 2131-

[2 Simo

150

Liposomes with Long Circu1ation

S.;

Morei

J.; Fonseca, C.;

[3 Mills

J.; Eichenbaum , G.; Needham ,

Duzgunes , N.; Pedrodo de Lima , M.;

D. , "Effect of Bi1ayer Cho1estero1

"On the Formu1ation of pH-sensitive

and Surface Grafted Po1y(ethy1ene

228

Watar

[40]Zhang , L.; Peng , T.; Cheng , S.; Zhuo ,

20148

2136(2007).

151

2014
|

Re1ease 44 , 1-9(1 997).

[24]Gerasimov, 0.; Boomer, J.; Qualls ,
M.; Thompson , D. , "Cytoso1ic Drug

glyco1) on pH-induced Re1ease of

R. , "Destabi1ization of Liposomes

Time" , Adv. Drug De1iver. Rev. ,56 ,

Contents from Liposomes by Po1y(2-

by Uncharged Hydrophi1ic and

947-965(2004).

ethy1acry1ic acid)" , J. Liposome Res.

Amphiphi1ic Po1ymers" , J. Phys.

9, 275-290(1 999).

Chem. B 108 , 7763-7770(2004).

De1ivery Using pH- and Light-

[30]Drummond, D.; Zignani , M.; Leroux ,

sensitive Liposomes" , Adv. Drug

J. , "Current Status of pH-sensitive

De1iver. Rev. , 38 , 317-338(1 999).

[25]Sharma , A.; Sharma, U. , "Liposomes

Tirrell

[4 1]Lee , S.; Chen , H.; Dettmer , C.;

Liposomes in Drug De1ivery" , Prog.

"H. -Induced Re1ease of Contents of

O'Halloran, T.; Nguyen , S. , "Po1ymer-

Lipid Res. 39 , 409-460(2000).

Phosphatidylcho1ine Vesicles Bearing

caged Lipsomes: a pH-responsive

[36]Maeda , M.; Kumano , A.;

in Drug De1ivery: Progress and

[31]U ster, P.; Deamer, D. , "pH -Dependent

Surface-bound Po1ye1ectro1yte

De1ivery System with High Stabi1ity" ,

Limitations" , In t. J. Pharmaceut. 154,

Fusion of Liposomes Using Titratab1e

Chains" , J. Am. Chem. Soc. 110 ,

J. Am. Chem. Soc. 129 , 15096-

123-140 (1 997).

Po1ycations" , Biochemistry 24 ,

7455-7459(1 988).

15097(2007) ,.

[26]Kibanov, A.; Schevchenko , T.;

R u

1-8(1 985).

[37]Cho , E.; Lim H.; Kim , H.; Son , E.;

[42]Kono , K. , "Thermosensitive Po1ymer-

B.; Seip , R.; Chin , C. , "Ultrasound-

[32]Gad , A.; Si1ver , B.; Eytan , G. ,

Choi ,H.; Park , J.; Kim , J.;Kim J. ,

modified Liposomes" , Adv. Drug

trigger Re1ease of Materia1s Entrapped

"Po1ycation-induced Fusion of

"Ro1e of pH-sensitive Po1ymer-

De1iver. Rev 53 , 307-319(2001).

in a Microbubb1e-1ipoosme Contructs:

Negative1y Charged Vesicles" ,

1iposome Comp1ex in Enhancing

A Too1 for Targeted Drug De1ivery" , J.

Biochim. Biophys. Acta. , 690 , 124-

Cellu1ar Uptake of Bio1ogically Active

"Temperature-sensitive Liposomes:

Contro l. Re1ease , 148 , 13-17(2010).

132(1 982).

Drugs" , Mater. Sci. Eng. C, 29 , 774-

Liposomes Bearing Po1y(N-

778(2009).

isopropy1acry1amide)" , J. Contro l.

[27]Geers , B.; Lentacker, 1.; Sander, N.;

[33]Yamazaki , Y.; Nango , M.;

Matsuu

[4 Kono

K.; Hayashi , H.; Takagishi , T. ,

Re1ease 30, 69-75(1 994).

Demeester, J.; Meairs , S.; Se Smedt,

M.; Hasegawa , Y.; Hasegawa , M.;

[38]Kono , K.; Zenitani , K.; Takagish , T. ,

S. , "Se1f-assemb1ed Liposome-1oaded

Oku , N. , "Po1ycation Liposomes ,

"Nove1 pH-sensitive Liposomes:

Microbubb1es: The Missing Link for

a N ove1 N onvira1 Gene Transfer

Liposomes Bearing a Po1y(ethy1ene

Nanopartic1e , and Conjugated

Safe and Efficient Ultrasound Trigger

System, Constructed from Cety1ated

glyco1) Derivative with Carboxy1

Formu1ations of Anticancer Agents" ,

Drug De1ivery" , J. Contro l. Re1ease ,

Po1yethy1enimine" , Gene Ther. , 13 ,

Groups" , BBA-biomembranes , 1193 ,

C1in. Cancer Res. 11 , 8230-

152 , 249-256(2011).

1148-1155(2000).

1-9(1 994).

8234(2005).

[28]Eng

K.; Leeper , D.; Cater , J.;

[34] Schfera , J.;

Hbe1

S.; Bakowsky,

[3 Yuba

[44]Zamboni ,

V.

"Liposoma1 ,

E.; Kojima C.; Harada , A.;

[45]Paasonen , L.; Romberg , B.; Storm, G.;

Thist1ethwaite , A.; Tupchong L. ,

U.; Aigner , A. , "Liposome

Tana ;

S.; Kono , K. , "pH-

Yiperttu1a , M.; Uriti , A.; Hennink ,

McFarlane , J. , "Extracellu1ar pH

po1yethy1enimine Comp1exes for

Sensitive Fusogenic Po1ymer-modified

W. , "Temperature-sensitive Po1y(N-

Distribution in Human Tumours" , Int.

Enhanced DNA and siRNA De1ivery" ,

Liposomes as a Carrier of Antigenic

(2-hydroxypropy1)methacry1amide

J. Hyperthermia , 11 , 211-216(1995).

Biomateria1s , 31 , 6892-6900(2010).

Proteins for Activation of Cellu1ar

mono/di1actate )-Coated Liposomes

Immunity" , Biomateria1s 31 , 943-

for Triggered Contents Re1ease" ,

951(2010).

Bioconjugate Chem. , 18 , 2131-

[2 Simo

150

Liposomes with Long Circu1ation

S.;

Morei

J.; Fonseca, C.;

[3 Mills

J.; Eichenbaum , G.; Needham ,

Duzgunes , N.; Pedrodo de Lima , M.;

D. , "Effect of Bi1ayer Cho1estero1

"On the Formu1ation of pH-sensitive

and Surface Grafted Po1y(ethy1ene

228

Watar

[40]Zhang , L.; Peng , T.; Cheng , S.; Zhuo ,

20148

2136(2007).

151

2014
| 1

Pegylated Liposomal Doxorubicin

[55]Russell-Jones , G.; McTavish , K.;

Moreau , P.; Leroux , J., "On the

Tagged with Newly Developed

McEwan , J.; Rice , J.; Nowotnik ,

[60]Ni , S.; Stephenson, S.; Lee , R. , "Folate

Characterization of pH-sensitive

Monoclonal Antibody GAH , in

D. , "Vitamin-mediated Targeting as

Receptor Targeted Delivery of

Liposome/Polymer Complexes" ,

Colorectal Cancer Xenografts" ,

a Potential Mechanism to Increase

Liposomal Daunorubiicn into Tumor

Biomacromolecules , 4, 240-248(2003).

Cancer Sci. 95 , 608-613(2004).

Drug Uptake by Tumors" , J. Inorg.

Cells" , Anticancer Res. 22 ,

Biochem. 98 , 1625-1633(2004).

2135(2002).

2131

S.; Kim , J. , "Temperature-

[51]Park , J.; Hong , K.; Kirpotin , D.;

sensitivity of Liposomal Lipid

Colbern , G.; Shalaby, R.; Baselga ,

[56]Zalipsky , S.; Brandeis , E.;

[6 1]Lee , R.; Low, P. , "Folate-mediated

Bilayers Mixed with Poly

J.; Shao , Y.; Nielsen , U.; Marks ,

Newman , M.; Woodle , M. , "Long

Tumor Cell Targeting of Liposome-

(N -isopropylacrylamide-co-acrylic

J.; Moore , D.; Papahadjopoulos ,

Circulating , Cationic Liposomes

entrapped Doxorubicin in Vi tro" ,

acid)" , J. Bio l. Chem. , 121 , 15-

D.; Benz , C. , "Anti-HER2

Containing Amino-PEG-

Biochim. Biophys. Acta 1233 , 134-

19(1997).

Immunoliposomes: Enhanced

phosphatidylethanolamine" , FEBS

144(1 995).

[48]Gabizon , A.; Shmeeda, H.; Horowitz ,

Efficacy Attributable to Targeted

Lett. 353 , 71-74(1 994).

A.; Zalipsky, S. , "Tumor Cell Targeting

Delivery" , Clin. Cancer Res. 8 ,

of Liposome-entrapped Drugs with

1172-1181(2002).

[47]Kim. J.;

[6 Gabizon

A.; Horowitz , A.; Goren , D.;

[57]Gabizon , A.; Horowitz , A.; Goren ,

Tzemach , D.; Shmeeda, H.; Zalipsky,

D.; Tzemach , D.; Mandelbaum-

S , "In Vivo Fate of Folate-Targeted

Phospholipid-achored Folic acid-PEG

[52]Mastrobattista , E.; Koning , G.;

Shavit, F.; Qazenand, M.;. Zalipsky,

Polyethylene-glycol Liposomes in

Conjugates" , Adv. Drug Deliver. Rev.

Storm , G. , "Immunoliposomes for

S. , "Targeting Folate Rreceptor

Tumor-bearing Mice" , Clin. Cancer

56 , 1177-1192(2004).

the Targeted Delivery of Antitumor

with Folate Linked to Extremities

Res. 9, 6551- 6559(2003).

Adv. Drug Deliver. Rev. 40 ,

of Poly( ethyleneglycol)-grafted

[63]Herbert, v.; Zalusky, R. , "Interrelations

Liposomes: in Vitro Studies" ,

of Vitamin B12 and Folic acid ,

[49]Sugano , M.; Egilmez , K.; Yokota ,

J.; Chen , F.; Harding , J. , Huang , S.;

Dru"

103-127(1 999).

Bankert R. , "Antibody Targeting

[53]Hattori , Y.; Kawakami , S.; Yamashita ,

Bioconjug. Chem. 10 , 289-298(1 999).

Metabolism: Folic acid Clearance

of Doxorubicin-loaded Liposomes

F.; Hashida , M. , "Controlled

[58]Goren, D.; Horowitz , A.; Tzemach , D.;

Studies" , J. Clin. Invest. 41 , 1263-

Suppresses the Growth and Metastatic

Biodistribution of Galactosylated

Tarshish , M.; Zalipsky, S.; Gabizon ,

Spread of Established Human Lung

Liposomes and Incorporated

A.; "Nuclear Delivery of Doxorubicin

[64]Chiang,Y.; Cheng , Y.; Lu , C.; Yen , Y.;

Tumor Xenografts in Severe Combined

Probucol in Hepatocyte-selective

via Folate-targeted Liposomes with

Yu L.; Yu , K.; Lyu , S.; Yang , C.; Lo ,

Immunodeficient Mice" , Cancer Res ,

Drug Targeting" , J. Contro l. Release

Bypass of Multidrug-resistance Efflux

C. , "Polymer-Liposome Complexes

60 , 6942-6949(2000).

69 , 369-377(2000).

Pump" , Clin. Cancer Res. 6 , 1949-

with a Functional Hydrogen-Bond

1957(2000).

Crosslinker for Preventing Protein

[50]Hamaguchi , T.; Matsumura , Y.;

152

Contro l. Release 92 , 49-67(2003).

[46]Roux , E.; Lafleur , M.; Lataste , E.;

[54]X

R.; Hong , S.; Feng , L.; Rong , J.;

1276(1962).

J.; Annapragada , A.; Natarajan ,

Adsorption and Improving Tumor

Glycan Labeling Based on Ligand-

J.; Bellamkonda , R. , "Controlled

Accumulation" , Chem. Mate r., 25 ,

Hosokawa , S.; Tagawa T.; Kakizoe ,

Targeted Liposomes" , J. Am. Chem.

Targeting of Liposomal Doxorubicin

4364-4372(2013).

T. , "Antitumor Effect of MCC-465 ,

Soc. , 134, 9914-9917(2012).

via the Folate Receptor in Vitro" , J.

Nakanishi , Y.; Muro , K.; Yamada ,

Chen X. , "Cell-Selective Metabolic

Y.; Shimada, Y.; Shirao , K.; Niki , H.;

228

[5 Saul

20148

[65]Chiang , Y.; Lo , C. , "pH-Responsive

153

2014
| 1

Pegylated Liposomal Doxorubicin

[55]Russell-Jones , G.; McTavish , K.;

Moreau , P.; Leroux , J., "On the

Tagged with Newly Developed

McEwan , J.; Rice , J.; Nowotnik ,

[60]Ni , S.; Stephenson, S.; Lee , R. , "Folate

Characterization of pH-sensitive

Monoclonal Antibody GAH , in

D. , "Vitamin-mediated Targeting as

Receptor Targeted Delivery of

Liposome/Polymer Complexes" ,

Colorectal Cancer Xenografts" ,

a Potential Mechanism to Increase

Liposomal Daunorubiicn into Tumor

Biomacromolecules , 4, 240-248(2003).

Cancer Sci. 95 , 608-613(2004).

Drug Uptake by Tumors" , J. Inorg.

Cells" , Anticancer Res. 22 ,

Biochem. 98 , 1625-1633(2004).

2135(2002).

2131

S.; Kim , J. , "Temperature-

[51]Park , J.; Hong , K.; Kirpotin , D.;

sensitivity of Liposomal Lipid

Colbern , G.; Shalaby, R.; Baselga ,

[56]Zalipsky , S.; Brandeis , E.;

[6 1]Lee , R.; Low, P. , "Folate-mediated

Bilayers Mixed with Poly

J.; Shao , Y.; Nielsen , U.; Marks ,

Newman , M.; Woodle , M. , "Long

Tumor Cell Targeting of Liposome-

(N -isopropylacrylamide-co-acrylic

J.; Moore , D.; Papahadjopoulos ,

Circulating , Cationic Liposomes

entrapped Doxorubicin in Vi tro" ,

acid)" , J. Bio l. Chem. , 121 , 15-

D.; Benz , C. , "Anti-HER2

Containing Amino-PEG-

Biochim. Biophys. Acta 1233 , 134-

19(1997).

Immunoliposomes: Enhanced

phosphatidylethanolamine" , FEBS

144(1 995).

[48]Gabizon , A.; Shmeeda, H.; Horowitz ,

Efficacy Attributable to Targeted

Lett. 353 , 71-74(1 994).

A.; Zalipsky, S. , "Tumor Cell Targeting

Delivery" , Clin. Cancer Res. 8 ,

of Liposome-entrapped Drugs with

1172-1181(2002).

[47]Kim. J.;

[6 Gabizon

A.; Horowitz , A.; Goren , D.;

[57]Gabizon , A.; Horowitz , A.; Goren ,

Tzemach , D.; Shmeeda, H.; Zalipsky,

D.; Tzemach , D.; Mandelbaum-

S , "In Vivo Fate of Folate-Targeted

Phospholipid-achored Folic acid-PEG

[52]Mastrobattista , E.; Koning , G.;

Shavit, F.; Qazenand, M.;. Zalipsky,

Polyethylene-glycol Liposomes in

Conjugates" , Adv. Drug Deliver. Rev.

Storm , G. , "Immunoliposomes for

S. , "Targeting Folate Rreceptor

Tumor-bearing Mice" , Clin. Cancer

56 , 1177-1192(2004).

the Targeted Delivery of Antitumor

with Folate Linked to Extremities

Res. 9, 6551- 6559(2003).

Adv. Drug Deliver. Rev. 40 ,

of Poly( ethyleneglycol)-grafted

[63]Herbert, v.; Zalusky, R. , "Interrelations

Liposomes: in Vitro Studies" ,

of Vitamin B12 and Folic acid ,

[49]Sugano , M.; Egilmez , K.; Yokota ,

J.; Chen , F.; Harding , J. , Huang , S.;

Dru"

103-127(1 999).

Bankert R. , "Antibody Targeting

[53]Hattori , Y.; Kawakami , S.; Yamashita ,

Bioconjug. Chem. 10 , 289-298(1 999).

Metabolism: Folic acid Clearance

of Doxorubicin-loaded Liposomes

F.; Hashida , M. , "Controlled

[58]Goren, D.; Horowitz , A.; Tzemach , D.;

Studies" , J. Clin. Invest. 41 , 1263-

Suppresses the Growth and Metastatic

Biodistribution of Galactosylated

Tarshish , M.; Zalipsky, S.; Gabizon ,

Spread of Established Human Lung

Liposomes and Incorporated

A.; "Nuclear Delivery of Doxorubicin

[64]Chiang,Y.; Cheng , Y.; Lu , C.; Yen , Y.;

Tumor Xenografts in Severe Combined

Probucol in Hepatocyte-selective

via Folate-targeted Liposomes with

Yu L.; Yu , K.; Lyu , S.; Yang , C.; Lo ,

Immunodeficient Mice" , Cancer Res ,

Drug Targeting" , J. Contro l. Release

Bypass of Multidrug-resistance Efflux

C. , "Polymer-Liposome Complexes

60 , 6942-6949(2000).

69 , 369-377(2000).

Pump" , Clin. Cancer Res. 6 , 1949-

with a Functional Hydrogen-Bond

1957(2000).

Crosslinker for Preventing Protein

[50]Hamaguchi , T.; Matsumura , Y.;

152

Contro l. Release 92 , 49-67(2003).

[46]Roux , E.; Lafleur , M.; Lataste , E.;

[54]X

R.; Hong , S.; Feng , L.; Rong , J.;

1276(1962).

J.; Annapragada , A.; Natarajan ,

Adsorption and Improving Tumor

Glycan Labeling Based on Ligand-

J.; Bellamkonda , R. , "Controlled

Accumulation" , Chem. Mate r., 25 ,

Hosokawa , S.; Tagawa T.; Kakizoe ,

Targeted Liposomes" , J. Am. Chem.

Targeting of Liposomal Doxorubicin

4364-4372(2013).

T. , "Antitumor Effect of MCC-465 ,

Soc. , 134, 9914-9917(2012).

via the Folate Receptor in Vitro" , J.

Nakanishi , Y.; Muro , K.; Yamada ,

Chen X. , "Cell-Selective Metabolic

Y.; Shimada, Y.; Shirao , K.; Niki , H.;

228

[5 Saul

20148

[65]Chiang , Y.; Lo , C. , "pH-Responsive

153

BP

Polymer-liposomes for Intracellular

?

| i

Extracellular Matrix Switched-

| ""? 1

12

on Targeted Cancer Therapy" ,

! Automotive

| y

50

12

| 3 7

12

| v :J. r

12

| 1: '/ 7 :1:/

24

10

I /1-'<:

12

II

I T '7 r

12

12

I ""?-7 '7

| 3e ::r..

26

14

I SYSTEMS

12

| :1

1)

24

16

I Y7

17

I Linux

l :t

19

I NETWORK

20

I -J( 1

23

I 7 7

26

24

I / "J.'/

24

25

I ;-

12

Drug Delivery and Tumor

Biomaterials , 35 , 5414-5424(2014).

:
:

Technology

r .

7 -t"J.

::r.._,/ "
7

12

12
12

~ ::z. _

'/

"/

24
12

48

H{

. 1:'

)1.- }f

" ;..-

12

154

22 8

'.

BP

Polymer-liposomes for Intracellular

?

| i

Extracellular Matrix Switched-

| ""? 1

12

on Targeted Cancer Therapy" ,

! Automotive

| y

50

12

| 3 7

12

| v :J. r

12

| 1: '/ 7 :1:/

24

10

I /1-'<:

12

II

I T '7 r

12

12

I ""?-7 '7

| 3e ::r..

26

14

I SYSTEMS

12

| :1

1)

24

16

I Y7

17

I Linux

l :t

19

I NETWORK

20

I -J( 1

23

I 7 7

26

24

I / "J.'/

24

25

I ;-

12

Drug Delivery and Tumor

Biomaterials , 35 , 5414-5424(2014).

:
:

Technology

r .

7 -t"J.

::r.._,/ "
7

12

12
12

~ ::z. _

'/

"/

24
12

48

H{

. 1:'

)1.- }f

" ;..-

12

154

22 8

'.

I(

10 2

3 4

A B c

'

J:rI.
1

'

i~

(
)

228

20148

157

I(

10 2

3 4

A B c

'

J:rI.
1

'

i~

(
)

228

20148

157

TEL: 02-87125539 686 688

(Heterogeneous Catalysis)
(Crystals and Crystallinity in Polymers)

: EIi Ruckenstein Haiyou Wang

: Claudio De Rosa Finizia Auriemma

(ISBN)
:

: 764

978-0470175767

:Wiley

2013 11 4

: 480

Wiley

: 20143 24

(ISBN)

: 978-1118546901

WATER AT

(Water at Interfaces)

3D X

Jordi Fraxedas

(ISBN)

CRC

: 978-1439861042

Press

: 20143 24

: 288

(Chemistry of Sustainable Energy)

Nancy

(ISBN)

Chapman

: 446

z;EJ E

E. Carpenter
: 978-1466575325

and Hall/CRC

20143 28

(Supercritical Fluid Technology for Energy and Environmental Applications)

1
1
.i

: Vladimir AnikeevMaohong Fan I

(ISBN)

: 978-0444626967

Elsevier

: 20143 29
: 284

228

20148

159

11

TEL: 02-87125539 686 688

(Heterogeneous Catalysis)
(Crystals and Crystallinity in Polymers)

: EIi Ruckenstein Haiyou Wang

: Claudio De Rosa Finizia Auriemma

(ISBN)
:

: 764

978-0470175767

:Wiley

2013 11 4

: 480

Wiley

: 20143 24

(ISBN)

: 978-1118546901

WATER AT

(Water at Interfaces)

3D X

Jordi Fraxedas

(ISBN)

CRC

: 978-1439861042

Press

: 20143 24

: 288

(Chemistry of Sustainable Energy)

Nancy

(ISBN)

Chapman

: 446

z;EJ E

E. Carpenter
: 978-1466575325

and Hall/CRC

20143 28

(Supercritical Fluid Technology for Energy and Environmental Applications)

1
1
.i

: Vladimir AnikeevMaohong Fan I

(ISBN)

: 978-0444626967

Elsevier

: 20143 29
: 284

228

20148

159

11

ft "10

1 11.74% '
4% '

6 75

87.57.5

100

1 730

2 735

1/3 '
2502 140

13

'2

228

20148

161

ft "10

1 11.74% '
4% '

6 75

87.57.5

100

1 730

2 735

1/3 '
2502 140

13

'2

228

20148

161

.......

.
..

2014 |||||| | .....32.....333332.2.2.32333

9 : 1
2.

3.

4. (
)

5.

6.

@
@

()

: 1
2.

3.

4.

5.

6.

@
@
@

:
:

'

JIS/ ~7~ y 2012

.......

.
..

2014 |||||| | .....32.....333332.2.2.32333

9 : 1
2.

3.

4. (
)

5.

6.

@
@

()

: 1
2.

3.

4.

5.

6.

@
@
@

:
:

'

JIS/ ~7~ y 2012

a
':.1//

11

'7 -7 4F

OHM

7' -:1 'J

;t-1- -:1

7 -(

J'-

(polyfile)

'- '/ ~ 1)F

1- lJ

7 L.-7-

BIO INDUSTRY

C Q ham radio

/::1

7-J'- :.1 7

.,. ,,-

-t

M&E
FPD World Semiconductor

eye

TECHNO

MJ

'-

AUDIO TECHNOLOGY

. -{'-

OPENDESIGN

IJ

1 1 ..

"\-t -

"\

-7"1 7 1- "tf :.1/

AUDIO CRAFT MAGAZIE

- t J'-

SHEET METAL & FAB CATOR

Matsushita Technical Joumal

CAR & MAINTENANCE

7 -{ ..

//

ECO INDUSTRY

- !If

BE

a+u

77

lllImJJ. ~lB!1 ;

(0 )871 -55 9 686 688 '

KOBOLD Messring GmbH

measurmg

monitoring

.....

_;

l~

analysing

-.

()

EE
E

()

()

()

Dsseldorf, Germany, 2-4 December 2014

pH

()

jj (/)

HEN

M E 2

Web-Site : www.kobold.com

~~

114 123 247 1

TEL: 02-8792 6335 FAX: 02-8792 6115

E-mail : info.tw@kobold.com

Biennial Valve World Conference & Exhblflon

CONFERENCE

Suppor ed by

www.vIveworldexpo.com

ene''irl

Sponsored

Hl( NEWAYPENTAIR - /
KITZ VEIAN
L~
MRC Globar
VlRIiO

rotorl+

Kaigo (0. , Ltd.

8F.3 , No.9 , Oehuei Street_ Taipei 10461. Taiwan
Te l. +886 (2) 2595421 2- fax +886 (2) 25955726
messeduesseLdorf@kaigo.com.tw

www.kaigo.com.tw

Messe
Dsseldorf

 x
E

It._ .

HEPA i\. (11 500"(;)

X
'Ill

(100'C )

HEPAi!( 500"(;)

1t

A {}

( )

HEPA ( 500"(;)

90

':{).
{) GMp.

..!IlI

HEPA ( 500'C)

COOLER BELT CONVEYING FLAKES

TUV

13500

13500Liter PLOUGHSHARE MIXER

I ATOMIZER PULVERIZER I

AIR CLASSIFY PULVERIZER

HORIBA PRECISA
powder handling

hEMqp

established in 1982

* Preci

powder handling

established in 1982

SHE HUI MACHINERY CO. , LTD.

SHENZHEN XIEHONG MACHINE CO. , LTD.

SHE HUI MACHINERY CO. , LTD.

SHENZHEN XIEHONG MACHINE CO. , LTD.

: 123-2 3 ()

: 37 11 14

: 123-2 3 ()

: 37 11 14

TEL:02-29956168
FAX:02-29958328
E-mail: s heh u i99@ms32.hine t. net

:7

TEL:02-29956168
FAX:02-29958328
E-mail: s heh u i99@ms32.hine t. net

:7
http://www.mill-machine.com.tw

http://www.mill-machine.com.tw

 x
E

It._ .

HEPA i\. (11 500"(;)

X
'Ill

(100'C )

HEPAi!( 500"(;)

1t

A {}

( )

HEPA ( 500"(;)

90

':{).
{) GMp.

..!IlI

HEPA ( 500'C)

COOLER BELT CONVEYING FLAKES

TUV

13500

13500Liter PLOUGHSHARE MIXER

I ATOMIZER PULVERIZER I

AIR CLASSIFY PULVERIZER

HORIBA PRECISA
powder handling

hEMqp

established in 1982

* Preci

powder handling

established in 1982

SHE HUI MACHINERY CO. , LTD.

SHENZHEN XIEHONG MACHINE CO. , LTD.

SHE HUI MACHINERY CO. , LTD.

SHENZHEN XIEHONG MACHINE CO. , LTD.

: 123-2 3 ()

: 37 11 14

: 123-2 3 ()

: 37 11 14

TEL:02-29956168
FAX:02-29958328
E-mail: s heh u i99@ms32.hine t. net

:7

TEL:02-29956168
FAX:02-29958328
E-mail: s heh u i99@ms32.hine t. net

:7
http://www.mill-machine.com.tw

http://www.mill-machine.com.tw

I"'f' 11"

SAIN GOBAIN

2014
8 267

/
/
/

/
/
/;
/

100
cGMP CIP SIP

ASME

- BPE - PICI S

1t

I;

1t

~t |
'.lf: f

jRlj

t;

m~n'l i~Se'al@
Spring-Energized Seals

E( 521)

E /

: ( 855 )

/
/

/105 51 3()

TE(02)87125539()

FAX!(02)87126567

A A a

http://www.mmmpc.com.tw

E.mail :

. CIP/SIP/ASME

- BPE-PIC/S 10

00

(WFI

SYSTEM)

(PFW SYSTEM)

mmm 11 @mmmpc.com.tw()

/4256 g

TE(04)22511670

FAX!(04)22521315

: 50261920
1385
/

/m

Head Office : 3F., No.51 , 5ec. 4 , Nanjing E. Rd., 50ngshan Dis t.,

SHANG YUH MACHINE CO. , L TD.

: 389 46

Taipei City 105 , Tai wan

Welcome to contact with us by the above address.

/()

: 14

TEL:(886-2)8601-4966 < REP)

FAX : (886-2)8601-2866
http://www.shang-yuh.com
E-mail: shang-yuh@shang-yuh.com

Omni Seal@

.; 250 5 0 0

TEL:

G810X0003

(010)68433147

I"'f' 11"

SAIN GOBAIN

2014
8 267

/
/
/

/
/
/;
/

100
cGMP CIP SIP

ASME

- BPE - PICI S

1t

I;

1t

~t |
'.lf: f

jRlj

t;

m~n'l i~Se'al@
Spring-Energized Seals

E( 521)

E /

: ( 855 )

/
/

/105 51 3()

TE(02)87125539()

FAX!(02)87126567

A A a

http://www.mmmpc.com.tw

E.mail :

. CIP/SIP/ASME

- BPE-PIC/S 10

00

(WFI

SYSTEM)

(PFW SYSTEM)

mmm 11 @mmmpc.com.tw()

/4256 g

TE(04)22511670

FAX!(04)22521315

: 50261920
1385
/

/m

Head Office : 3F., No.51 , 5ec. 4 , Nanjing E. Rd., 50ngshan Dis t.,

SHANG YUH MACHINE CO. , L TD.

: 389 46

Taipei City 105 , Tai wan

Welcome to contact with us by the above address.

/()

: 14

TEL:(886-2)8601-4966 < REP)

FAX : (886-2)8601-2866
http://www.shang-yuh.com
E-mail: shang-yuh@shang-yuh.com

Omni Seal@

.; 250 5 0 0

TEL:

G810X0003

(010)68433147

C02

API 610 ,API 671

~ E I ~OKrA I

e ()

! 1
8

TEL: 04-2359 3278

FAX: 04-2359 7578

38 17 1

L932-7828
)'I~

94 2

5-2180

22862115

http://www.pneumtech.com.twJ
9

C02

API 610 ,API 671

~ E I ~OKrA I

e ()

! 1
8

TEL: 04-2359 3278

FAX: 04-2359 7578

38 17 1

L932-7828
)'I~

94 2

5-2180

22862115

http://www.pneumtech.com.twJ
9

BL~TEK@
( ,E

Since 1985

aiiEEZB .8. 278-3'0.

BTH

M533

~t 1
"'" 591

'A"'"

API

~.
15014001

G K

API 600/ API 602/ API 603

~
ASME N

NPT

e TS
"fo'.

ATC

CfJPED

AD2000

G.t.R

Nors.rd

36

TSC

\1

US$000000

BTE

BTE

BSF

BPA

71509001 , API 60 , API Q1 , API 6A , CE I PEO , AB5 , TA Luft API 607 , API 6FA, A5ME

Allianz

BTS

N & NPT, 51L2 & 3, 150

15848-1 2003

B~TK@
E-mail:tw'blot ek."eom .tw

http://www.blotek.com.tw

DiIKSON-\iLVE Diekson Industrial CO. , Ltd.

()

11268 400

16( )501 Q

TEL: +B6-592-577-3100 1576-0607

FAX: +86-592-576-0620

BLOTEK ELECTRIC MACHINERY CO. , LTD

11268 , FI. 1, No .4 00 , Daye Road ,Beitou District ip Taiwan

TEL: +BB6-2-2897-1919
FAX: +BB6-2-2897-2111
Websile: http://www.diekson-valve.com Mail Address: diekson-valve@diekson-valve , com

1 11 53 8 49 1
LANE 8 , TIEN-MOU E. RD. , TAIPEI , TAIWAN , 11153

TEL:(02)2873-4729 Rep.

FAX:(02)2875-1068
11

BL~TEK@
( ,E

Since 1985

aiiEEZB .8. 278-3'0.

BTH

M533

~t 1
"'" 591

'A"'"

API

~.
15014001

G K

API 600/ API 602/ API 603

~
ASME N

NPT

e TS
"fo'.

ATC

CfJPED

AD2000

G.t.R

Nors.rd

36

TSC

\1

US$000000

BTE

BTE

BSF

BPA

71509001 , API 60 , API Q1 , API 6A , CE I PEO , AB5 , TA Luft API 607 , API 6FA, A5ME

Allianz

BTS

N & NPT, 51L2 & 3, 150

15848-1 2003

B~TK@
E-mail:tw'blot ek."eom .tw

http://www.blotek.com.tw

DiIKSON-\iLVE Diekson Industrial CO. , Ltd.

()

11268 400

16( )501 Q

TEL: +B6-592-577-3100 1576-0607

FAX: +86-592-576-0620

BLOTEK ELECTRIC MACHINERY CO. , LTD

11268 , FI. 1, No .4 00 , Daye Road ,Beitou District ip Taiwan

TEL: +BB6-2-2897-1919
FAX: +BB6-2-2897-2111
Websile: http://www.diekson-valve.com Mail Address: diekson-valve@diekson-valve , com

1 11 53 8 49 1
LANE 8 , TIEN-MOU E. RD. , TAIPEI , TAIWAN , 11153

TEL:(02)2873-4729 Rep.

FAX:(02)2875-1068
11

/
:

4t;J:t R

:YLINDRr

.y

. /

./

. T/Y

./

..j4i: '3 'a

-~~9

..t;J8.~ER
Vessel

"1"3 1 VACUUM
E

, 33

fi !:J I Tft?EFHtNE

4NU;. ~~ E
CAPS

SHANG YUH MACHINE CO. , LTD.

: 242 1389 46

:244 14

: (886-2)8601-2866

COMPANY:N0 .46, LN . 389 , HUACHENG RD. , XINZHUANG DIST. , NEW

TAIPEI CITY 242 , TAIWAN
FACTORY:NO.14 , GONG 8th RD. , GONG 2 INDUSTRIAL DIS
Ll NKOU DIST, NEW TAIPEI CITY 244 , TAIWAN .
TEL: (886-2)8601-4966 (REP.) FAX: (886-2)8601-2866

http://www.shang-yuh.com

E-mail: shang-yuh@shang-yuh.com

: (886-2) 01-4966 ( )

100%8inleeel
-

@
286-9 4F 1

TEL:(07)822-2918()

FAX:(07)812-3938
E-mail:fengguh@ms8.hinet.net

13

/
:

4t;J:t R

:YLINDRr

.y

. /

./

. T/Y

./

..j4i: '3 'a

-~~9

..t;J8.~ER
Vessel

"1"3 1 VACUUM
E

, 33

fi !:J I Tft?EFHtNE

4NU;. ~~ E
CAPS

SHANG YUH MACHINE CO. , LTD.

: 242 1389 46

:244 14

: (886-2)8601-2866

COMPANY:N0 .46, LN . 389 , HUACHENG RD. , XINZHUANG DIST. , NEW

TAIPEI CITY 242 , TAIWAN
FACTORY:NO.14 , GONG 8th RD. , GONG 2 INDUSTRIAL DIS
Ll NKOU DIST, NEW TAIPEI CITY 244 , TAIWAN .
TEL: (886-2)8601-4966 (REP.) FAX: (886-2)8601-2866

http://www.shang-yuh.com

E-mail: shang-yuh@shang-yuh.com

: (886-2) 01-4966 ( )

100%8inleeel
-

@
286-9 4F 1

TEL:(07)822-2918()

FAX:(07)812-3938
E-mail:fengguh@ms8.hinet.net

13

?!:|!:

~~

1fNt .@

****

1fNt ~

:
1.
2.

3.
4.

5. SCS14
6.

7.

8.

Gla8s~llnd

Equlpmnt

CERTIFICATE OF
AUTHORIZATION

"

................. d Noc.....""-.....--

....

. h }

co '""....._.."1III......~.-...'"""-

-_.jod"..~.__.........-"

--

....."...__MIIceJ' 111
{

..

".'--"
..

""""'"
'"."

--....."".-

CVUI'1CATE

4'_.{).4<.tL.
0-....1M

...

....-

cu-

ASME

CHIEN MACHINERY CO.. LTD.

E-mail:magic.pum p@msa.hinet.net
14

1 2 6 6
No.Ln. 126. Dolon9 Rd. , Donshui Disl.. New Toipei City 25 1. Toiwon
: (02) 09-1100

: (02) O 005

http://www.magicpump.com.tw

Hp:/w.airpower.com.t~ ~

f!"r~~'"
407 39 1

TEL:03-4340-836

TEL:04-2359-7300
FAX:04-2359-7305 TEL:06-2719-900
tp ://www.airpower.com.tw
E-mail :email@airpower.com.tw
15

?!:|!:

~~

1fNt .@

****

1fNt ~

:
1.
2.

3.
4.

5. SCS14
6.

7.

8.

Gla8s~llnd

Equlpmnt

CERTIFICATE OF
AUTHORIZATION

"

................. d Noc.....""-.....--

....

. h }

co '""....._.."1III......~.-...'"""-

-_.jod"..~.__.........-"

--

....."...__MIIceJ' 111
{

..

".'--"
..

""""'"
'"."

--....."".-

CVUI'1CATE

4'_.{).4<.tL.
0-....1M

...

....-

cu-

ASME

CHIEN MACHINERY CO.. LTD.

E-mail:magic.pum p@msa.hinet.net
14

1 2 6 6
No.Ln. 126. Dolon9 Rd. , Donshui Disl.. New Toipei City 25 1. Toiwon
: (02) 09-1100

: (02) O 005

http://www.magicpump.com.tw

Hp:/w.airpower.com.t~ ~

f!"r~~'"
407 39 1

TEL:03-4340-836

TEL:04-2359-7300
FAX:04-2359-7305 TEL:06-2719-900
tp ://www.airpower.com.tw
E-mail :email@airpower.com.tw
15

v.

rR BEW

J SHUN-YI MACHINERY
TX

MODEL:TX-1-3

TH

THL

TMD (lj\)

THV

TSW

THD

TS

TMD ()

DISC

}: -1080ml./min

THV ()

THS

227 . 231 . 233

FA)( : (02)2995-7458
E-mail: shunyimc@ms15.hinet. net

TEL:

(07)226-9896

l( JI( )

TEL : 592-710-9991-3

FAX: 592-710-9996

h p://www.shun-yi.com.cn

TEL: 86-512-6257-0717

E-mail: shun-yi@shun-yi.com.cn

)1

111 : 13917176462

TEL: 20-8551-2161

FAX: 20-8758-3416

17

v.

rR BEW

J SHUN-YI MACHINERY
TX

MODEL:TX-1-3

TH

THL

TMD (lj\)

THV

TSW

THD

TS

TMD ()

DISC

}: -1080ml./min

THV ()

THS

227 . 231 . 233

FA)( : (02)2995-7458
E-mail: shunyimc@ms15.hinet. net

TEL:

(07)226-9896

l( JI( )

TEL : 592-710-9991-3

FAX: 592-710-9996

h p://www.shun-yi.com.cn

TEL: 86-512-6257-0717

E-mail: shun-yi@shun-yi.com.cn

)1

111 : 13917176462

TEL: 20-8551-2161

FAX: 20-8758-3416

17

l ~

E!.1=1 .~III. -J =

Globe Valves
FABA I

FABA90.

Control valves
Supra I*
spindle

1-piec and

STEVI

STEVI

2-piece

~:

metal to metal seat

SAFE

m-B

SAFE

",- S-ca-w

mLW-E
Fa-na-R
UV-p
n-

hu R

ZETRI~ ~

nr aL'

Safety valves

Butterfly Valves

-29 'C+427 C

it //l/
ABS PET PP
;

Control valves
RANGERQCT

Model 520/521

. TFE

live-Ioaded"

304SST f

. cv710

' 1440ps

_19S C 400 C
0

bellow

"

: I)

: Y j
()0 7](

it

Croesus
18

C!!;

lndustrial Corporation

: 144 5 5 9 3

256 9

TEL:(02)2557 -9955
FAX:(02)2557 -9959 , 2557-9653
E-mail:croesus9@ms35.hine t. net
E-mail:croesus_tpe@yahoo.com.tw

TEL:(07)312-1609 FAX:(07)312-1664
E-mail:croesus.ka@msa.hine t. net

5.

2. IG

6.

3.

4.

8.

TEL:886-5-5571169
FAX:886-5-5571759

TEL:86-21-57370066
FAX:86-21-57370055

30

63

E-mail: nianhung@ms23.hine t. net

E-mail: shnianhung@shnianhung.com

l ~

E!.1=1 .~III. -J =

Globe Valves
FABA I

FABA90.

Control valves
Supra I*
spindle

1-piec and

STEVI

STEVI

2-piece

~:

metal to metal seat

SAFE

m-B

SAFE

",- S-ca-w

mLW-E
Fa-na-R
UV-p
n-

hu R

ZETRI~ ~

nr aL'

Safety valves

Butterfly Valves

-29 'C+427 C

it //l/
ABS PET PP
;

Control valves
RANGERQCT

Model 520/521

. TFE

live-Ioaded"

304SST f

. cv710

' 1440ps

_19S C 400 C
0

bellow

"

: I)

: Y j
()0 7](

it

Croesus
18

C!!;

lndustrial Corporation

: 144 5 5 9 3

256 9

TEL:(02)2557 -9955
FAX:(02)2557 -9959 , 2557-9653
E-mail:croesus9@ms35.hine t. net
E-mail:croesus_tpe@yahoo.com.tw

TEL:(07)312-1609 FAX:(07)312-1664
E-mail:croesus.ka@msa.hine t. net

5.

2. IG

6.

3.

4.

8.

TEL:886-5-5571169
FAX:886-5-5571759

TEL:86-21-57370066
FAX:86-21-57370055

30

63

E-mail: nianhung@ms23.hine t. net

E-mail: shnianhung@shnianhung.com

/
/

TEL:(07)8214538

FAX:(07)8232238

16 .

29.

17 .

30.

1 .

18 .

31

4.

19 .

32.

7.

20.

33.

8.

20.

34.

9.

23.

35. 1

10 .

24.

36.

i2f

25.

37.

12 .

26.

38.

13 .

27.

14 .

28.

15 .

28.

. seepex

(stripper)
IPA()

GMMP

GMB

;J;~:-800C-+2800C

;J)Ei :-20 C-+130 C

316
:90W. 200W. 400W. 550W

:316
:60W
:8M
:20 Ll min

:31M
:95 Ll min

GMSW
:-80 C-+280 C
:316
:1-7.5HP
:60M
:600 Ll min

:-30 C-+230 C
:316
:1-5HP
:91M
:56 Ll min

I ~~~o~~
;~:-800C-+2800C

:316
:7.5HP-25HP
:133M
:1400 Ll min

TEL: 07-3720913

FAX: 07-3720923

: 814 395 -17

http://www.ricopump.com.tw
!

E f

2726567

DIN

:
/!

2. ?

3. ?

( )

5. /? ()

I | I

4. ? ()

?
:

90-100

80-90

70-80

60-70

60

90-100

80-90

70-80

60-70

60

90-100

80-90

70-80

60-70

60

90-100

80-90

70-80

60-70

60

90-100

80-90

70-80

-70

60

TEL:(0223656107 .

z~;~EE

?:
?:

NEDERMAN FIL TERBOX

NEDERMAN

99%

D.O.P.TEST 99.97%

EL~...Il

:
:
:

: :]
:

:
()

E-mail:

E
E _ 1
E

1 1

[I.'"I. ..m.DIJ imllllIJ

23

Vacuum p

: 2.3" (58mm)
: 1

: 2.3"(58mm) /4.0"(100mm)
: 1

:3 4 5 6 8
: DC4-20mA / DC 0-1 OV ;
RS-485 ;

: 3 4 5 6
: DC4-20mA ; RS-485 ;

: 2.3" :48XN+66mm
4.0. :96XN+66mm
196mm mm

BCD & Binary 15 bits

:48XN+66mm
196mm mm

BUSC H

: 2.3 (58mm) /4.0"(100mm)

: 2

: 2.3" (58mm)
: 3

: 4.0' (1 OOmm)
: 3-

: 3
: DC4-20mA ; RS-485 ;

: 3
: DC4-20mA ; RS-485 ;

: 3 4 5 6

: 2.3" :210mm 196mm

4.0" :354mm 300mm
34mm

34mm

BUSCH

: DC4-20mA ; RS-485 ;

:210mm 196mm

: 96xN+66mm
300mm ()

OEM

;44mm

E-mai1 E-mai1

tttiffR

69 1

Tel (02)2662-0775 I Fax (02)2662-0796

info@busch.com.tw I www.busch.com.tw
25

Vacuum p

: 2.3" (58mm)
: 1

: 2.3"(58mm) /4.0"(100mm)
: 1

:3 4 5 6 8
: DC4-20mA / DC 0-1 OV ;
RS-485 ;

: 3 4 5 6
: DC4-20mA ; RS-485 ;

: 2.3" :48XN+66mm
4.0. :96XN+66mm
196mm mm

BCD & Binary 15 bits

:48XN+66mm
196mm mm

BUSC H

: 2.3 (58mm) /4.0"(100mm)

: 2

: 2.3" (58mm)
: 3

: 4.0' (1 OOmm)
: 3-

: 3
: DC4-20mA ; RS-485 ;

: 3
: DC4-20mA ; RS-485 ;

: 3 4 5 6

: 2.3" :210mm 196mm

4.0" :354mm 300mm
34mm

34mm

BUSCH

: DC4-20mA ; RS-485 ;

:210mm 196mm

: 96xN+66mm
300mm ()

OEM

;44mm

E-mai1 E-mai1

tttiffR

69 1

Tel (02)2662-0775 I Fax (02)2662-0796

info@busch.com.tw I www.busch.com.tw
25

 TAIB.O N1 G

: SUS304 , SUS316 , SUS316L , SUS904 , SUS904L , SM0254 , Titanium ,

Titanium-Paladium , Nickel , Nickel alloy, Hastelloy-C , Hastelloy-B

: NBR , EPDM , CR , Butyl , Vito Teflon , Silicon , Reflon l!il

SPIRAL

PLASTIC

PLAIN PLATE

: Max .45kg/cm

: PVDF PP PE

: -30'C ~+ 140'C

;i

450'C

ALL WELDED WIDE GAP

: 3mm-30mm
: 700 0 C

GAB Neumann GmbH

Graphite Annular-groove
Silicon Carbide SiC

2 BI
26

SERU INTERNATIONAL CO..LTD.

Max.1000mmaq
900'C

TANTALUM HEAT EXCHANGER

(Ta)

201 6

(02)2702-0199
E-mail:seru@ms37.hine t. net

(02)2708-7272
http://www.seru.com.tw

 TAIB.O N1 G

: SUS304 , SUS316 , SUS316L , SUS904 , SUS904L , SM0254 , Titanium ,

Titanium-Paladium , Nickel , Nickel alloy, Hastelloy-C , Hastelloy-B

: NBR , EPDM , CR , Butyl , Vito Teflon , Silicon , Reflon l!il

SPIRAL

PLASTIC

PLAIN PLATE

: Max .45kg/cm

: PVDF PP PE

: -30'C ~+ 140'C

;i

450'C

ALL WELDED WIDE GAP

: 3mm-30mm
: 700 0 C

GAB Neumann GmbH

Graphite Annular-groove
Silicon Carbide SiC

2 BI
26

SERU INTERNATIONAL CO..LTD.

Max.1000mmaq
900'C

TANTALUM HEAT EXCHANGER

(Ta)

201 6

(02)2702-0199
E-mail:seru@ms37.hine t. net

(02)2708-7272
http://www.seru.com.tw

( 5)

mv

: 906

: (07) 699-8063

m
g

|VFS :

.iIS
.

|AFM :

: (07)699-8385

it~
.~

| :

.I
.
.

.:.

AFH iG

VFsllll

TEEEZiiiii

H.QNG SHUEN INDUSTRIAL CO.'l~TD.

28

1~r(11

h;p;i~.hst;;o~~~im~i~h;95848@hot~~i1~~~

21

(02)2786-7221

FAX: (02)278

( 5)

mv

: 906

: (07) 699-8063

m
g

|VFS :

.iIS
.

|AFM :

: (07)699-8385

it~
.~

| :

.I
.
.

.:.

AFH iG

VFsllll

TEEEZiiiii

H.QNG SHUEN INDUSTRIAL CO.'l~TD.

28

1~r(11

h;p;i~.hst;;o~~~im~i~h;95848@hot~~i1~~~

21

(02)2786-7221

FAX: (02)278

eepex@com
Progressive Cavity Pump
seepex | |
Bottrop seepex 40

seepex

.
.

7.k

./

HEF

.;

C]S

Ap,plicatins :

API 676 Upstream I Downstream:

Produced water I condensate
pen I closed drain

500

CanrJedpu p

.80m

Flare knock-out dru pump

NPSH ()

NAC E/Ali EX

Drilling
Q

T78

EW

mm

-
Ekt F

30

Oily' wate r separation

G~ude oil

. >50 bar (>70 psi)

Multi - P l7l ase

HyroGycloe fee~

m3 /h (2200 GPM)

mud
FPSO I'-FSO

seepex@com

FFFrcdnHUET

all things flow

Asia Pacific Head Office

seepex (M) Sdn. Bhd
59-1 , Jalan PJU 1/37 Dataran Prima
47301 Petaling Jaya Selangor D. E., Malaysia
Tel +60 3 7880 6951
Fax +60 3 7880 6959
E-mail: seepex.m@seepex.com
Webpage: www.seepex.com
Taiwan Contact
10663 237 13

Tel 02771078621 Fax 0277107868

Mobile 09285183011 E-mail: tliu@seepex.com

31

eepex@com
Progressive Cavity Pump
seepex | |
Bottrop seepex 40

seepex

.
.

7.k

./

HEF

.;

C]S

Ap,plicatins :

API 676 Upstream I Downstream:

Produced water I condensate
pen I closed drain

500

CanrJedpu p

.80m

Flare knock-out dru pump

NPSH ()

NAC E/Ali EX

Drilling
Q

T78

EW

mm

-
Ekt F

30

Oily' wate r separation

G~ude oil

. >50 bar (>70 psi)

Multi - P l7l ase

HyroGycloe fee~

m3 /h (2200 GPM)

mud
FPSO I'-FSO

seepex@com

FFFrcdnHUET

all things flow

Asia Pacific Head Office

seepex (M) Sdn. Bhd
59-1 , Jalan PJU 1/37 Dataran Prima
47301 Petaling Jaya Selangor D. E., Malaysia
Tel +60 3 7880 6951
Fax +60 3 7880 6959
E-mail: seepex.m@seepex.com
Webpage: www.seepex.com
Taiwan Contact
10663 237 13

Tel 02771078621 Fax 0277107868

Mobile 09285183011 E-mail: tliu@seepex.com

31

UDBAD tiFEZFd

ra

/;

MAGNETIC DRIVE PUMP IN CATEGORY OF LARGE FLOW OR

CGMP

FILT

""

B PCB VCP
..3HP-5HP-7.5HP
2HP-3HP-5HP

_...

I;

MPX SERIES

KXH/K)J ERIES

....

l
7 .0.0 OOt/Min

KPF/KKF SERIES

1 37820F2
20F-2 ,378 Wunsin

Rd. Sec.1 Taichung iwan

408

TL:04-23208766 FAX:04-23204815
~-mail: unikem.inc@msa.hine t. net
http://www.unikem.com.tw

UDBAD tiFEZFd

ra

/;

MAGNETIC DRIVE PUMP IN CATEGORY OF LARGE FLOW OR

CGMP

FILT

""

B PCB VCP
..3HP-5HP-7.5HP
2HP-3HP-5HP

_...

I;

MPX SERIES

KXH/K)J ERIES

....

l
7 .0.0 OOt/Min

KPF/KKF SERIES

1 37820F2
20F-2 ,378 Wunsin

Rd. Sec.1 Taichung iwan

408

TL:04-23208766 FAX:04-23204815
~-mail: unikem.inc@msa.hine t. net
http://www.unikem.com.tw

ZS

/ (3Y

/ 6Y / 8Y)

mw

:0.05mm I-(/) 0.1 mm ,

0.2rnm

@ :.3mm O.4mm
0.5m mm

O.8mm 1.0mm

~4
~

b@

HIP

: 105 * 105 * 20mm

HIP
:2mm-15mm : 0 - 300mm

: 2
: 273 10

TEL : 03-3125869

FAX: 03-3125862

E-mail: service@oc-tec.com

http://www.oc-tec.com

7 -

ZS

/ (3Y

/ 6Y / 8Y)

mw

:0.05mm I-(/) 0.1 mm ,

0.2rnm

@ :.3mm O.4mm
0.5m mm

O.8mm 1.0mm

~4
~

b@

HIP

: 105 * 105 * 20mm

HIP
:2mm-15mm : 0 - 300mm

: 2
: 273 10

TEL : 03-3125869

FAX: 03-3125862

E-mail: service@oc-tec.com

http://www.oc-tec.com

7 -

Hastelloy 82 , 83 , 84 , C276 , C22 , C4 , X

lncoloy 800 , 800H 1 HT, 825 , 718 , X-750

lnconel600 , 601 , 625

Carpenter 20C83

Monel 400 , K500

Nickel 200 , 201

Kovar

Tantalum
Zirconium 702
Invar36 , Invar42

Ei

Clad Plat:e & Clad piping

Titanium Grade 1 , 2 , 3 , 5 , 7 , 12

Copper Nickel 90 1 10 C70600 ,

7 0/30 C71500

Duplex 531803/2205 , 532760 ,

S32750/2507 , 2304

5tainless 300 1400 series , 904L ,

2545MO 1 6Mo, 253MA, AL-6XN

PVC

Carbon & AII0y 5teel : A 179, A 106 ,

A~92 A2 10 A213 A333 A334 A335

A387 , A515 , A516 , ...etc.

El~

419 7

TEL: 886-2-2723-0977
FAX: 886-2-2722-5923
http://www.wideshine.com.tw/
E-mail: wideshine@wideshine.com.tw

3ft

Hastelloy 82 , 83 , 84 , C276 , C22 , C4 , X

lncoloy 800 , 800H 1 HT, 825 , 718 , X-750

lnconel600 , 601 , 625

Carpenter 20C83

Monel 400 , K500

Nickel 200 , 201

Kovar

Tantalum
Zirconium 702
Invar36 , Invar42

Ei

Clad Plat:e & Clad piping

Titanium Grade 1 , 2 , 3 , 5 , 7 , 12

Copper Nickel 90 1 10 C70600 ,

7 0/30 C71500

Duplex 531803/2205 , 532760 ,

S32750/2507 , 2304

5tainless 300 1400 series , 904L ,

2545MO 1 6Mo, 253MA, AL-6XN

PVC

Carbon & AII0y 5teel : A 179, A 106 ,

A~92 A2 10 A213 A333 A334 A335

A387 , A515 , A516 , ...etc.

El~

419 7

TEL: 886-2-2723-0977
FAX: 886-2-2722-5923
http://www.wideshine.com.tw/
E-mail: wideshine@wideshine.com.tw

3ft

| r
-

s...."

95%

'

Em
E

()

Water

JE|

//

: (200.C-400.C)

: 1.

2. -99%

3.Thermal Nox

auH HMRunu

%%

J 12

J
.

'

@ETZITFE!
38

99 2

TEL:886-2-29384848()

:
:
:

FAX:886-2-29384864

http://www.geto.tw
E-mail:geto@ms17.hine t. net
20148

BP

Polymer-liposomes for Intracellular

?

| i

Extracellular Matrix Switched-

| ""? 1

12

on Targeted Cancer Therapy" ,

! Automotive

| y

50

12

| 3 7

12

| v :J. r

12

| 1: '/ 7 :1:/

24

10

I /1-'<:

12

II

I T '7 r

12

12

I ""?-7 '7

| 3e ::r..

26

14

I SYSTEMS

12

| :1

1)

24

16

I Y7

17

I Linux

l :t

19

I NETWORK

20

I -J( 1

23

I 7 7

26

24

I / "J.'/

24

25

I ;-

12

Drug Delivery and Tumor

Biomaterials , 35 , 5414-5424(2014).

:
:

Technology

r .

7 -t"J.

::r.._,/ "
7

12

12
12

~ ::z. _

'/

"/

24
12

48

H{

. 1:'

)1.- }f

" ;..-

12

154

22 8

'.

M
-nueo

wmVN

-hun

VH

!F

'

..... \

NT$400

_ ~

~
\ / ;AA /

>

\\
4
~/
}
& $
_.
u
\

\P~

\:

k
\
./

\&

y
J
\_ y

\ bd

?
\

h
i
~
~

;7' _/ };
\
;
\----~
~

--

lL. $
50
2

0'
O
3+ 1;

NT$ 400

8 3 t 5 6 ~

NT$600

. .

NT$300

..

NT$350

:
:

--9
c(--~-
-
- - - - - - - - - - - - - - - - - - - ---.-- - - - - - - - 7--- ----------- -"-

1{:

:
i :

..iIIIIIIII.-3.

..

I E

$4500
0'
6+2:

|
|
|

()

:2
505

0150

1350
0
1080
0
1080
0

TEL:02-87125539 # 688.686

I /|

|
I I 250

0 I 450
0 I
I I 20
0 0 I 360

0 I
1
20

0 13
0
60
0 1

:25

///:

(z
>

:
:

; :
:
2

:
l :
;:
;

; :

...~()

"'-1

&

...

...

TEL : (02)8630-5555
FAX: (02)2619-5299
:0938-056698

E-mail : heatec@ms24.hinet.n